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Sources of diagnostic noises to
be considered during a routine
abdominal auscultation.
In addition to visceral-peristaltic
activity, these sounds may have
thei r ori gin in visceral-parietal
friction as well as in vascular
and muscular activi ties.
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When cardiac
complaints occur
in the absence
of organic findings,
underlying
anxiety may be
one factor
The influence of anxiety on heart function
Excessive anxiety is one of a combina,
tion of factors that may trigger a series of
maladaptive functional reactions which can
generate further anxiety. Often involved in
this vicious circle are some cardiac arrhyth,
mias, paroxysmal supraventricular tachycar,
dia and premature systoles. When these
symptoms resemble those associated with
actual organic disease, the overanxious
patient needs reassurance that they have no
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sive anxiety and emotional overreaction
would be medically beneficial.
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Introduction
The Clinical Laboratory in Medical Practice

This issue of the Medical College of Virginia
Quarterly is devoted to the 44th Annual McGuire
Lecture Series held in March 1973, under the
auspices of the Division of Clinical Pathology, Department of Pathology, and the Department of
Continuing Education. The program was designed
specifically for the nonpathologist physician and
addressed itself to two broad goals: first, to provide a summary of recent advances in practical
laboratory medicine and second, to offer a blueprint for quality assurance to those physicians who,
of necessity, must operate their own office clinical
laboratory. We were particularly pleased that the
McGuire Lecturer this year was Dr. George Z.
Williams, the first Professor of Clinical Pathology
and Director of Laboratories at the Medical College of Virginia, and presently Director of the
Institute of H ealth Research in San Francisco,
California.
GEORGE P. VENNART, M.D.

Chairman, Division of Clinical Pathology
Professor of Pathology
M edical College of Virginia
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Advancing Technology of Clinical Laboratory
Practice*
GEORGE Z. WILLIAMS, M.D., D.Sc.
Director, Institute of Health Research; Clinical Professor of Clinical Pathology ,
University of California, San Francisco

In spite of the temporary antitechnology attitude of a portion of our society, the future will be
an era of automated technology. Buckminster Fuller
( 1) has reviewed the progress of industrial technology and points out that continuing scientific advances are inevitable and that technical applications
will provide more equitable distribution of wealth,
more time, more opportunity for education and inteliectual pursuits. lfe predict~ that technology will
produce enough for all of mankind by efficient use
of energy. He observes that the overall efficiency of
the use of energy by man was 1 % until the tum of
the century; it has grown to 4% since then.
Some modern devices and systems of energy
conversion to productive work reach 10-15% and
the potential of such machines as rockets is 7 5-80 % .
By 1900 the industrial revolutions of civilization had
provided their benefits to approximately 1 % of mankind, spreading to 5 % of the world's population by
1920, 20% by 1940 and 44% by 1970. The growth
curves depicting several technological indices in figure 1 provide convincing evidence of the remarkable
accomplishments to be expected by extrapolation
into the next several generations. The advances in
communication up to the Telstars presently encircling the earth, in transportation by rocketing to
the moon and in the scientific discoveries exemplified by the use of the chemical element~, illustrate
the accelerated expansion of the benefits of science
to man. A similar curve could be constructed for the
advancement of medical science and its miraculous
achievements when compared to health conditions
in past centuries.
* Presented by Dr. Williams at the 44th Annual McGuire Lecture Series, March 23 , 1973, at the Medical College of Virginia, Richmond.
MCV QUARTERLY 9(4): 293-297, 1973

Science and technology have brought us to
where we are and can be credited for all the "good"
things we have. If scientific advances are not used
for the benefit of mankind, the fault lies with the
users, the people, not with the technology of science.
Technology has brought a distribution of wealth to
larger and larger numbers of the world's population
in terms of food, communication, education and
medicine. Today, fewer starve than ever before; the
average life expectancy in developed countries has
increased from 42 years to 80 years. Few in the
world are ignorant of the happenings over the planet;
radio and television are worldwide, and air transportation now reaches all points. Fuller reminds us
that if we discarded all these advances at their
present state, two-thirds of the world's population
(two billion) would starve within six months, all
communications would stop, people would be isolated into intolerable pockets of high density and
cities would become inescapable centers of anarchy
and violence. On the other hand, it is amusing to
conjecture that if we discarded all the political
ideologies, politicians and bureaucratic systems but
retained our technological advances, the world would,
in all probability, go on progressing, probably with
less difficulty and turmoil. Nuclear energy was discovered by scientists, bombs were dropped by politicians. The thought occurs-is it rational to leave
the decisions of the future to the politicians, or
should they be left to those whose intellects, judgment and industry have bettered the physical and
intellectual life of half the world beyond their fondest
expectations of a short century ago? Recognition of
what science has so fa r accomplished for man justifies the optimism that scientists will continue to mold
a better life tomorrow for all the world's people.
293
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Fig. I-Exponential growth curve of man's utilization of
technology and scientific discovery.

Focusing on health and medical care, although
development in medicine has necessarily lagged
somewhat behind industry, there has been a parallel
upswing of remarkable advances in the fields of
human genetics, chemistry, physiology and mental
capability. There is no question but that the sciences
of physics, chemistry, physiology, morphology,
psychology, logic and computer applications will
continue to rapidly advance health knowledge. Automation must inevitably utilize fewer resources at a
lower cost to provide more and better health and
medical care to all.
The New Era of Scientific Medicine. Science
is the systematic study of nature; bioscience applies
scientific methods to the understanding of animate
nature. Applications of scientific methods of discovery and analysis and the synthesis of knowledge
concerning the nature of man have just begun.
Growth ahead will be as rapid and phenomenal as
advances in energy use, transportation and communication have been in the past. The computer
potential in the study of man is in its initial exploratory phase, and practical applications in medicine have barely begun.
It is understandable that the laboratory, in its
role of providing standardized and quantitative scientific measurements, will continue to grow as the
primary source of reliable information concerning
health and disease. To realize the importance of further advances, we can remind ourselves that, as with
the technology of food distribution and communication in society, if we should destroy all modern applications thus far accomplished in medicine, chaos
would reign . Think of the plight of today's dense
population centers with no vaccines, no public health

control of water, of insect disease vectors or food, no
medical instruments, no drugs, no hormone or vitamin biologics, no antibiotics. The resulting disaster
is unimaginable.
The laboratory of the future will probe not only
deeper with newer tools of medical research, but it
will apply the burgeoning new knowledge to maintain health and more effective therapy as well as to
improve early diagnosis. To accomplish this at acceptable costs, however, automation, miniaturization,
computerization and systemization are necessary.
Primary Laboratory Functions. The laboratory
is the facility for the measurement of body functions
and states of various constituents and for such activities as testing chemical reactions. Quantitative information is extracted from body fluids, products and
tissues. Blood and urine contain enormous amounts
of chemical and physiological information, which
Dr. Irvine Page (2) compares with the use of coded
computer tapes. This "coded information" must be
discovered, identified and decoded. The data must
be correlated and synthesized into understandable
information, describing in medical terms the whole
integrated organism of man during his varying reactions in health and disease. This task is only in the
design stage. Our tools are still relatively crude.
There are many steps in the development of this
expanded role of the future laboratory. Immediate
needs include:
1. New tests for functions and constituents
yet undiscovered;
2. Frequently repeated sets of test measurements to reveal the kinetic nature of physiological and chemical activities and to delineate the limits of variation;
3. Improvement of precision and accuracy;
4. Limitation of blood and tissue samples to
micro amounts for large batteries of analyses;
5. Miniaturization of equipment;
6. Automation for speed and elimination of
error and laboratory bias (variability);
7. Computerized instant and long-term quality control;
8. Computerized data collection, correlation
and reconstitution into usable physiological
and biochemical information;
9. Identification of deviated test results which
warn of trouble;
10. Standardization of methodology and inter-
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pretation to permit comparability of data;
11. Regional health and medical data banks to
prevent wasteful and costly duplications of
examinations and testing and to provide
lifetime health records.
The direction of development of the clinical
laboratory in the future is already apparent. Mechanization and automation of the repetitive manipulations such as sample transport, pipetting, mixing,
temperature control, end-point determination and
reaction rate measurement are greatly improving
precision and eliminating human errors. New transducers for detecting changes in constituents-their
states and rates of change-are being devised and
applied. Advances in gas-liquid chromatography,
thermal microcalorimetry, laser beam technology,
nuclear beam technology, nuclear magnetic resonance measurements, x-ray spectrography, radioimmune assay, mass spectrography and ion-electrode
devices remain to be miniaturized, standardized,
automated and calibrated. In one decade, the amount
of blood sample required for a set of 10 or 12 analyses has been reduced from 100 to 1 ml-two orders
of magnitude! Crude dual channel test instruments
have advanced to 20 and 22 channels. Rates of
measurements of reactions have shortened from minutes to seconds; precision has improved from 10%
to less than 1 % error for many tests.
Automation has amplified the productivity of
the technical staff by factors of two, four and ten
for different types of tests, and occasionally, by a
factor of 100 for some, such as antibiotic sensitivity
microtiter automation and the newer instruments for
enzyme reaction rate analysis. At the laboratories of
the National Institutes of Health, even the earlier
phases of automation permitted doubling the test
work load without increasing the technical staff.
Computational capability has advanced in two
decades from the use of the mechanical desk calculator and slide rule to the programmed electronic
calculator first, and more recently, the minicomputer.
Five years ago, a laboratory processing a million
tests per year needed a million dollar computer system. With the application of computer technology
and economy, the same laboratory today, needs only
ten tiny preprocessing computers, each built into a
set of specific instruments, at a comparable computer
capability at a cost of less than $300,000. Nowhere
is economic efficiency progressing as rapidly as in
computer automation technology. Five years ago,

computers served laboratories as expensive data collection, storage, calculation and printing machines.
Today, they are beginning to be used for their true
value in high speed correlation analyses, process control and conversion of data into information.
Several examples may serve to indicate the
trends for the future. In figure 2, the rate and character of aggregation of human platelets are recorded
on a chart; this is partial mechanization. Pipetting
and transport are still manual as is the conversion
of the charted analog curve to numerical representation. This exciting new test of platelet activity, which
detects hyperactive or deficient platelet functions,
and thereby identifies high risk "clotters" and "bleeders," requires automation and integration into the
computer system so that one technologist can more
precisely perform ten tests in the time now required
for one. The model "S" electronic blood cell counter,
now a familiar instrument in many larger laboratories, provides four measurements and three derived
results (total of seven results) in hematology with a
precision at least ten times that of the traditional
manual methods and at a speed and capacity which
can approach a hundredfold improvement if need be.
Enzyme rate reactions used to be very slow and
tedious to measure by stopwatch, water bath and
manual colorimeter. Precision was difficult to obtain.
The semiautomatic bichromatic reaction rate analyzer improves precision to less than 1 % error for
some enzyme tests and at rates of 60-120 multiple
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Fig. 2-Measurement of the rate and degrees of platelet
aggregation by mecha nized instrumentation.
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Fig. 3-Automated chemical analyzer console containing
centrifuge and controls for speed, temperature and automatic washout of cuvettes.

point analyses per hour. With computer processing,
human reading, calculation and transcription errors
can be eliminated.
A new and innovative breakthrough in high
speed, microsample handling and multisample analysis was developed at the Oak Ridge National Laboratory by Dr. Norman Anderson, Director of the
Molecular Anatomy Program. Although precision
for the tests adapted to this instrument, so far, is
equal only to the best conventional methods, the
sample size of 1-10 ml, comparably small amounts
of reagent and high speed performance promise
remarkable improvements in multitest microanalysis
for the future. Figures 3, 4 and 5 illustrate the in-

Fig. 4-Systems Reaction-Analyzer-control panel, minicomputer and oscilloscope and television type screen displays
of chemical reactions occurring in each cuvette of centrifugal head.
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Fig. 5-Automated chemical analyzer. Transfer disc of
centrifuge head showing the two well chambers placed in
radial position for each of the 15 positions. The serum
sample placed in the inner well is run into the reagent in
the outer well and mixed by centrifugal force and finally
forced into the peripheral quartz cuvette chambers of the
rotor ( not shown).

novative principles and operation of this device
which, with its built-in computer, exemplifies future
automation in the laboratory. This device is a highspeed centrifugal analyzer using centrifugal forces to
mix a series of samples and reagent in microchambers and to transfer them into quartz window
cuvettes oriented radially in a teflon rotor. Computercontrolled synchronization permits serial multiple
readings of density or color reaction changes within
each cuvette. The rate of change in each sample is
depicted graphically on an oscilloscope or CRT
screen ( fig. 6) and is computed as a digital result
printed on an attached teletypewriter or via the computer system. Pipetting of sample and reaction is
performed with a mechanized autopipetter of high
precision.

F ig. 6-Enzyme reaction rate curve depicted immediately
on cathode ray tube screen.
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Finally, the heart of the laboratory of tomorrow-the computer. Due to the high costs of computer equipment and programming, initial attempts
at application in the laboratory were designed to
accomplish all possible operations with one large
general purpose machine. As was discovered in industry, this was found to be expensive and inefficient
in spite of the theoretical economic advantages of
having one machine for the performance of many
functions. With the exponential reduction in costs
of processors and memories and the miniaturization
of equipment, it is now feasible to employ many
special-purpose mini-minicomputers, programmed to
accomplish specific tasks for particular analytical instruments and to couple these in a network with one
minicomputer for final processing, collation and
report generation. This system frees the central coordinating minicomputer to accomplish the data correlation and interpretative functions while the other

dedicated instrumental computers (buffered interfaces) are "baby sitting" the analyzers and preprocessing the raw data. Figure 7 depicts the diagram of such a system which is being installed in our
new laboratory in San Francisco. Computers are
here to stay because they can perform, at the speed
of light, complex and repetitive computations, and
can sort, coordinate and analyze large quantities of
data too time consuming to be feasible if done
manually. They can synthesize new information from
multidimensional data, opening vast new areas of
analytical potential.
REFERENCES
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Utilization of Blood and Its Products*
ROBERT D. LANGDELL, M.D.
Professor of Pathology, School of Medicine,
University of North Carolina, Chapel Hill

The development of a system of plastic bags
connected by integral tubing for the collection,
processing and storage of blood has made it possible for selective transfusion of appropriate blood
components. It is now possible to select the blood
component that will correct a patient's physiologic
deficiency. This has resulted in better patient care
and in better utilization of blood since a single
unit of blood can be used to supply erythrocytes for
an anemic patient, platelets for a patient with
thrombocytopenia and factor VIII concentrate for
a patient with hemophilia.
In order to utilize blood and its components
optimally, there must be a close working arrangement between the blood bank personnel and the
clinical staff. At the time when blood is obtained
from a donor, a decision should be made concerning how the blood will be used. Several of
the components can be prepared only from fresh
blood. The equipment, supplies and personnel time
should be used to produce the maximum benefit
to the recipients of the blood. Although each unit
of blood could be separated into several useful components, it is a wasteful procedure if the components are not used. Each institution must determine its need for blood and blood components .
Those responsible for the operation of the blood
bank should not make unilateral decisions about
the preparation of blood components and the
clinical staff should not make unilateral decisions
about the use of blood components.
Packed Red Blood Cells. When blood is collected in the proper closed bag system, it is possible
to remove much of the plasma after sedimentation
or centrifugation without opening the container.
The resulting packed red blood cells remain viable
,:, Presented by Dr. La ngdell at the 44th Annual McGuire Lecture Series, March 23 , 1973 , at the Medical College of Virginia, Ri chmond .
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for transfusion purposes for 21 days when stored
under standard conditions. The obvious advantage
of transfusing packed red blood cells is that the
circulating erythrocyte mass of the recipient can
be increased without increasing the circulating
plasma volume. This minimizes the possibility of
circulatory overload. It has been estimated that up
to 80 percent of the transfusions should be in the
form of packed red blood cells (2).
Along with the plasma, most of the sodium
added in the anticoagulant solution is removed. This
can be an important factor when transfusions are
necessary in patients requiring limited sodium intake. In addition to the excessive amounts of electrolytes and citric acid, the plasma contains antibodies. One of the dangers in the universal donor
concept is that the plasma of group O individuals
contains antibodies against group A and group B
cells. These antibodies are removed along with
the plasma. Although type specific compatible
erythrocytes are the treatment of choice, in an
emergency situation when such blood is not available, group O packed red blood cells are an acceptable form of therapy.
Factor VIII Concentrates. The treatment of
hemophilia with plasma rather than whole blood
was an early form of component therapy. It was
found that plasma contains the material lacking in
hemophilia and except for the occasional patient
with anemia, whole blood is seldom needed for
the treatment of hemophilia. Although the antihemophilic factor in plasma is relatively labile, it
can be maintained in plasma stored below -18 °C.
Until relatively recently, plasma removed from
whole blood within a few hours of collection and
then promptly frozen was the only available source
of factor VIII for human use. Because of the relatively small amount of antihemophilic activity in
plasma, large amounts of fluid had to be infused
MCV QUARTERLY 9(4) : 298-300, 1973
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to significantly increase the circulating level in the
patient. In addition, the infused activity was retained in the circulation for only a short period
of time (4). Thus, therapy was restricted to the
amount of fluid that could be infused without causing overload.
In 1965, Pool and her associates (5) reported
that when frozen plasma was thawed slowly, a
poorly soluble, gelatinous precipitate was formed.
This material, called cryoprecipitate, was found to
contain a considerable amount of the antihemophilic activity of plasma. Thus, it became possible
to concentrate and collect factor VIII of plasma
in a closed bag system. The resulting material contains, on the average, about half of the antihemophilic activity of the original plasma and in a
relatively small volume.
Although the treated plasma can be returned
to the cellular component and used as whole blood,
most have found it better to utilize the plasma for
other purposes. The residual plasma can be used
for all conditions where plasma is indicated other
than for the treatment of hemophilia.
Platelet Concentrates. Fresh whole blood contains viable platelets which will function when
transfused. When platelets are needed to control
bleeding in a patient with thrombocytopenia, however, a large amount of blood must be infused to
increase the platelet level in the circulation. Platelets
can be separated from whole blood and transfused
in a relatively small volume.
Platelets have a specific gravity of 1.040 while
the specific gravity of erythrocytes is about 1.095
(3). Since platelets are lighter than erythrocytes,
the red blood cells can be sedimented by low speed
centrifugation while the platelets remain suspended
in plasma. In this way platelets can be separated
from whole blood in a closed bag system. Platelets,
however, have a very short shelf life and to be
effective must be infused promptly after collection.
Although platelets lose viability rapidly, approximately half of the recovered platelets are still effective after 72 hours of storage. Most workers, though,
feel that platelets should be used within the first
48 hours after collection. Although there is some
evidence that room temperature storage has some
advantages, it is felt that best results are obtained
when platelets are stored at 4 °C. Additional studies
of storage are necessary to determine optimal
conditions ( 1) .
Platelets can be given along with the plasma

as platelet rich plasma. It is usually necessary,
however, to give the platelets recovered from six
units of blood to achieve the desired effects and it
is normally not desirable to give this amount of
fluid. The usual practice is to concentrate the
platelets by centrifugation and remove all but approximately 30 ml of plasma. Following centrifugation, it may be difficult to resuspend the platelets.
Gentle agitation after storage for about one hour
has been found to result in a satisfactory product.
It is generally recommended that platelets be infused through a filter to remove any large
aggregates.
Plasmapheresis. One of the limitations of obtaining blood is that approximately six-to-eight
weeks are required for the regeneration of erythrocytes. For this reason, the interval between individual donations of blood should be at least eight
weeks. The regeneration of the fluid volume and
plasma proteins is more rapid. With a series of
bags connected by integral tubing, it is possible to
withdraw blood from a donor, separate the erythrocytes from the platelet rich plasma and return
the erythrocytes to the donor. This process, called
plasmapheresis, can be repeated at frequent intervals
without danger to the donor.
This technique has several advantages when
the needs for platelets and plasma are great. A
relatively small number of donors can supply considerable amounts of platelets and plasma. There
is increasing evidence that when platelets are given
over a prolonged period, antibodies to platelets
develop in the multitransfused patient. These antibodies appear to be directed against the histocompatibility antigens of the HL-A system. Those
institutions which use platelet transfusions on a
long-term basis have found that best platelet survival occurs when there is an HL-A compatibility
between donor and recipient. It is generally felt
that if a series of platelet transfusions are required,
it is best to obtain platelets by plasmapheresis from
a few histocompatible donors rather than utilizing
platelets from a number of random blood donors
(7).

Frozen Red Blood Cells. With currently available techniques, erythrocytes retain sufficient viability for transfusion purposes for only 21 days.
For this reason blood supplies must be continuous
and the blood bank must be able to predict its
needs so that sufficient blood will be available and
yet there will not be wastage due to excessive
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amounts of erythrocytes lost by out-date. An obvious solution would be to develop a method of
preservation of blood for longer periods.
A number of chemical additives have been
used in an attempt to prolong the viability of
erythrocytes. The most promising has been adenine
(6). With the addition of adenine at the time of
collection, there is evidence that erythrocytes remain viable up to 40 days under the usual storage
conditions. At the present time, however, there is
not sufficient evidence to be certain of the safety
of this material for human use .
Other workers have demonstrated that erythrocytes suspended in cryoprotective solutions retain
viability almost indefinitely when stored at low
temperatures. Before the erythrocytes can be infused , the cryoprotective materials must be removed.
The supplies and equipment necessary for preparation, storage and washing make this technique rather
expensive. Although the techniques are practical,
the cost for a unit of such blood is almost prohibitive for routine use. If methods can be developed to decrease the cost, there are many advantages to such a technique.
Leukocyte-Poor Blood. There are many known
antigens associated with erythrocytes, but most of
these are only occasionally of clinical significance.
For practical purposes, it is only necessary to
routinely test for ABO and Rh antigens. In a
similar way there are a number of antigens associated with leukocytes, but these are usually of
little clinical significance. In multitransfused patients, however, the leukocytes may cause reactions.
To prevent these reactions it may be necessary to
give leukocyte-poor blood. Recently it has been
recognized that leukocyte antigens may have an
adverse effect on organ transplantation. It has been
suggested that patients with chronic renal disease
who may be candidates for renal transplantation
should be given only leukocyte-poor blood.
The specific gravity of granulocytes is 1.0871.092 and the specific gravity of lymphocytes is
1.070 ( 3). Thus differenti al centrifugation to prepare
leukocyte-poor erythrocytes is rather difficult. There
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are techniques by which most of the leukocytes can
be separated from erythrocytes but these techniques
are tedious and time consuming. In order to remove
the leukocytes and their antigens it is necessary
that fresh blood be used. In those institutions that
have a frozen blood program, it has been found
that this preparation is an excellent source of
leukocyte-poor erythrocytes.
Summary. At the present time there are a
number of blood components that are more suitable
for transfusion purposes than is whole blood. In
order to make maximum use of blood, it is necessary that there be close cooperation between the
blood bank personnel and those responsible for
patient care.
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Meaningful Toxicology*
ROBERT V. BLANKE, Ph.D.
Associate Professor of Clinical Pathology, Medical College of Virginia
Health Sciences Division of Virginia Commonwealth University, Richmond

Before discussing this subject in a "meaningful" way, we must have some agreement as to
what is meant by the term "toxicology." Toxicology
includes such widely diverse areas as the chemistry
of toxic substances, the signs and symptoms elicited
by such substances, the detection and identification
of toxic substances in a wide variety of specimens,
the interpretation of analytical results and the
treatment · of toxic episodes. Although in recent
years, toxicology has dealt with the problem of drug
overdosage almost exclusively, it must be appreciated that any chemical substance, when absorbed
in sufficient quantities to produce an adverse effect,
is toxic. This would include common substances
such as ordinary table salt and range through substances generally recognized as poisonous such as
strychnine. In addition, the broad field of toxicology
is concerned with the effects of acute overdosage
of toxic agents as well as the effects of long-term,
chronic exposure to these agents. The scope of
toxicology, therefore, may extend from the study
of a single element such as lead to a complex,
chemically uncharacterized substance such as snake
venom ; from an overdose of heroin to the effects
of long-term exposure to low levels of pesticides
on anticonvulsant therapy. For the purpose of this
discussion, we shall narrow the limits of the broad
field of toxicology considerably, but it is important
to be aware of the breadth and depth to which toxicology may at times extend.
Clinical toxicology laboratories generally have
two main functions . The first and most apparent
is the identification and quantitation of toxic substances in specimens from patients brought to the
,:, Presented by Dr. Blanke at the 44th Annual McGuire Lecture Series, March 23, I 973, at the Medical College of Virginia, Richmond.
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Emergency Room after a possible acute toxic
episode. In general, the clinician needs the laboratory results promptly in order to answer questions such as: What toxic substance, if any, is present? If present, is the quantity consistent with the
signs and symptoms displayed by the patient? Will
the quantity of toxic substance present influence the
choice of the treatment? Do the laboratory findings
confirm the history, diagnosis or clinical impression?
The second general function of the clinical
toxicology laboratory is to monitor certain chemical
substances in patients. This may be done for the
purpose of maintaining therapeutically effective drug
levels such as in epileptic patients, or for the purpose
of determining the effectiveness of a treatment procedure in reducing levels of toxic agents. A relatively recent area of interest may also include the
determination of metal levels in cases of industrial
exposure or when alteration in metal metabolism
may be associated with a clinical condition.
Both of these general functions utilize common
laboratory facilities and personnel, so that it is reasonable that the clinical toxicology laboratory be
engaged in both activities. Since the goals to be
achieved by these two functions are quite different,
the approaches to the achievement of these goals
must be considered separately. In general, in order
to fulfill its role in dealing with the emergency situation, the toxicology laboratory must provide 24hour service and utilize reliable, rapid methods resulting in a short turn-around time to be of maximum
use to the clinician. The monitoring of chemical substances in patients can usually be achieved within a
normal workday using dedicated procedures on a
relatively continuous basis. Ideally, of course, with
unlimited facilities, personnel and support, these
goals can easily be achieved. Since most laboratories
can never hope to enjoy this luxury, a more prag301
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matic approach must be taken which involves compromises between the ideal and the practical.
Since there are literally thousands of toxic substances which may be encountered in clinical toxicology, it is absolutely essential at the outset that these
substances be examined realistically, making a selection of those which are commonly encountered in the
community served by the clinical laboratory. Some
substances are common to almost all treatment facilities while others may be unique to a particular
locality. Rural and urban communities, for example,
may differ as to the relative importance of problems
relating to narcotics and pesticides. An important
industry in a specific area may present specific
toxicological problems which would not usually be
encountered elsewhere.
It is commonly acknowledged that good communication between the clinician and the laboratory
facility is essential for the production of meaningful
laboratory results. Unfortunately, the gap between
acknowledging this truism and its implementation is
difficult to bridge. Lines of communication between
the clinical toxicology laboratory and the clinician
can be 'established initially by identifying the priority
by which new toxicological procedures should be
made available. It is essential that the laboratory
understand the problems of the clinician and that
the clinician understand the problems of the laboratory. For example, it may be important in a specific
case to identify whether a patient has ingested an
overdose of lysergic acid diethylamide (LSD). It is
possible to assay LSD levels by radioimmunoassay,
but does the need occur often enough to justify the
expenditure of funds for equipment and personnel to
make this assay procedure available on a "STAT"
basis? Conversely, the laboratory may have an elegant method for measuring fluoride levels in serum,
but is it of practical use to the clinician when 24
hours are required to obtain test results?
It is better for a clinical toxicology laboratory
to conduct a relatively small number of tests by
reliable methods in reasonable time periods than to
attempt to handle all types of situations which might
arise. Once having agreed upon a basic nucleus of
tests, the laboratory can adapt and evaluate published procedures to give the clinician results which
are meaningful both in reliability and in turn-around
time.
It is essential that once lines of communication
are opened, they be maintained in both directions.
It is the responsibility of the laboratory to inform the
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clinician as to what can or cannot be done within
the constraints imposed upon it in a given situation.
It is the responsibility of the clinici·an to request
reasonable and specific tests, supplying sufficient
information to permit the laboratory some leeway in
establishing priority with which specimens will be
processed and to provide proper and adequate
specimens for analysis.
The "unknown" toxic agent is always a difficult
problem to handle. Again, good communication can
help to partially resolve the problem. Most clinical
toxicology laboratories have the ability to conduct
a variety of screening tests. None of these is allinclusive and most of them are chiefly of value when
they are negative. Some screening tests are of the
spot-test type, which can be conducted on urine or
gastric contents after a minimum of handling. Others
can be used to screen for metals, alcohol, other
volatile substances or narcotic drugs . The simple request for "toxicological screening" or "test for
poisons" presents a dilemma to the clinical toxicology laboratory. Should the screening tests be
directed toward detecting drugs of abuse or heavy
metals? Should pesticides be considered or is the
patient a known alcoholic? Valuable time can be
saved and costs minimized by a brief history or
clinical summary of the patient's condition. If
nothing else, this would indicate to the toxicology
laboratory what substances are not likely to be
present.
Ideally, a clinical toxicology consultant should
be available to contribute personal expertise in the
resolution of these difficult problems. Many toxicology laboratories have the experience and necessary resource material to aid the clinician in making
a proper evaluation. Additionally, there are other
resources available provided they are utilized. The
poison control center, drug information center, and
specialists in specific areas can make important contributions to patient management. Thoughtful planning and interdepartmental or interagency support
can significantly assist, provided arrangements can
be made in advance to utilize these resources properly. Obviously, an emergency at 2 :00 a.m. is not
the time to decide where to look for help or how to
carry out a difficult laboratory test.
The development of a regional poison control
center has been found to be the most effective way
to resolve these problems in many communities.
Properly coordinated, such a regional center could
supply information, treatment and laboratory facili-
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ties to a large area. This would ensure that costly
equipment and skills could be most effectively used
to serve a large geographic area. Costs for a specific
test, for example, which may be difficult to justify
due to infrequent occurrence in a given institution,
might be practical if the frequency of occurrence
were increased by serving a larger area.
Functioning lines of communication are also
important in deriving meaningful toxicological data
from laboratory procedures not related to the emergency room. Frequently, the toxicology laboratory
is requested to develop or add to the armamentarium
of tests available, a procedur·e identifying a specific
drug in serum. The fact that the laboratory may
have a certain instrument or procedure available
does not necessarily enable the laboratory to apply
that instrument or procedure to a specific test. Since
the development of gas-liquid chromatography which
now makes possible the detection of a vast number
of drugs, it is frequently assumed that this is the
answer to all drug analyses. Frequently, it is not
possible in a practical manner, to modify a gas
chromatograph, in order to shift it from a routine,
smoothly operating procedure to a special application. Not only will the parameters of the new test
be somewhat different but sample preparation is almost always the major problem. One of the difficulties confronting the toxicology laboratory is removing the toxic agent from the specimen submitted
in such a manner and in such a state of purity that
a particular instrumental procedure can be used for
its identification and quantification. In addition,
many substances which are rapidly metabolized may
not even be detected in biological specimens. Thus,
although the parent drug may be easily identified in
a standard solution, the presence or absence of that
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drug in biological material may be a much more
complex problem. Detection and estimation of metabolites may be the only method by which the
original drug can be detected. These and similar
problems should be discussed between the clinician
and the toxicology laboratory in order that both may
understand the usefulness or limitations of a given
analytical procedure.
Finally, in order for the toxicology laboratory
results to be meaningful to the clinician, some interpretation of the results is necessary. Tables of
normal values are of little use since frequently
there are no "normal" values for toxicological analyses. In the case of drugs, therapeutic levels may
be available but these must be interpreted cautiously,
since some patients may develop tolerance to a
given drug after prolonged therapy and others may
exhibit a hypersensitivity to very low levels of
drugs. It is becoming increasingly common that
drug combinations may be present and little information is now available as to drug interactions.
Here, again, the clinical toxicologist and those
sources of information previously mentioned can
be utilized, so that the clinician may benefit more
from the services of the toxicology laboratory.
In summary, "meaningful" toxicology can be
realized only when the clinical toxicology laboratory
provides more than a place where tests are run.
Thoughtful and well-planned coordination of the
laboratory's efforts with the efforts of the clinician
can be provided by establishing and maintaining
good communication between the parties. Outlining
the proper procedure for establishing this communication is relatively simple. Making it work requires a constant, willful expenditure of effort in both
directions.

Microbial Monitoring* **
HARRY P. DALTON, Ph.D.
Associate Professor of Clinical Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

The "tubular" schematic of mammalian structure is a well-known concept that has been in use for
years, but nowhere is this concept more useful than
in understanding the man microbial interphase (fig.
1). The diagram emphasizes the fact that humans
are subjected to microbial invasion from two areas
where bacterial populations exist in large numbers.
The first of these is the internal flora of the respiratory, intestinal and lower urinary tract which, along
with the skin organisms, make up the endogenous
microorganisms of the body. The second area, the
periphery of the diagram, contributes the external or
exogenous flora. The numbers and types of organisms found here are unpredictable since they depend
upon environmental factors. Infections which are
caused by the endogenous flora are considered opportunistic infections, while those derived from the
exogenous flora are termed nosocomial infections.
The need for monitoring both areas for alteration in microbial flora, which may result in invasion
or adverse effect on internal organs of the host, has
been an accepted scientific fact of modern medicine
for years. Questions remain, however, on how much
monitoring needs to be done. What areas of the
patient and the environment should be tested, and
what are the practical uses of the results of such
monitoring? Before attempting to answer these questions, let me give you an overview of how microbial
monitoring has been used at the Medical College of
Virginia hospitals and other institutions to identify
and solve problems related to nosocomial and opportunistic infection.
Changes in Etiology of Bacteremia. One area
that has been under constant surveillance in our in,:, Presented by Dr. D alton at the 44th Annual McGuire
Lecture Series, March 23, 1973, at the Medical College of
Virginia, Richmond.
* * Portions of this work were supported by NASA
grant NGL-47-002-020.
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stitution is that of blood cultures or bacteremia. The
numbers and types of microorganisms present in
blood cultures have been recorded over the last 20
years. The data document that there have been profound changes in types of bacteria primarily associated with this infection (fig. 2). This graph shows
the percentage of patients from whom gram-positive
and gram-negative organisms were isolated during a
20-year period at the Medical College of Virginia
hospitals. Since 1960, the percentage of patients
with gram-negative bacteremia has continuously increased, while during the same period the percentage
of patients subjected to gram-positive bacteremia
declined (fig. 3). This graph demonstrates the number of patients who had bacteremias with some of
the more common organisms associated with this
type of infection. Perhaps the most striking results
are those for 1970. In this year, the number of bacteremias by Escherichia, Klebsiella, Enterobacter
and Serratia was in the neighborhood of 260 patients.
In the same year, there were about 60 Staphylococcus aureus bacteremias, a ratio of over four gramnegative bacteremias for every one staphylococcus
bacteremia. It is also distressing to note that there
has been no decrease in the upward slope of the
gram-negative organisms over the last 20-year period
but rather an acceleration in this upward slope for
the last five-year period.
Alterations of Endogenous Flora. The reason
for this shift in the etiology of bacteremia is not
known. A number of possibilities immediately present themselves, such as age of the population tested,
types of surgical procedures performed and types of
medication given. All may play a role in the alteration of results. In regard to medication, particular
attention has been paid to such agents as corticosteroids, as they have been related to changes in the
immunological response of the host which may allow
alteration in microbial flora.
MCV QUARTERLY 9(4) : 304- 309. 1973
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More recently it has become evident that antibiotics may be responsible for allowing endogenous
organisms to manifest pathogenicity. There is evidence that many of the gram-negative infections are
endogenous in source, and the organisms of these
infections in the immunologically depressed or debilitated patients are selected for by the use of antibiotics. An example of this is shown in figure 4.
The study was done in cooperation with D r.
B. W. Haynes of the Department of Surgery at the
Medical College of Virginia. A patient, who had
suffered a 23 % total body burn, was given penicillin
to protect him from the common exogenous pyogenic
organisms such as Staphylococcus aureus and beta
hemolytic streptococcus. Bacterial monitoring of the
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burn lesion, using a standard technique, shows the
success of this therapy, for early in the course of this
patient's treatment both of these organisms were
present but did not colonize the burn lesion ( 2).
Penicillin, however, did not stop colonization of the
lesion by gram-negative organisms consistent with
the endogenous flora of the patient. Such organisms
as Proteus, Enterobacter and Pseudomonas rapidly
increased in number and only decreased after eschar
removal with healing of the lesion. Only then was
there a return of gram-positive organisms associated
with normal flora ( fig. 5). When broad-spectrum
antibiotics are included in the antibiotic regimen,
there may occur an emergence of a large number of
organisms resistant to all the antibiotics used. In this
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patient, penicillin, streptomycin and gentamicin were
given. The burn area was colonized by neither grampositive nor gram-negative bacteria but rather by the
yeast, Candida albicans, an organism known for its
resistance to antibiotics. Again, a normal grampositive flora was not established until eschar removal
and healing of the lesion.
In our laboratory, we have been able to alter
the normal flora of the hamster by giving large doses
of oxicillin. In the upper respiratory tract of ten
treated animals, there was a decline in the number
of alpha hemolytic Streptococcus and Neisseria, with
an increase in the number of Escherichia, Proteus,
and Enterobacter. In three of the ten test animals,
gram-negative bacteremias were demonstrated by
heart blood cultures and in three of the ten test
animals, death occurred from gram-negative pneumonia within 72 hours of treatment. The normal
untreated controls during this period remained
healthy and had no evidence of infection ( 6) .
The medical literature also describes numerous
examples of alteration in the etiological agents of
infections which may be associated with treatment.
Rogers ( 8) contrasts the etiologic agents of pneumonia found during a preantibiotic era ( 19381940) with that of a postantibiotic era (195519 5 8) . In the first period, there was an 8%
incidence of gram-negative pneumonia, while in the
latter period during the antibiotic era there was a
3 8 % incidence of this type of infection. Lerner ( 5)

LL

BURNED 2/4 / 70
WT. 120
AGE 23
20% TBB
DISCHARGED 4 / 14 / 70

I 08

V)

10 7

! - - - P E N I CI LLIN

~

~

~

~
~
Cl;

"':::,
.,

PROTEUS MIRABHIS

GENTAMICIN
COLISTIN

V)

10 6

PSEUDOMONAS KUBSIE LLA

/\

10 5

0:,

~

10 4

TABLE

I

TYPES OF THERAPEUTIC REGIMEN A SSOCIATED WITH
ENDOGENOUS MICROBIAL FLORA ALTERATIONS

Irradiation
Antimetabolites
Antibiotics

Corticosteroids
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Dermal preparations

also has reported an increase in gram-negative pneumonia in nonhospitalized patients. Price (7), in
1970, presented strong evidence that the extensive
use of antibiotics in a neurology ward resulted in
an epidemic of Klebsiella infection which only subsided with the withdrawal of antibiotics from ward
use and a more judicious use of antibiotics after
the withdrawal period. Can one predict with certainty whether a particular therapy will cause serious
overgrowth? Of course, the answer is "No." One
can, however, be alert to the therapeutic regimen
that has a potential to cause such trouble (Table 1).
This table shows those therapeutic regimens which
have been associated with gram-negative opportunistic infection (1, 4). The list is by no means
exhaustive, and many other examples can be found .
Those listed in this table are known to have been
associated with gram-negative infections at this institution or they have been cited repeatedly in
literature. The common causes for alteration in
flora according to these sources are: irradiation,
antimetabolites, antibiotics, corticosteroids, immunosuppressants and dermal preparations.
The combined findings leave little doubt that
the physician must appreciate the microbial ecology
of the human and treat it as much as possible with
an agent that will not drastically alter the normal
microbial flora. In other words, the attending physician should be an ecologist concerned with the very
personalized microflora of his patient. This is not a
very radical statement since the medical profession
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Intravenous infusion
Dialysis
Parental feeding
Catheterization of blood vessel
Catheterization of urinary tract
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Suturing
Punch biopsies
Bone marrow aspiration
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TABLE 3
FREQUENCY OF ISOLATION FROM

100

SKIN CULTURES OF

VARIOUS SPECIES OF BACTERIA

Staphylococcus epidermidis
Bacillus species
Streptococci
Enterococci
Diphtheroids
Here/lea
Escherichia
Staphylococcus aureus
No growth

86 (85 %)
42 (42 %)
29 (29 %)
16 (15 % )
13 (13 % )
4 ( 4%)
2 ( 2%)
2 ( 2%)
4 ( 4%)

Here/lea vaginicola isolated from skin of two patients on
hospital day 1 for one patient and hospital days 26 and 29
for another.
Escherichia isolated from skin of two patients on hospita l
days 4 and 11, respectively.
(All gram-bacilli were isolated from upper extremities.)

has been concerned with the total environment of
the patient for centuries.
Introduction of Exogenous Microbes. I have
spent the time so far discussing only endogenous
flora. What about exogenous flora or nosocomial
infection? What role do these agents play in present
day disease? One aspect of this problem is the number of new medical techniques and devices that
require direct communication into the internal organs. Not only have a large number of new devices

been added in the last 20 years, but also there has
been a vast increase in the use of older procedures
such as venipunctures. These procedures, unless
careful aseptic technique is employed, serve as vehicles for the entry of exogenous organisms into the
internal organs. In Table 2, you will find the techniques that have been repeatedly associated with
nosocomial infections (1 , 4). As in the last table, the
list is not exhaustive and there are other procedures
which have been associated with this condition. The
role th at these manipulations may play in contributing to nosocomial infections cannot be overemphasized. Let me give you two examples of how these
procedures may allow the entry of organisms into
the vascular system. The first example has to do
with the effect of venipuncture on 100 hospitalized
patients. This work was done in conjunction with
Dr. Richard Duma of the Division of Infectious
Disease. We have listed in Table 3, the types of
organisms recovered from the antecubital area of the
right arm, prior to cleaning the site for venipuncture.
Staph epidermidis and Bacillus species were most
commonly recovered, followed surprisingly by
Enteric streptococci, Herellea and Escherichia. The
purpose of the venipuncture was for obtaining blood
cultures. This allowed, therefore, the correlation of
the organisms recovered from blood cultures with
those found on the skin surface. Table 4 shows the
results of this correlation. Ten individuals had positive blood cultures; in eight of these, there was no

TABLE 4
RELATIONSHIP OF POSITIVE BLOOD CULTURES TO CULTURES OF OVERLYING SKIN IN

Culture number

Blood culture
(organisms)

1
2

Pneumococcus
Pneumococcus

3

Streptococcus

4
5
6
7

Anerobic diphtheroids
Bacillus species
Micrococcus species
Here/lea vaginicola

8
9

Cryptococcus
Escherichia species &
Cryptococcus
Aspergi/lus

10

L- Left, R- Right, A- Arm , H- Hand

Skin culture
( organisms)
S. epid., Diphth.
S. epid., Bacillus
sp., a strep. (Ent.)
S. epid., Bacillus
sp. ( a strep. cultured
from skin of opposite arm)
S . epid. & Bacillus sp.
Bacillus sp.
S. aur.
H. vaginicola, S. epid.,
a strep. (Ent.), & Bacillus sp.
S. epid.
S . epid., & Bacillus sp.
S. epid., & Bacillus sp.

JO PATIENTS

Site of cultures

Day of hospitalization

L. & R . A.
L. & R . A.
L.A.

L.A.
L. & R . A.
R . A.
L. & R. A.

26

L.A.
L. & R.H.

16

R. A.

3
10
3
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TABLE 5
COMPARISON OF COMMON ORGANISMS ISOLATED
FROM BLOOD CULTURES 1969-1968
Number of Patients
Genus

1969

1968

% Change

Escherichia

84

70

+20

Aerobacter }
Klebsiella
Serratia

102

109

-7

30
38
34
58
11 , 380

27
40
37
47
11 , 117

Proteus
Pseudornonas
Staph aureus
Pneurnococcus
Number of cultures taken

+10
- 5
-8
+23
+l

relationship between the organisms recovered from
blood cultures and those isolated from the skin. But
in two patients, numbers three and seven in Table 4,
the same organisms found on the skin were also
present in the blood cultures, indicating that the
needle at venipuncture may have been contaminated
at the site of entry and may have pushed organisms
into the vessel. The data certainly indicate that this
occurs infrequently, but the mere fact that it can
occur at ali should sensitize medical personnel to
the need for good aseptic technique.
The second example that we will use to demonstrate how nosocomial infection can be spread
will involve the use of i.v. infusion (Table 5). This

table shows the percent increase of common bacteremia organisms for the years 1969-1968. You
will note that when the two periods are compared,
there has been a small increase in many of the
organisms, but well within the percent increase that
was discussed previously. Table 6 compares the first
six-month period of 1969 and the first six-month
period of 1970 for the same organisms shown in the
previous table. You will note that there is a tremendous increase in the percentage of recovery, particularly with the gram-negative organisms. During
this 1970 period, Dr. Richard Duma and Dr. Jack
Warner (3) did an extensive in-use study ori the
i.v. systems throughout the hospital. They sampled

TABLE 7
BACTERIOLOGIC STUDIES ON 24 VOLUME CONTROL
INTRAVENOUS INFUSION SETS IN 24 PATIENTS
Culture Results
Type of
Set
Number
Set
3A
6A
7
9
10
12

25
25
25
50
50
50

14
16

50
75

17

25

20
23
24
25
26

50
50
25
50
50

31
37
38
41

50
50
25
50

48
55
58
60
61
62

25
25
25
50
50
50

Inside of
Cylinder

Mirna

Serratia
Enterobacter

TABLE 6
COMPARISON OF MICROORGANISMS CULTURED FROM BLOOD
ACCORDING TO NUMBER OF PATIENTS AND CULTURES
JANUARY TO JUNE 1969--1970
Number of Patients
Genus
Staphylococcus aureus
Here/lea
Aerobacter
Candida
Klebsiella
Proteus
Escherichia
Alpha Streptococcus
Serratia
Pneurnococcus
Number of cultures

1969

1970

% Change

14
5
10
12
31
14
42
27

33
11
22
23
58
21
55
32
JO
28
6,688

+135
+120
+120
+91
+87
+so
+30
+19
0
- 16
+19

IO

33
5,584

E. epiderrnidis
Flavobacteriurn
Hemolytic
Streptococcus
Candida species

Inside of
Bottle Cap
Corynebacteriurn
Mirna
Mirna
Klebsiella
S. epiderrnidis
Pseudornonas
E . coli
Serratia
Enterobacter
Serratia
E.coli
Flavobacteriurn
E.coli
Corynebacteriurn
Flavobacteriurn
Bacillus species

Candida species
Mirna

Corynebacteriurn
Flavobacteriurn
Candida species
Enterobacter
S. epiderrnidis
Corynebacteriurn
Bacillus species
S. epiderrnidis
Flavobacteriurn

Blank space represents sterile culture.
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the internal reservoir of the i.v. sets while they were
being used on the wards (Table 7). The results of
this survey demonstrated that many of the same
organisms which increased in 1970 were to be found
as contaminant in the i.v. fluid itself. A correction of
this situation brought a decline the next year in the
Klebsiella, Enterobacter, and Serratia organisms isolated from bacteremia.
Studies such as these are found throughout the
literature and are associated with many procedures.
We all tend to neglect these results, however, thinking our ward and office procedures are above these
dreaded possibilities; unfortunately, unless constant
in-use monitoring of these procedures is done, we
just do not know that they are.
Value of Microbial Monitoring. With this overview as background, let me restate my original questions and answer them as best I can. What patients
need to be monitored bacteriologically? Any debilitated individual under therapy or subjected to the
procedures described here should be carefully followed by clinical and laboratory methods for the
possibility of an emerging opportunistic or nosocomial infection. What areas need to be monitored?
All of the patient's environment conducive to microbial growth should be tested to insure that proper
housekeeping procedures are being carried out but
more importantly, equipment and infusions which go
directly into the internal organs should be tested for
sterility while in use. How often should monitoring
be done? As often as necessary to convince the skeptical physician that good aseptic technique in microbial clean environment is available for his patient.
The patient himself should be monitored also to
insure that endogenous organisms are not adversely
affecting him. What is the practical value of the
results of such monitoring? One direct benefit to the
patient is that such testing can alert the physician
that a particular therapeutic regimen may be altering

the microbial flora. There are also indirect benefits
as problems are identified and solved by good in-use
monitoring at the patient levels. There will be a
decrease in the number of organisms with which the
patient comes into contact. This should allow for a
decline in the number of infections. Lastly, but perhaps most importantly, microbial monitoring of
numerous patients allows the acquisition of valuable
epidemiological data which contribute to our understanding of the dynamic ever-changing world of
biology and medicine.
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Newer Techniques in Clinical Cytology:
Aspiration Biopsy and Brushing Cytology*
WILLIAM J. FRABLE, M.D.
Professor of Surgical Pathology and Director of Cytopathology,
Medical College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond

Since its introduction some twenty years ago
the Papanicolaou technique for cervical-vaginal
cytology has had a tremendous impact on the detection of precancerous lesions and in situ cancer in
the female genital tract. It has forced the clinician
and pathologist to study the "early lesions" of cancer,
particularly in the female genital tract and has
brought about a better understanding of their biology.
Cytology has over the years been extended to other
areas, particularly the respiratory tract. Two recent
areas of emphasis are the thin-needle aspiration
biopsy and direct brushing of mucosal surfaces
through the various fiber optic scopes now available,
particularly for the respiratory and gastrointestinal
tract.
Thin-Needle Aspiration Biopsy. This is an
old technique having been employed at Memorial
Center for Cancer and Allied Diseases for over
thirty years. It has never become popular in the
United States, but in the last ten or fifteen years has
become widely used in Europe, particularly in the
Scandinavian countries. At the Karolinska Institute,
approximately 12,000 such aspirations are done per
year, mainly for mass lesions of the breast, prostate,
lung, thyroid and lymph nodes. The technique renders a rapid diagnosis, particularly on benign and
malignant tumors, and is usually done on an outpatient basis. In the setting described, a saving of
time and expense to the patient is obvious.
The technique of thin-needle aspiration is done
with a narrow gauge 22 or 23 needle of various
lengths, percutaneously, without anesthesia. Because

of the nature of the needle it is nontraumatic and less
painful than a venipuncture. Important is the use
of a syringe such as the Franzen type, which may
be operated with one hand (11). The other hand is
used to fix the tumor mass and thereby control the
needle point. The type of syringe holder that will
employ disposable 20 ml plastic syringes is illustrated in figure 1.1
The needle attached to the syringe is introduced
into the mass to be aspirated without the application
of vacuum. The vacuum is applied and the needle
is moved back and forth in the mass several times.
The operator should watch the barrel of the syringe
and avoid getting material into the barrel. It is not
necessary to obtain a core of tissue, but if tissue
fragments are obtained that is an added bonus. The
idea is to obtain cells and to keep the material within
the needle.
If a cyst is aspirated this may be evacuated by
filling the syringe. If the fluid is clear it is unrewarding to process it either as a smear from the cell
button of the centrifuge specimen or by one of the
filter techniques, either nucleopore or millipore. If
the fluid is cloudy or hemorrhagic it is advisable to
process it as described, either by filter techniques or
smears from the cell button. Cell blocks are not useful but any fragments of tissue may be processed as
a biopsy. ·
Once the needle has been moved back and
forth in the mass several times the pressure in the
syringe is allowed to equalize before the needle is
removed from the mass. This is extremely important.

* Presented by Dr. Frable at the 44th Annual McGuire
Lecture Series, March 23 , 1973, at the Medical College of
Virginia, Richmond .

1 The Cameco Syringe Pistol® purchased from Precision Dynamics Corporation, 3031 Thornton Ave., Burbank,
California 91504.
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Fig. I-Syringe pistol for thin-needle aspiration biopsy.

It prevents a chance to deposit the cells along the

needle tract. The syringe is then withdrawn and the
needle is held over plain glass slides while the
syringe is removed. Air is then introduced into
the syringe, the needle reattached and a small drop or
two of material is expressed onto the slides. There is
usually enough material to make two or three slides.
Smears are prepared much in the manner of
making a blood smear, but the entire slide need not
be covered and the material may be confined in a
smaller area. Smears to be stained by the Papanicolaou technique should be immediately fixed while
still wet in methyl alcohol. Smears for May-Grunwald Giemsa stain or Wrights-Giemsa or hematoxylin and eosin are allowed to air dry. In addition,
on air dried smears we have used a metachrome B
stain with success. This is the same stain that we
employ on frozen section material. Smears prepared
in this way may be made permanent by simply washing the metachrome B stained slide with water, allowing this to evaporate and then coverslipping with
Permount®.
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European investigators have favored the hematology stains while pathologists in the United States
have favored the hematoxylin and eosin or Papanicolaou stain. I have found the metachrome B stain
combined with the Papanicolaou stain to be extremely useful.
In the aspiration biopsy technique using the
thin-needle, the clinical evaluation is extreme,ly important. Since the material is small in amount and
of a cellular type rather than a tissue fragment,
clinical evaluation of the mass and its orientation
becomes of utmost importance. The greatest success
with this technique has been when the pathologist
who is reading the aspiration has also taken the material. He has palpated the tumor mass and has a
first hand knowledge of the clinical situation. If
clinicians wish to adopt this technique and send their
material to be read by a pathologist, then they must
supply extremely detailed clinical information to
avoid errors, especially of the false positive type. The
technique has been used particularly to aspirate
lymph nodes with metastatic tumors, for breast tumors, thyroid lesions, salivary gland tumors, lung
tumors through the transthoracic route, prostate and
kidney tumors and soft part sarcomas. There has
been limited use in bone tumors. Prostate aspirations
are done transrectally with a metal guide which fits
over the examining finger and is so positioned that
the tip of the needle will pass into the mass palpated
by the tip of the examining finger.
Results. Results from several selected sites in
a large series are summarized in Table 1. One of
the most useful areas has been cervical lymph nodes,
particularly for metastatic tumors. It can be seen
that in a large series of cases there were no false
positive reports and only a small percentage of false
negative reports. Primary sites of these metastatic
tumors were equally divided between those above
the clavicle and those below (11 ) . In 3 5 % of these
cases the aspiration was the first indication of cancer (11) . Zajicek, et al. (27), obtained similar
results in 1,200 consecutive aspirations of cervical
nodes.
Two difficult areas are congenital cysts of the
neck and carotid body tumors. Engzell and Zajicek
( 8) reported the aspiration of 100 consecutive congenital cysts of the neck and compared these with
100 aspirations of cases of metastatic squamous cell
carcinoma. They made a definite diagnosis from the
aspiration in 83 % of the cysts and in 95 % of the
carcinomas. The diagnostic accuracy varied with the
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TABLE 1
THIN-NEEDLE ASPIRATION BIOPSY RESULTS IN SELECTED SITES

Head and Neck
Cervical Lymph Nodes ( 11)
Salivary Gland Tumors (4, 5, 6, 7, 26)
Benign Mixed Tumor
Malignant Mixed Tumor
Adenoid Cystic Carcinoma
Acinic Cell Carcinoma
Warthin's Tumor
Oncocytoma
Mucoepidermoid Carcinoma
Thyroid (3)
Carcinoma
Cystic Nodules
Struma
Breast (15)
Benign Nontumor
Benign Tumor
Carcinoma
Prostate (12)
Carcinoma
Lung (2)
Carcinoma
Benign conditions

* 5.3%

No. of Cases

Correct Diagnoses

False Positive

False Negative

257
368
(215)
(7)
(45)
(34)
(45)
(4)
(18)
258

93.7%

0

6.3 %

(177)

(61)
(20)
1429
(305)
(251)
(873)
IOI
125
(101)
(24)

93.0%
100.0%
66 .0%
65 . 0%
80.0%
100.0%
62.0%
94 . 0%
98 . 0%
100. 0%

4.0%
0
0
0
0
0
0
0
0
0

3. 0%
0
33.0%
35 . 0%
20.0%
0
38.0%
6.0%
2.0%
0

88.0%
89.0%
89.2%

0 . 2%
0*
0

12.0%
11.0%
10.8 %

93.6%

2.4%

4.0%

89.0%
40 .0%

0
5.0% @

11.0%
55.0%

of cases suspected as carcinoma were all histologically proven fibroadenomas

@ one case

location of the cyst, being only 5 5 % in medial cysts
and 92 % in lateral cysts. They found benign looking
squamous cells in 6% of the smears from metastatic
carcinoma.
Engzell, et al. ( 10), have reported their experience with 13 cases of aspiration of carotid body
tumors. In one case, there were no cells and in two,
metastasis was suspected from an unknown primary.
Three cases were diagnosed as neurofibroma or
neurofibrosarcoma and in seven cases a correct diagnosis of carotid body tumor was made. The authors
indicate some caution in aspirating this tumor when
it is suspected, as one of their cases became hemoplegic following the procedure.
Aspiration of salivary gland tumors has generally been quite successful by this technique as indicated in Table 1 ( 4, 5, 6, 7). Adenoid cystic
carcinoma, acinic cell carcinoma and mucoepidermoid carcinoma carry fairly high false negative rates
(26). Follow-up on benign mixed tumors indicates
no increase in recurrence rate due to the aspiration technique. In seven cases following resection,
the needle tract was serially sectioned and no tumor

cells were found ( 5). Important in the aspiration
smears in the diagnosis of adenoid cystic carcinoma
are mucinous globules. These were present in 22
of 45 patients ( 6). While the false negative rate for
adenoid cystic carcinoma over the 24-year period
of the original study is high, it has improved over
the last 11 years, being only one out of 23 aspirations or 4 % ( 6). This is true also for 34 cases
of acinic cell carcinoma in which aspirations of the
last 11 years have resulted in a false negative rate of
two in 16 or 12 % (7).
Other salivary gland carcinomas are too infrequent to document the reliability of the technique.
The most difficult has been mucoepidermoid tumors
of low grade malignancy. In the report by Zajicek
and Eneroth ( 26), 18 cases of mucoepidermoid
carcinoma yielded only cystic fluid , cell detritus and
lymphocytes. Poorly differentiated mucoepidermoid
carcinoma as well as the unclassified adenocarcinomas were easily identified by the aspiration technique.
Clinicians have been reluctant to aspirate thyroid lesions, but this has been done with considerable
success at the Karolinska Institute. R esults indicate
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no false positives in carcinoma, cystic nodules or
struma, and a small percentage of false negatives in
carcinoma and cystic nodules ( 3) .
The major area of interest in the United States
has been needle aspiration of the breast. Franzen
and Zajicek ( 15) have attained a high degree of
accuracy with this technique, not only with carcinoma, but with the benign disease. A conservative
attitude is required in dealing with breast lesions
since radiation or surgical treatment is frequently
done on the basis of aspiration diagnosis. False
negative aspirations are generally on the basis of
tumors less than 1 cm, very fibrotic, poorly cellular carcinomas or failure to aspirate the residual
mass after evacuating a cyst. With increased experience in the recent series, the false negative rate
has been cut to 5 % .
It can also be seen from Table 1 that the aspiration technique is highly accurate in prostate carcinoma. Since the approach is transrectal, there have
been a few cases, less than 2 % , of gram negative
septicemia attributable to the aspiration ( 12).
The lung has been the most recent area where
the thin-needle technique has been used. Lesions
of the lung yield grudgingly to diagnostic techniques of exfoliative cytology or conventional bronchoscopy and biopsy. Prior to the thin-needle
technique, a large bore-type needle was used with a
frequent tendency to hemorrhage, pneumothorax or
air embolism. Dahlgren (2) has used the thin-needle
technique under fluoroscopic control with only topical skin anesthesia. In 101 malignant tumor cases,
there have been no false positives and in the 24
benign conditions, only one false positive. In the
total series of 3,000 thin-needle aspirations, there
have been no complications (2). Sputum cytology
in the same material has yielded only a 40% diagnostic rate. Nasiell (22) correctly diagnosed from 83
lung cancer cases, 72 % by the thin-needle technique. About half of the false negative cases had
inadequate material. The results were better than
conventional sputum cytology. The technique is
thought by that author to be particularly good for
peripheral and small tumors or for clinically inoperable cases. The author reported no complications.
Sanders, et al. (25), also reported a large series of
164 patients with an accuracy of 84 % in malignant
neoplasms. The authors did not find the technique
accurate in nonmalignant localized parenchymal disease and not particularly good in chest wail or diffuse parenchymal disease. They did find it helpful
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in the mediastinal mass lesions, particularly pericardia!, bronchogenic or thymic cysts. They listed the
contraindications as: 1 ) hemorrhagic diathesis, 2) a
patient on anticoagulants, 3) severe pulmonary hy. pertension, 4) pulmonary hydatid cyst, 5) uncontrolled cough, 6) advanced emphysema, 7) patient
with suspected arteriovenous malformation.
These authors used the large bore needle (2.13.0 ml) and had a 30% complication rate of small
pneumothoraces. This needle is twice as large as
that recommended in the thin-needle technique from
the European workers (25). Most of these pneumothoraces were asymptomatic. Five percent in this
series, however, required tube drainage. In the
follow-up of this series, there were no verified cases
of tumors spread by the needle technique employed.
Janower and Land (20) also used the thicker
needle of the Vin-Silverman type. As expected, they
had a 10-15% minimal complication rate of hemoptysis and pneumothorax. These larger needles cannot be recommended any longer, therefore, in this
technique.
The most frequent criticism leveled at the thinneedle technique is the implantation of tumor cells
along the needle tract. Berg and Robbins ( 1), in
a 15-year follow-up of 370 cases of breast cancer
that were aspirated and 370 matched controls, found
that the long term prognosis slightly favored the
aspirated cases. This would seem to indicate no untoward effects from the thin-needle aspiration technique. Engzell, et al. (9), have also studied aspiration experimentally in the popliteal lymph node in
rabbits seeded with the Vx2 carcinoma cells. The
efferent lymphatics and efferent vein were cannulated
and material was collected during the aspiration with
massage of the lymph node. In one case out of 16,
tumor cells were found in the blood and lymph after
massage and thin-needle aspiration.
The authors (9) also reported the clinical
follow-up of 124 cases of benign mixed tumors after
ten years and found three local recurrences at 4, 5
and 9 years. No tumor was found in the needle
tract on s~rial sectioning. In addition, they studied
242 patients with prostate carcinoma who had been
followed for five years after thin-needle aspiration.
One patient of this group developed transrectal
growth three years after needle aspiration. It would
seem from these studies that this technique is safe
from the criticism of implantation of tumor cells in
the needle tract.
Brushing Cytology. The second area of cyto-
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logic investigation has been brushing cytology using the various fiber optic scopes, particularly in
the respiratory and gastrointestinal tract. In the respiratory tract, this is the outgrowth of the selective
catheterization technique of Nordenstrom and Carlens (23) and the disposable bronchial brush designed by Fennessey (13, 14).
We prefer the bronchial brushing under direct
vision using the fiber optic bronchoscope. This allows visualization of any lesion in the major and
most of the secondary bronchi as well as the respiratory excursions. Any lesion seen may be sampled directly and the brush may be pushed into the
parenchyma of most of the bronchial segments for
peripheral sampling. Our experience to date, involves
39 cases with cytologic abnormalities, including 16
carcinomas mostly of the squamous type and 18
cases with various atypias of reserve cell hyperplasia,
squamous metaplasia or bronchial hyperplasia. We
have had four unusual cases as follows: cytomegalic
inclusion disease in a transplantation case, pneumocystis carinii in a patient with myeloma, adenovirus
infection and the identification of ferruginous bodies
along with atypical alveolar pneumonocytes.
We have had the best success in smear preparation by having a technologist available in the room
where the brushing is being done to make the smears.
Two or more smears are made using totally frosted
Dakins slides 2 which have been premoistened with
ethyl alcohol. These are immediately fixed in 95%
ethyl alcohol. Just because the slides are damp, cellular material is not lost and drying artifacts which
occur very rapidly with bronchial epithelial cells are
avoided. This is extremely important. Failure to follow this simple technique will result in poor quality
smears and will discourage the physicians from using
this very valuable technique. Following the making
of the smears, we shake the brush in a small amount,
10 ml, or physiologic saline or Polysal®3 ; from this
material filters are prepared, either nucleopore or
millipore. The material is all stained by the Papanicolaou technique. If fragments of tissue ar.e obtained,
as they occasionally are, they may be processed as a
biopsy.
The results from several series are reported in
Table 2 (16, 17, 18) . A false positive rate has been
obtained in these series of less than 1 % or one
2 Trident Microscope Slides-Rectangular Dakin, Aloe
Scientific, St. Louis, Missouri 63103.
3 Polysal®
Balanced Electrolyte Injectable. Cutter
Laboratories Inc., Berkeley, California 94710.

case. The best results are reported by Hattori et al.
( 18), who attained an accuracy of 91.6 % in 12
cases of lung cancer. In this series there were no
false positive cases. Even in the community hospital
where there might not be special interest in this technique, Funkhouser and Meininger ( 17) reported
70% accuracy. Combining this with bronchial and
sputum exfoliative cytology, an overall accuracy of
83 .8% was obtained in the diagnosis of lung cancer.
Contraindications to the technique as outlined
by Janower and Land (20) are patients who
are in poor general condition or who cannot tolerate
any bronchial irritation. The advantages to the technique, in our opinion, are that the quality of the
material is greatly improved from the cytologic point
of view. Secondly, a more specific diagnosis can be
rendered, particularly in inflammatory and infectious
conditions. Thirdly, secondary segmental bronchi
and peripheral lesions can be reached and bronchi
can be selectively sampled, particularly in "early"
lung cancer cases.
The technique is also very valu able in lesions
of the esophagus and stomach. The Japanese have
pioneered the technique through their use of fiber
optics. In their hands, with the early diagnosis of
gastric cancer by this method, they have reported a
survival in 365 patients of 92.5 % for five years
( 19). While this technique has not generally been
used in the United States, the results reported by
Prolla et al. (24), summarized in Table 2, are
quite impressive. The false positive rate is very low
and is better than conventional lavage cytology. The
false negative rate is much lower than the conventional lavage cytology. The advantages are the simultaneous brushing with endoscopy. The cytology is
selected from the lesion seen. The cytologic procedure takes only a short time in contrast to the
collection, preservation and centrifugation for conventional lavage cytology. The preservation and cellularity of the material is much better and there are
no complications (21). Our own experience with
this technique in a limited series to date would confirm all of these findings. Particularly to be stressed
is that the quality of the material cytologically is
much improved.
Summary. Reviewed in this paper are two cytologic techniques, thin-needle aspiration and brushing cytology, which have added immeasurably to the
diagnosis of particularly malignant disease in a variety of areas. The advantages of the techniques are
that they bring the cytology closer to the source of
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TABLE 2
BRUSHING CYTOLOGY
RESULTS IN SELECTED SITES
No. of Cases
114
Bronchi and Lung* (16, 17, 18)
269
Stomach and Esophagus (24)
(54)
Carcinoma and Lymphoma
(215)
Benign Conditions
* Combination of three series
t No false negatives among malignant tumors
@ One case

the lesion, particularly in the brushing cytology; the
quality of the material is much improved over conventional cytologic techniques and the complications
to the patient and the expense of the procedures are
minimal.
Author's note: Grateful acknowledgment is given
to Mrs. Harriet Kent who prepared the manuscript.
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Laboratory Aspects of Venereal Disease*
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Richmond

Introducing the laboratory aspects of venereal
diseases, I would like to define the criteria according
to which certain infectious diseases are considered
to be "sexually transmitted." The expression "sexually transmitted disorder" is less weighted with
moral overtones than the term "venereal" and may
therefore be more acceptable to both medical practitioners and the general public.
Sexually transmitted diseases are best considered as a group of lower genitourinary inflammations related to sexuality, rather than in the narrower
sense of two or three disorders associated mainly
with sexual promiscuity. Not all lower genitourinary
tract infections are characterized by a discharge, but
those which are may be due to a variety of causes.
When these infections are caused by a microorganism which exists primarily in the genital epithelium,
that infection is rarely transmitted except by sexual
intercourse. Intercourse must, therefore, have taken
place with an individual already infected who had
contracted the disease in the same way. On the other
hand, when the responsible microorganism might
possibly exist in other sites, although usually sexually transmitted, coitus with an infected individual
is not essential. Both conditions, however, are
strictly "venereal."
Although many different microorganisms or
parasites may be sexually transmitted, only those
commonly transferred in this manner oan be said to
be venereal. A list of microbial agents associated
with venereal disease is shown in Table 1. Only the
diseases caused by those agents which appear in
italics are reportable in this country, according to the
U. S. Public Health Service. There is, however, a
difference from country to country as to which

* Presented by Dr. Escobar at the 44th Annual McGuire Lecture Series, March 22, 1973, at the Medical College of Virginia, Richmond .
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venereal diseases are notifiable. A few of these
diseases are endemic in almost every part of the
world. Some of them, notably syphilis, have become
sporadic in certain countries.
The disruption of the natural clinical and immunological responses of the infected individuals by
the liberal use of antibiotics places a greater responsibility on the interpretation of laboratory results
and on the judicious performance of serological tests
in the absence of clinical signs. As far as we know,
no treponemal resistance has yet arisen to the antibiotics usually recommended. Nevertheless, higher
doses of antibiotics are considered more essential
today than two decades ago.
Ulcerative and vesiculopapular lesions of the
genitalia are commonly secondary to infective causes
within the lower genitourinary tract, or are due to
such lesions as herpes simplex, thrush or scabies.
Chancroid and the conditions discussed along with
it are becoming less common; their importance lies
in the necessity to exclude syphilis. The cause of
urethritis, vaginitis or cervicitis cannot always be
determined. Consideration must be given to such
factors as trauma, irritation, allergy and primary or
secondary infection. It is often possible to make an
etiological diagnosis, or at least an assessment of the
probable cause, after both partners have been seen
and examined. The incidence of these conditions
shows no sign of diminishing. The inflammation resulting from sexually transmitted infection varies
greatly in severity and extent. The potentially most
damaging disease is syphilis, which unless treated, is
frequently a life-long disease and may also infect the
fetus in utero. Other infections presenting as sores
which include chancroid, granuloma inguinale and
lymphogranuloma venereum result as a rule in few
complications. Any infectious discharge from the
genital tract may proceed to a variety of complica317
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TABLE l
MICROBIAL AGENTS OF VENEREAL DISEASE

Protozoan:
Yeast-like:
Mycoplasma :
Bacteria:

Bedsonia:
Virus:

Trichomona vagina/is
Candida albicans
M . hominis, "T" strain
Trepo11ema pal/idum
Neisseria go11orrhoeae
Haemophilus ducreyi
Donovania gra11u/omatis
Lymplwgranuloma venereum
Trachoma-inclusion conjuctivitis
Herpes hominis, type 2

tions, local or general, mild or severe. About 5 %
of males with gonorrhea seen in the venereal disease
clinics are asymptomatic. Eighty percent of females
with gonorrhea, however, are asymptomatic and remain in the population as an infectious reservoir.
Gonorrhea in the male is predominantly symptomatic, motivating most patients to seek medical attention (5). The principal disorders which occur are
inflammations of the pelvic organs and tissues and
their sequelae, or rheumatism and arthritis.
If asked about the type of microorganisms associated with venereal disease, probably many would
refer immediately to syphilis and gonorrhea and state
that chancroid and lymphogranuloma venereum are
not commonly found in medical practice. As a matter of fact, even recent textbooks on the subject of
microorganisms associated with venereal disease
refer to agents such as Chlamydiae (trachoma-inclusion conjunctivitis (TRIC) agents and lymphogranuloma venereum, mycoplasma, Candida albicans and
Trichomonas vaginalis, but fail to add herpesvirus to
the list. I wish to emphasize, however, that TRIC
agents and lymphogranuloma venereum are not viruses and are infrequent etiological agents of venereal
disease. On the other hand, during the last several
years, herpes simplex (also called herpes hominis),
type 2, has been shown here and elsewhere to be sexually transmitted and of high incidence in the general
population. More importantly, it has been incriminated in uterine cervical carcinoma in connection
with coitus, showing an increased frequency where
there is an earlier onset of sexual intercourse, a large
number of sex partners and when the individual
remarries in later life.
Because of the limited amount of time available
for a comprehensive discussion on the laboratory
aspects of all venereal diseases, I will comment only

briefly on those infections of minor clinical importance or on those which occur only rarely in this
country. The sequence in which these will be presented, however, does not necessarily correlate with
their frequency of occurrence. Trichomonas vaginalis
is a common cosmopolitan parasite of both males
and females. Infection rates vary greatly but may be
high in some areas especially where female hygiene
is poor. Coitus is the common mode of transmission,
but contaminated towels, douche equipment, examination instruments and other objects may be responsible for some new infections. Infants may be infected at birth. Most infections in both sexes are
asymptomatic or cause minor symptoms. Control
of this parasite requires detection and treatment of
the infected male sexual partner at the same time
that the infected female is treated. Laboratory diagnosis consists of microscopic examination of vaginal
or urethral secretions or discharge for characteristic
motile trichomonads. Dried smears may be stained
with hematoxylin or one of the Romanowsky stains
for later study. Culture of vaginal or urethral discharge, of prostatic secretion or of a semen specimen may be indicated when direct examination is
negative.
Candida albicans is probably one of the most
common causes of vulva! and vaginal symptoms,
flourishing particularly in pregnancy, following antibiotic therapy and when glycosuria is present. A
low-grade urethritis and balanoposthitis in men not
infrequently accompanies a genital candida infection
in their consorts. Fresh wet preparations of the
vaginal fluid mixed with 10% potassium hydroxide
or Gram-stained vaginal smears may lead to the
detection of yeasts or blastospores or, less commonly,
filaments or hyphae can be seen.
Mycoplasma hominis and T strains are yet to
be conclusively demonstrated as the primary etiological agents of genitourinary infections. Some
mycoplasmas are inhabitants of the normal genitourinary tract, especially in females. Moderately high
serum antibody titers to Mycoplasma hominis and
T strains (tiny colonies, requiring 10% urea for
growth), however, can accompany their presence
and they have been cultured occasionally from focal
genital abscesses. Special enriched media are required for growth. These organisms are inhibited by
tetracycline but not by penicillin in clinical dosages.
This is consistent with the clinical response to therapy of a significant proportion of patients with a
nonbacterial inflammation.
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Chancroid, granuloma inguinale and lymphogranuloma venereum are sexually transmitted in a
large proportion of cases. They are usually described
together since they are usually associated with
genital "sores." They are relatively rare and are
most prevalent in warmer climates or seaboard cities.
Haemophilus ducreyi, the cause of chancroid,
can be detected by smears or cultures from a suppurating ulcer which usually show a mixed bacterial
flora, including Gram-negative rods in chains. Serologic tests are rarely done. The Ducrey skin test
(Haemophilus ducreyi suspension) usually is positive
within three-to-five weeks after infection. A positive
skin test, however, cannot differentiate between old
and recent infection.
Donovania granulomatis, the cause of granuloma inguinale, can be cultivated in complex bacteriologic media but this is rarely attempted in
practice. Histologic demonstration of intracellular
"Donovan bodies" in biopsied material most frequently supports the clinical diagnosis. Serologic
tests are not useful. Lymphogranuloma venereum
can be recovered by inoculating pus from suppurating lymph nodes into embryonated eggs but the
procedure is not practical. Serologic tests, usually
complement-fixation, can demonstrate a fourfold
antibody titer rise between paired sera collected two
weeks apart. The Frei skin test is frequently used to
support the clinical diagnosis and it usually becomes positive two-to-three weeks after infection and
remains positive for life, but recently the test has
been negative in a significant proportion of proved
infections. This skin test reflects reactivity to a groupspecific antigen which is shared by all members of
the group. Past infection with psittacosis or trachoma,
therefore, may give rise to a positive Frei test as
readily as past infection with lymphogranuloma
venereum.
Inclusion conjunctivitis usually manifests itself
as an acute conjunctivitis of the newborn, or as a
venereal disease and eye infection of adults. Immunofluorescence of Giemsa-stained smears of
scrapings from the eye, the cervix, or the male
urethra may show typical crescent-shaped inclusion
bodies in epithelial cells. Culture in irradiated cells
may permit isolation of chlamydiae.
From 1947 to 1955, one of the most dramatic
and precipitous declines in the history of our country
in the reported morbidity of a chronic, social, communicable disease was recorded. This disease was
syphilis. Since 1955, a pronounced upward trend
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has been observed for syphilis, occupying together
with gonorrhea a very prominent place among the
ten chief causes of morbidity as illustrated in figure
1. There is also growing divergence between the
curves representing the incidence of syphilis and of
gonorrhea, with a greater rise in the latter. The
majority of undiscovered syphilis in the past, today
and for the foreseeable future is latent syphilis which
presents no signs, symptoms nor findings in the
patient other than those demonstrated by appropriate
serologic testing. The value of a serological test
depends on its sensitivity (ability to react in the presence of syphilis), specificity (inability to react in the
absence of syphilis), and reproducibility. The types
of serologic tests for syphilis are listed in Table 2.
The fluorescent treponemal antibody-absorbed
(FTA-ABS) is the most sensitive test available. It
becomes reactive early in primary syphilis, and it
remains positive almost always indefinitely even after
apparently adequate therapy. Occasional false
positive results have been reported, but rarely in
more than one percent of cases. Venereal Disease
Research Laboratory (VDRL), Kolmer complementfixation (KCF), and Kolmer Reiter protein (KRP)
or Reiter protein complement-fixation (RPCF) are
less sensitive and less specific. In numerous conditions, both acute and chronic, the reagin or nontreponemal tests react nonspecifically in 30-40%
of late or inadequately treated cases of syphilis; these
tests are nonreactive. Our own clinicolaboratory
studies at the Medical College of Virginia have confirmed these findings. Figure 2 illustrates graphically
the humoral immune responses, as detected by the
FTA-ABS and the VDRL tests, respectively. Observe that, unless one is dealing with a biological
false positive result, a reactive VDRL is always
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tivity comparable to that of the blood FTA-ABS.
For the sake of brevity, I would like to refer the
reader to three major publications resulting from
clinicolaboratory studies done in our institution ( 1,
2, 4). Recommendations for the use of these tests
can be found there and in some more recent work
presented at the American Society of Microbiology
Annual Meeting held in Philadelphia in April 1972
(3). The effect of antibiotic therapy on antibody titer
can be seen in figure 3. No posttherapeutic change
can be observed for the FTA-ABS, but the VDRL
reactivity gradually disappears after treatment during a period of time proportional to the length of
active syphilis infection; that is, the longer the active
infection, the longer the time required for serological
reversion from reactive to nonreactive.
The number of reported cases of gonorrhea
from 1950 to 1972 is shown in figure 4, which

DISTRIBUTION OF REPORTED CASES OF
GONORRHEA DURING 1950 TO 1972 IN THE US.A.
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accompanied by a reactive FTA-ABS. A nonreactive
VDRL together with a reactive FTA-ABS, however,
may occur in early primary or late syphilis. No
reagins can be found in about 40% of untreated
patients with tertiary syphilis whose FT A-ABS antibodies are present for life.
Among the complications of late syphilis, neurosyphilis has been particularly difficult to diagnose,
due to the lack of sensitivity of certain laboratory
tests such as the VDRL and treponema pallidum
immobilization (TPI) , the obscurity of the clinical
symptoms, the rising incidence of its atypical forms
and the well-known occurrence of nontreponemal
seronegative neurosyphilis. The FT A and FT A-ABS
tests were first adapted for use with cerebrospinal
fluid (CSF) at the Medical College of Virginia, demonstrating considerably higher specificity of the FTA
for the CSF than for blood with a degree of sensi-
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indicates an upward trend in the incidence of gonorrhea in the United States, as in other parts of the
world; thus, gonorrhea has become the leading reportable disease in this country. For example, an
incidence of 137 cases of gonorrhea per 100,000 in
1957 had risen to more than 307 per 100,000 in
1971. Also, it is well known that the actual number
of cases of gonorrhea is almost four times the total
number reported to health authorities by all sources.
The age-specific case rates by sex in the United
States during 1971 are illustrated in figure 5. One
of the major problems in the control of this disease
is the existence of a large number of unidentified
asymptomatic females estimated to range between
640,000 and 1,000,000 cases. The comparative sensitivity of the Thayer-Martin medium versus smear
techniques using cervical specimens is 88 % and
54%, respectively. A list of cultural diagnostic techniques is presented in Table 3. Presumptive and
definitive tests are included. Although serological
procedures are still under evaluation, complementfixation tests are sometimes performed on individuals
with negative cultures who are suspected of harboring chronic gonococcal infection. These tests, however, lack specificity and reliability. Antibodies
detected by immunofluorescence are promising in
gonococcal arthritis.
Intensified research is required on the biochemical and immunological aspects of venereal diseases.
This research might soon lead us not only to a simplified serologic screening test for gonorrhea (the absence of which in a large part accounts for the rise in
its incidence as compared to syphilis) but might also
lead to an immunizing procedure against treponemal
diseases such as syphilis. For years attempts at controlling gonorrhea were abandoned in favor of "treat-
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TABLE 3
PRESUMPTIVELY POSITIVE CULTURAL DIAGNOSIS

Typical Colonial Morphology
Oxidase-Positive Colonies
Gram-Negative Diplococci
DEFINITELY POSITIVE CULTURAL DIAGNOSIS

Sugar Fermentation Reaction
Fluorescent Antibody Staining

ing it out" of existence with increasingly larger doses
of penicillin. A decade ago the less sensitive strains
requiring 0.1 unit of penicillin per ml for inhibition
in vitro were extremely rare in clinical practice, but
strains requiring 0.5 unit per ml are now common.
Today many strains of gonorrhea are so resistant to
penicillin that a dose so large as to approach the
outer limits of safety is needed to effect a cure.
The recent recognition of the relatively frequent
sexual transmission of herpes simplex and its association with cervical carcinoma following the improvement in virological techniques suggests the important role of viral agents in venereology. The tests,
specimens required and time needed for the laboratory diagnosis of herpes simplex infection are listed
in Table 4. Most of these procedures are performed
routinely in our laboratory, including those for the
differentiation of types 1 (oral) and 2 (genital).
Other viruses may with time be shown to be
sexually transmitted under certain circumstances,
such as the hepatitis virus. Progress cannot be made
against any of the venereal diseases without interdisciplinary cooperation between the venereologist
and other medical specialists such as obstetricians,
gynecologists and general practitioners. At the same
time, cooperation of these individuals with public
health workers, epidemiologists and researchers as
well as with the teacher, health educator and social
worker must be forthcoming not only at the patient
and institutional level, but also on an interstate,
national and international basis. The paramount importance of transfrontier cooperation is illustrated by
a recent report of a California prostitute with secondary syphilis who kept a diary. It was found that
among some 310 males who were involved as contacts, 168 (all long distance truck drivers) were
traced. This threat of spreading disease extended
over 34 states in this country and into Canada and
Mexico. This epic of epidemiology was written by a
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LABORATORY METHODS FOR HERPES SIMPLEX VIRUS (HSY)
Method
Light microscopy for
multinucleated giant
cells and inclusion
bodies,
Immunofluorescence
for antigen
Electronmicroscopy
for viral particles
Tissue culture* for
virus isolation
Serology for antibodies
Histology

Specimens

Time
Required

Scrapings from base of f-1 hr.
lesions on glass slides

Vesicle fluid, scrapings,
biopsy of brain or
other tissue
Vesicle fluid, scrapings,
biopsy of brain, liver
and other organs
Vesicle fluid, scrapings,
CSF, biopsy or postmortem tissues
Acute and convalescent sera (at least a
week apart) CSF
Biopsy or postmortem
tissues in fixative

staff reporter and appeared in a periodical infrequently seen by "highly dedicated physicians"namely the Wall Street Journal (1970).

2 hrs.

1- 2 hrs.

24- 96 hrs.

24 hrs.

24 hrs.

* Special procedures (plaguing, type of CPE, etc.)
available for differentiation of HSY-I from HSV-2.
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The information gained through the autopsy
has played an important role in the evolution of
knowledge of human disease. At the time of Semmelweiss, bedside symptoms and signs plus postmortem examinations were the only investigative
tools available to study and understand the causes
and progression of disease, to assess the efficacy of
therapy and to monitor the quality of medical care.
Feedback provided by postmortem examination was
highly instrumental in the development of physical
diagnosis. The autopsy was virtually the sole means
of classifying disease. In the process, the autopsy
spawned and furthered the development of almost
every contemporary technique for the diagnosis of
disease of which radiology and electrocardiography
are notable examples. Once developed and refined,
such clinical sciences have assumed a direction and
ideology aimed at the living patient and paradoxically, the contribution of the autopsy to patient care
has steadily diminished. Advances in the clinical sciences have depended more on achievements made in
biologic science and less on necropsy in large part
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because modern biological techniques have not been
employed in postmortem examinations. As a result,
the clinical sciences have been cut loose from the
conceptual base previously provided by information
obtained at autopsy.
The autopsy has provided, and still provides, the
stimulus for many attempts to reproduce disease in
experimental animal models. This approach has become increasingly difficult, however, in the case of
human disease, principally shock. The study of
some pathological states in animal models requires
testing in several species and final confirmation in
man before this knowledge can be applied to living
patients. In our studies the application of cell biology
techniques at autopsy has permitted the generation
of new hypotheses which are more amenable to further exploration in experimental models and can be
more precisely related to human disease.
The chief limitation for the interpretation of
observations made in the routine autopsy is caused
by the delay in obtaining tissue following somatic
death. The resultant autolytic changes invalidate most
ultrastructural, biochemical and functional studies.
Investigations utilizing contemporary refined techniques from the experimental laboratories of university pathology departments are, however, the very
ones needed to restore the postmortem examination
to a primary role in patient care and in quality con-
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trol of health care. The use of biopsy obviates time
delay. While much valuable information can be and
is obtained from biopsy, there are distinct limitations:
a) The small size of biopsies restricts the number of
analytical techniques that can be applied; b) Often,
medical indications for biopsy do not outweigh the
risks involved for seriously ill patients; c) Finally,
the fact that complete organ sampling cannot be
performed make this contribution of limited value
in the study of systemic disease.
A potential limitation in applying an immediate
autopsy technique is the selection of patients for any
contemplated multidisciplinary approach. The voluminous data generated by intensive care units have
made valuable contributions to medical knowledge
and patient care, yet little of these data has been
related to phenomena at the tissue and cellular level.
It seems logical then to direct an intensive approach
to this population of patients. Especially needed, we
feel, are morphologic, biochemical and functional
observations on tissues removed immediately after
death in order to correlate them with clinical data.
The initial objective of the immediate ·autopsy
is directed to the evaluation of cellular and subcellular changes in major organ systems in cases of shock.
Shock frequently accompanies trauma and constitutes a significant determinant of the posttraumatic
morbidity and mortality, a major cause of death.
Antecedent diseases resulting in shock are legion and
shock is a component of the terminal phase of numerous illnesses of many causes. Morphologic techniques used in the routine autopsy do not permit
separation of the cellular effects of shock from the
effects of certain underlying diseases which cause
shock. For example, in acute myocardial infarction
with cardiogenic shock it is often impossible to distinguish the extent of primary myocardial injury from
the damage secondary to shock. Although we know
that there are common pathways of cellular reaction
to a diversity of injurious agents, variations exist.
Our studies have demonstrated that a distinction can
be obtained between the effects of antecedent disease and the effects of shock when precise clinical
data are correlated with ultrastructural, biochemical
and functional assays at immediate autopsy. This
permits better understanding of the cellular shock,
which is of importance in the utilization of autopsy
technique to the study of other diseases. Without
knowledge of the changes resulting from shock, adequate evaluation of autopsy data in other diseases
may be difficult or impossible.
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The Immediate Autopsy Program at the University of Maryland is conducted by the Pathology Department in conjunction with the Maryland Institute
for Emergency Medicine. The primary purpose of the
program is to document and clarify the pathological
changes leading to organ failure in cases of shock
and trauma. This paper demonstrates that tissues
obtained at immediate autopsy yield valid observations on the pathogenesis of cellular injury in shock.
Methods have been discussed in detail elsewhere (5);
the autopsy procedure, however, will be briefly outlined below.
Immediate autopsy is made possible by two
legal instruments existing in the State of Maryland:
a) the Medical Examiners' Law which charges the
Medical Examiner with the responsibility of determining the cause of death and investigating medicolegal and biological factors in deaths due to violence, traffic accidents and unexplained natural death;
b) the Anatomical Gift Act, similar to laws enacted
in many states and aimed at obtaining organs for
transplantation, whereby the patient or his next of
kin can give permission for autopsy prior to death.
All the individuals studied include cases of
"brain death" as determined by the Harvard criteria ( 1). Once somatic death is determined by the
absence of heart beat, pulse and respiration, as well as
an isoelectric EKG, the rapid sampling phase of the
immediate autopsy is begun. The prosector, together
with the ten-member team, does a rapid sampling of
several organs for study by light and electron microscopy, immunofluorescence, enzyme histochemistry
and studies of organelles after homogenization and
differential centrifugation. Following the rapid sample phase, a routine autopsy dissection is performed.
Simultaneously, the intracranial contents are
perfused in situ via polyethylene tubing inserted
through the right common carotid and after ligation
of the three other major cervicocranial arteries. The
fixative is composed primarily of aldehydes.
Concepts of Cell Injury. Since Rudolph Virchow's famous papers of about one hundred years
ago, we think of disease in terms of cellular changes,
and define disease as the summation of the effects of
injury as well as the responses of cells to injury. Injury is defined as an event that alters cellular homeostasis. If the injury is lethal, such as complete ischemia
or anoxia, there will be a reversible phase prior to the
time of cell death. If the blood supply or oxygen are restored during this reversible stage the cell can recover, return to the normal state of homeostasis and
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continue functioning. At some point, however, damage
becomes irreversible and the cell is said to die; even if
the blood supply is restored recovery does not occur.
Instead, the cell undergoes necrosis and gradually
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approaches equilibrium with the environment. Thus
there is a reversible and an irreversible phase
following a lethal injury. Shown in figure 1 are some
of the key organelle changes which characterize these

.
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TIMEFig. I-Stages of cell injury. This diagram represents a conceptualization of the results of cell injury. Time is plotted along the abscissa
and the range of homeostatic ability along the ordinate. An injury is applied at the arrow. This injury may be sublethal or acutely
lethal. Lethal injury will be considered first. Curve C represents a homeostatic ability. Recovery can occur, however, if the injurious
stimulus is removed prior to the point of cell death. Such recovery may proceed along the curve C' or C". Stages 2 and 3 represent
progressive changes during this period. Stage 2 is characterized by dilatation of the endoplasmic reticulum and slight clumping of the
nuclear chromatin. Some ribosomes may also be detached from the endoplasmic reticulum and the entire cell may be slightly swollen.
Condensing of the mitochondria, additional swelling of the cell and the appearance of blebs along the cell membrane are characteristic of stage 3. After the point of cell death, recovery can not occur even if the injurious stimulus is removed and the cell is said
to enter the phase of necrosis. Stages similar to those in stage 3 occur in stage 4. In stage 4, however, some mitochondria are markedly
swollen, others have portions that are condensed and other portions that are swollen. Stage 5 depicts a typical morphologic picture
of cell necrosis during which the cell undergoes degenerate degradation by autolysis and denaturation. In this and later stages, myelin
figures appear along the cell membrane, intracellular membrane systems are fragmented, interruptions occur in continuity of the
plasma membrane and the mitochondria show high amplitude swelling of the inner compartment with prominent flocculent densities.
Lysosomes are probably beginning to leak at this point although they may still appear intact. In some injuries, the cell is able to adapt
even to the presence of continued injury by attaining some altered steady state. This is depicted as curve B. A common sublethal
adaptation in which numerous secondary lysosomes are filled with digestive debris is represented in stage 2A. Note that incomplete
recovery during the reversible phases after lethal injury might also result in a new steady state depicted by the right-hand limb of
curves C' and C". From Trump, B. F., et al. (6). Used by permission.
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phases as observed in studies of experimental animals. For example, one of the earliest changes that
occurs following injury is dilatation of the endoplasmic reticulum (ER), which is associated with
early ion and water shifts within the cell. These
constitute a manifestation of reversible injury. Thereafter, the inner compartment of the mitochondria
undergoes condensation probably due to potassium
loss from that compartment; this, too, is reversible
and if blood supply is restored, the cell can survive.
Cells that are past the "point of no return" or have
entered the phase of necrosis typically show massive
mitochondrial swelling with formation of dense matrical inclusions in the inner compartment, presumably
due to denaturation of matrix protein. The permeability of the cellular plasma membrane leads to increased levels of intracellular enzymes in the plasma.
These enzymes include glutamic oxalacetic transaminase and lactate dehydrogenase. Nuclei swell and
undergo karyolysis. In late phases of necrosis lysosomal enzymes such as acid phosphatase can be demonstrated in the serum.
Immediate autopsy vs. routine autopsy. The
state of preservation of tissue, in this case liver,
removed at immediate autopsy within minutes of
death (fig. 2), is contrasted with a sample of liver
removed from the same patient after the customary somatic death-fixation interval ( 12 hours) had
elapsed (fig. 3). A "differential necrosis" of centrilobular zones is noted in the later specimen which
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is not present in the immediate autopsy sample.
Given only the routine sample, this could lead to
the erroneous conclusion that a terminal episode of
shock in this patient together with two earlier episodes had resulted in extensive central and midzonal
hepatic necrosis.
Instead, chronic injury over a one-month period
had resulted in a differential accumulation of lysosomes in centrilobular hepatocytes. Lysosomes were
precisely localized with an enzyme marker, acid
phosphatase, in the immediate specimen, but diffuse
reaction characterized the routine sample. Study of
the immediate sample by electron microscopy revealed enlarged lysosomes in this human liver (fig.
4). The remarkable degree of good ultrastructural
preservation obtained is evident and demonstrates
the feasibility of applying this technique to the study
of human disease. In a series of such p atients sustaining repeated episodes of shock, rather striking
increases in the amount of chemically assayed acid
phosphatase have been found in liver homogenates
as compared with patients not sustaining or in cases
with a single acute injury or shock (7). The numerous large lysosomes in liver cells contain various
types of debris much of which presumably resulted
from what is called autophagocytosis, a situation
whereby normal organelles, such as mitochondria,
are segregated within the lysosomal system and are
digested. This phenomena of autophagocytosis occurs through budding of portions of cytoplasm into

Fig. 2- (left) Light micrograph of centrilobular cell of liver from a 48-year-old man who had suffered several episodes of shock over a
32-day period. Note the excellent state of preservation of hepatic parenchymal cells. Note, however, that many of these cells contain
easily visible, eosinophilic cytoplasmic inclusions. Paraffin embedding, H & E, X 345. Fig. 3-(right) Portion of liver from the same
case from the routine autopsy taken 12 hours later. Note that in this picture typical coagulation necrosis of some of the centrilobular
hepatic cells can be seen. Paraffin embedding, H & E, X 345.
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Fig. 4-Electron micrograph taken from a specimen fixed at immediate autopsy from the same case shown in figure 2 illustrating
numerous large single membrane-bound inclusions in the hepatic parenchymal cells. These inclusions contain a variety of debris
principally lamellar and are interpreted as residual bodies (RB) resulting from incomplete digestion of material entering the lysosomal
system by autophagy and / or heterophagy. Nucleus (N), mitochondria (M), X 12,000.

intracellular cavities such as the endoplasmic reticulum followed by pinching off of the bud releasing the
segment of cytoplasm containing sequestered organelles and fusion with primary and/ or secondary lysosomes. This rather complex process involving cell
membrane movements is ATP-dependent and can be
reproduced experimentally by administering glucagon.
In the case of the rat model it appears that the
glucagon-induced autophagy is mediated through
cyclic AMP. It is entirely conceivable, therefore,
that in this particular patient, as well as in others with
shock, the increased autophagy is the result of changes
in hormonal levels; for example, increased levels of
glucagon in the plasma. With digestion, lipids are released giving rise to phospholipid bilayers sometimes
called "myelin figures ." The lysosomes in this patient

superficially resemble those seen in many of the "lipid
storage" diseases, such as the gangliosidoses in which
various types of cellular debris accumulate on the
basis of a lysosomal enzymatic defect. In this case
presumably there is no enzymatic defect, but rather an
overloading of the system due to induced autophagocytosis. This results in cells which are not killed but
are perturbed by the initial injury. Autophagocytosis
can be defined as a manifestation of sublethal injury.
Only an occasional hepatocyte was "necrotic" in the
immediate specimen, a fact which cannot be validly
assessed from the routine sample. The observation
that necrosis was more advanced in the routine ( delayed) sample is interpreted as the effect of increased
digestion by lysosomal enzymes following postmortem ischemic necrosis. In a sense, therefore, these
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Fig. 5-(left, top) Light micrograph of renal cortex from a 28-year-old man who did not have shock, but died following severe head
injuries. Note good preservation of renal corpuscle from the proximal tubules (PT) and distal tubules (OT). Paraffin embedding, H &
E, X 345. Fig. 6- (left, bottom) Semithin section from the same case shown in figure 5 illustrating the increased cytologic detail
visible with this technique. Note that now the brush border (BB) can be fairly delineated and numerous granules, most of which are
mitochondria (M), can be seen in the cytoplasm. Note also the lysosomes (Ly). The basement membrane (BM) can be clearly seen
along the outside of the tubule. Tubular lumen (TL), nucleus (N). Epon embedding, toluidine blue, X 865. Fig. 7-(right, top) Light
micrograph of the renal cortex from a 16-year-old girl who died six hours after an anoxic episode. Note the normal appearance of
the renal corpuscle (RC), proximal tubules (PT) and distal tubules (OT). One collecting tubule (CT) can be seen. With this technique
the tubules appear within normal limits. Paraffin embedding, H & E, X 345. Fig. 8-(right, bottom) Semithin section from the same
case. Note again the increased detail. Now, however, it is evident that the tubule-is not within normal limits but that the mitochondria
are swollen and have small extrinsic densities (free arrow) apparently equivalent to the flocculent densities seen in electron micrograph.
Epon embedding, toluidine blue, X 865.

liver cells .with more lysosomes become somewhat
like the normal pancreas which is known to undergo
much more rapid autolysis following death.
High Resolution Light Microscopy. Much additional information can be obtained when tissue for
light microscopy is embedded in epoxy resins as a
supplement to routine paraffin embedding. The structure seen in paraffin, as opposed to plastic embedded
immediate samples of kidney from a patient who did

not die in shock (figs. 5, 6), are contrasted with a
similar sample from a patient having a single acute
terminal shock episode (figs. 7, 8). Generalized cell
swelling (both cytoplasmic and nuclear) can be noted
in either paraffin or plastic embedded kidney from
the shock patient but can be more precisely assessed
in the plastic embedded specimen. Paraffin embedding results in comparatively poor preservation of
cellular structures. Numerous rounded bodies are
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noted within the cytoplasm of the plastic embedded
proximal tubule cells in both specimens. These are
mitochondria but are not readily visualized in the
paraffin sections. Furthermore, the mitochondria in
the shock kidney cells (fig. 8) are notably larger
and even exhibited punctate densities in epoxy semithin sections. Using electron microscopy ( fig. 9),
mitochondria are markedly swollen and exhibit flocculent matrix densities; there are features characterizing acute lethal cell injuries as derived from
varied model experiments in vivo or in vitro ( 5) .
The close correlation between light and electron
microscopy is then obvious and the light microscope
can thus be employed to evaluate tissue samples
larger than those that can be meaningfully studied
by electron microscopy.
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Correlation of Organelle Structure and Function. The immediate autopsy approach further permits a valid assessment of mitochondrial function
which is of profound importance in the pathogenesis
of cell injury in shock because mitochondria often
seem to be the deciding factor for cell survival.
Whether or not the mitochondria can recover and
make ATP following treatment of the cause of injury
seems to be the crucial question.
Mitochondria can readily be prepared from the
immediate autopsy specimens. Tissue is removed
and shortly thereafter homogenized and centrifuged
to obtain a mitochondrial suspension. Mitochondrial
function is then assayed using an oxygen electrode.
The chamber is designed so that substrates and
ADP can be added to the mitochondria suspension

Fig. 9- Electron micrograph of proximal tubules from the same case showing stage 5 changes as depicted in diagramatic form in
figure 1. Note the markedly swollen mitochondria (M) with flocculent densities (free arrow). Fragmentation of cisternae of endoplasmic reticulum (ER); nuclei (N) which show marked clumping of chromatin and several apparently intact lysosomes (Ly). Basement membrane (BM), interstitium (!), collagen fibers (C), X 10,000.
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to stimulate respiration. With mitochondrial respiration, a downward slope as a function of time depicts
the oxygen consumed. Given the amount of mitochondrial protein added, oxygen consumption per
milligram protein can be computed. Normal mitochondria exhibit tightly coupled respiration, meaning
that they do not respire in the presence of a substrate like succinate unless ADP is present. In other
words, the rate of respiration is limited either by the
amount of substrates or ADP which is going to be
phosphorylated; addition of mitochondria to the
chamber results in a gradual slope due to endogenous
substrates. When a substrate, for example, succinate,
is added there is only slight respiration, due to the
absence of ADP which is phosphorylated. With addition of ADP, there is a great increase in the rate of
respiration which continues until completion of the
phosphorylation of the ADP at which point the
slope of oxygen consumption levels off again. By
comparing the phosphorylation slope with the resting slope, a ratio is obtained which is a measure of
the efficiency of the mitochondria. If the mitochondria are completely damaged, there will be no change
in rate on adding the ADP. If they are normal
mitochondria or normally functioning, the rate will increase three- to ten-fold. Plotting phosphorylation
rate over resting rate is termed the respiratory control index which is utilized as a measure of mitochondrial functional integrity. A P / 0 ratio or an
ADP /0 ratio is computed from the amount of ADP
added, divided by the atoms of oxygen consumed.
When the amount of ATP that formed in the oxygen
electrode per milligram protein in both the liver and
kidney from a series of patients is plotted on a two
dimensional scale, one can discriminate two groups
of patients, one group with head injury which did
not have shock and one group of patients sustaining
shock ( fig. 10). In shock, apparently there is a
marked reduction in the ability of mitochondria to
make the ATP; this fact correlates with the morphology of mitochondria studied in plastic embedded
preparations and by light and electron microscopy
(figs. 6, 7). P / 0 ratios which should be around
2.5-3 for glutamate and about 1.5-2 for succinate,
are significantly reduced in shock ( 4) .
Studies of the Central Nervous System. The
final two cases are examples of the improved results
obtained in the interpretation of microscopic abnormalities of the brain whenever intravascular perfusion fixation and electron microscopic methods are
used according to the systems mentioned above. The
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first patient, neurologically normal for 72 years, died
after a prolonged period of marked hypotension with
a ruptured abdominal aneurysm. The second patient,
who had a lengthy history of inappropriate belligerent behavior, was stabbed and developed suppurative peritonitis and pulmonary edema. In both
instances perfusion fixation of the brain was started
about 25 minutes after somatic death.
Fixation of the central nervous system which
allows adequate cytological evaluation is difficult to
accomplish in part due to the relative inaccessibility
of the tissue. In other animals, it has been shown
that handling of the normal brain frequently results
in abnormalities referred to as "dark" neurons ( 2).
Thus, avoidance of tissue handling before fixation
has distinct advantages in the fixation of neuronal
and glial elements in the human brain. As for the
effects of prolonged death-fixation interval, we have
studied the ultrastructural effects of total ischemia in
feline cerebral cortex and have determined that pro-
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Fig. 10-Two dimensional scatter plot of morphological changes
in mitochondria compared with ability of the mitochondria to
synthesize ATP in vivo. On the morphological scale, 0 represents
mitochondria showing normal morphology and 4, mitochondria
with the most advanced changes. One, 2 and 3 are intermediate.
Note that two clusters are formed; the patients dying without
shock have better morphology and higher rates of ATP production in contrast to mitochondria from individuals with shock.
+ = succinate with pure head injuries; • = glutamate with
patients with head injuries without shock; X = succinate
with shock and O = glutamate with shock.
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Fig. 11-(left) Light micrograph of tissue from the cerebral cortex of a 72-year-old man who died with irreversible brain damage
following an 18-hour ischemic episode subsequent to a ruptured abdominal aneurysm. Note that in this pyramidal cell we can appreciate the nucleus and cytoplasm. Only rather indistinctly can portions of the chromidial substance be seen. Paraffin embedding,
H & E, X 865. Fig. 12- (right) Semithin section of cerebral cortex from the same case as in figure 11 showing greatly improved
cytologic detail. Now we can recognize an axon hillock (AH), cytoplasmic lysosomes (Ly), and in the adjacent neuropil, myelinated
nerve fibers (free arrows). Epon embedding, toluidine blue, X 865.

Fig. 13- Electron micrograph from the same case as in figures 11 and 12 showing a portion of a cortical neuron which exhibits stage 5
changes. The mitochondria (M) show flocculent densities, the endoplasmic reticulum (ER) is dilated as are the saccules of the Golgi
apparatus (Go). Several residual bodies (RB) which are presumably related to the patient's age are also seen; nucleus (N), X 15,000.
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Fig. 14-(left) Light micrograph of pyramidal cell from the cerebral cortex of a 50-year-old man who died with peritonitis and pulmonary failure. At the time of autopsy, severe atrophy of the brain was grossly apparent. In contrast to the patient shown in figures
11-13, this patient had only a brief terminal episode of hypotension. In this preparation, the neuron has an appearance which is
within normal limits. Paraffin embedding, H & E, X 865. Fig. 15-(right) Light micrograph of a semithin section from the same patient.
Note the large amount of lysosmal granules (free arrow) in the neuron, which correspond to brownish pigment seen in hematoxylineosin preparations. Note also numerous myelinated fibers (MF). Epon embedding, toluidine blue, X 345.

::Fig. 16-Electron micrograph of same case as in figures 14 and 15 showing numerous residual bodies (RB), profiles of rough endoplasm ic reticulum (RER), Golgi apparatus (Go), mitochondria (M) and numerous free ribosomes (R). All of these appear within normal
!limits. The numerous residual bodies which are much too frequent for this patient's age presumably reflect a diffuse metabolic disorder
iOf nerve cells. At the bottom of the picture a normal-appearing myelinated fiber (MF) can be seen; nucleus (N), X 20,000.
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found structural changes occur after 60 minutes, but
that these may be minimal before 30 minutes (3).
Finally, the improved resolution and, therefore,
information gained through electron microscopy can
also be appreciated by comparing the images obtained after paraffin embedding and processing, Epon
embedding and ultrastructural evaluation. Note that
in this instance electron microscopy not only reveals
alterations invisible in the paraffin-embedded material, but also permits separation between two different degrees of circulatory injuries to the brainone lasting up to 18 hours before death (figs. 11, 12,
13) and one probably lasting less than one hour
before death (figs. 14, 15, 16).
The application, therefore, of concepts and investigative techniques generated in research laboratories for studying cellular response to injury, provide powerful methods which will markedly improve
our understanding of human disease. It is possible to
conclude, on the basis of our studies to date, that
human shock has important and often disasterous
effects on cell function level. The cellular pathology
of shock has been a mystery for a long time. The
principle reason for the continuing mystery surrounding the pathology of shock is that the changes appear
to be mainly at the organelle level. In the future we
may think of shock more as a mitochondrial, lysosomal or cell membrane disease than as a disease with
primary organ targets.
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Viral hepatitis has been a major problem for
public health workers and for blood bankers. There
is much to be learned despite recent major advances
in the natural history of the disease, in some of its
epidemiological characteristics, and particularly in its
laboratory diagnosis. These discoveries will significantly reduce the rate of posttransfusion hepatitis. A
complete solution of the overall hepatitis problem
will be attained only when the causative role of the
agent, presumably a virus, has been conclusively
demonstrated. This will in turn produce more sensitive and specific diagnostic procedures and lead to
the development of effective, preventive and therapeutic measures. Specific laboratory diagnosis of
hepatitis became possible with the discovery of Australia antigen-a term used in 1964 ( 4) by its discoverer Baruch Blumberg. The observation that
Australia antigen or Au-1 was intimately related to
hepatitis B virus stimulated large numbers of investigators who developed overlapping systems of
nomenclature. Some of these terms, including those
recommended by the Committee on Viral Hepatitis of the Natural Research Council, are given in
Table 1. Henceforth, the symbol HB Ag will be used
as the synonym to Au-1.
The discovery of HB Ag has provided a specific
marker of infection with serum hepatitis, the most
common cause of posttransfusion hepatitis. This in
tum has permitted a partial solution to the blood

* Presented by Dr. Hossaini at the 44th Annual McGuire Lecture Series, March 22, 1973, at the Medical College of Virginia, Richmond.
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bankers' dilemma, namely, the detection of HB Ag
carriers before blood is collected for infusion.
The frequency of HB Ag in different blood
donor populations in the U. S. has been estimated
to be 0.1-0.5% among volunteer donors, and up to
2 % among paid donors of commercial blood banks
(6, 9, 14, 15, 16) . In other words, blood collected
from the latter group may have as high as 20 times the
risk of transmitting hepatitis as that obtained from
volunteer donors. A list of techniques for the detection of HB Ag is presented in Table 2, including their
relative sensitivity in reference to agar gel diffusion
(AGD) and the time required for results to be
obtained.
AGD was the ,first method available ( 3). This
method lacks sensitivity. Another disadvantage is
that it requires a minimum of one to seven days of
incubation before any results are seen. Moreover, it
requires that both antigen and antibody be sufficiently
potent and also of approximately equivalent concentration; otherwise, the results may be falsely negative.
AGD has the significant advantage, however, in that
it can discriminate between the components in complex mixtures. It offers a direct demonstration of
identity, partial identity or nonidentity between different antigens or antibody reactants. In addition,
sensitivity may be increased by certain modifications.
Precipitation lines of identity, partial identity, and
nonidentity on an agar gel plate are depicted in
figure 1.
Counterelectrophoresis (CEP) is the most commonly used version of the immunoelectrophoresis
M CV QUARTERLY 9(4): 334-341, 1973
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SCHEMATIC REPRESENTATION OF PRECIPITATION
LINES ON AGAR GEL PLATES SHOWING
VARIOUS IMMUNOLOGICAL RELATIONSHIPS

TABLEl
VIRAL HEPATITIS-

Old Terms
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NOMENCLATURE

New Terms

Committee on Viral
Hepatitis Div. Med.
Sc., NAS- National
Research Council

Virus B

SH antigen

Hepatitis B virus,

Serum hepatitis

Au / SH antigen

Hepatitis B antigen,
HBAg
Hepatitis B antibody, HB Ag or
anti-HB Ag

HBV

(SH)

Posttransfusion
Hepatitis antigen
(HA)
hepatitis (PTH)

Non Identity

Identity

Fig.

Long incubation
disease
HAA
Hemologous serum
jaundice
MS-2
Syringe jaundice
Virus A
Short incubation MS-I
disease
Infectious hepatitis

Partial Identity

Hepatitis A virus,
HAV

(IH)

Acute catarrhal
jaundice
Epidemic jaundice
Epidemic hepatitis

procedures. The principle of this method is somewhat more difficult to understand than AGD although it is as easy to perform. It has the advantage
of requiring only 30 minutes to two hours to obtain
results (8, 10). Like AGD, the CEP test utilizes agar
gel coated slides and the reactions appear as precipitation lines.

The complement-fixation (CF) test is considerably more complicated than AGD and CEP technically and in principle. It is not, therefore, as practical for mass screening. Generally it is more sensitive
than CEP (11, 12, 18, 20). The sensitivity of certain
CEP procedures, however, has been improved to
approach that of CF (11, 15, 19). Another disadvantage of CF tests is the scarcity of suitable antisera,
since many antisera are of low titer and are anticomplementary (AC).
The hemagglutination-inhibition (HAI) test
and the radioimmunoassay (RIA) procedures have
been reported to be much more sensitive than the
CEP and CF tests for the detection of both antigen
and antibody. The comparative sensitivity of CEP
and HAI is given in Table 3 as reported by Vyas
et al. (23). Vyas and Shulman (22) estimated that
HAI was 100 times more sensitive than AGD for
the detection of HB Ag. In addition to its relatively
high sensitivity, HAI has the advantage of simplicity.
Not all batches of antigen are satisfactory for coating
the reagent red cells, however, and some lots of anti-

TABLE 2
RELATIVE SENSITIVITY OF TESTS FOR A USTRALIA ANTIG EN IN REFERENCE TO GEL 0IFF US!ON

Test
Agar gel diffusion
Electron microscopy
Electroimmunodiffusion
a. Immunoelectrodiffusion
b. Tmmunoelectroosmophoresis
c. Counterelectrophoresis
Immunoelectronmicroscopy
Complement-fixation
Hemagglutination inhibition
Radioimmunoassay
Radioimmunoassay (solid phase)

Relative Sensitivity
1.0
I. 5

10 .0

11.0
100.0
1000.0
1000.0
600.0

Time
24 hrs.
2-6 hrs.
! -3 hrs.

2-6 hrs.
16 hrs.
2-4 hrs.
5 days
2-4 hrs.

Reference
Blumberg and Alter (4)
Almeida and Waterson ( I)
Duquesnoy and Becker (8)
Prince ( 17)
Gocke and Howe ( 10)
Almeida and Waterson (I)
Shulman and Barker (21)
Vyas and Shulman (22)
Lander. et al. ( 13)
Cawley (5)
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TABLE 3
COMPARISON OF CEP AND HAI FOR HB AG TESTING ON
SERA OF 700 PATIENTS WITH CLINICAL HEPATITIS.*

HAI+
HAI-

CEP+

CEP-

201

50
440

9

* The same goat anti-HB Ag was used for both CEP
and HAI.

serum are not suitable for agglutination and inhibition tests.
A number of RIA techniques have been
described. All utilize a radioiodinated marker, usually
HB antigen or its antibody labeled with !1 25 . The
Ausria-125® of Abbott seemed to be a promising
technique because of its high sensitivity with potential
screening of blood donors (14, 19). Recent studies,
however, have revealed that there may be an inherent serious pitfall in this particular procedure ( 1).
A small percentage of the reactions seems to be
falsely positive thus necessitating further tests if mislabeling of individuals as carriers of HB Ag is to be
avoided.
Soon after reagents for the detection of HB Ag
became commercially available, the Medical College
of Virginia Blood Bank began screening donors by
the AGD procedure. The Virology Laboratory at the
Medical College of Virginia instituted the CF test
using antiserum provided by NIH to test patients
suspected of having viral hepatitis. When CEP kits
became available early in 1971, because of the low
sensitivity of AGD, it was decided to conduct a study
to evaluate the relative sensitivity of the new method;
thus, each of 300 sera were tested by AGD, CF and
CEP. The sera were obtained from patients suspected clinically of having viral hepatitis.
Some of the results of this initial study are
given in Table 4 showing the relationship between
CF titers and the reactions of the 300 sera in the
AGD and CEP tests. Of the 300 sera tested, 22.3%
were positive by CF, whereas 12% and 10.6% were
positive by CEP and AGD, respectively. The highest
serum dilution giving a positive reaction by AGD
was 1 : 16, while CEP failed to detect dilutions higher
than 1: 64. This study, like a number of others, indicated that AGD is the least sensitive method and
that CF is the most sensitive of the three techniques.
The sensitivity of AGD in this study was some-

what higher than that reported by other workers.
This enhancement was probably related to antiserum
titer and the placement of patient sera adjacent to
wells containing HB Ag-positive serum (reinforcement pattern). Although this study did not provide
evidence for a significant difference in the sensitivity
of the CEP as compared to AGD, it was decided to
abandon the latter procedure in favor of the former
because the performance of CEP could be shortened
to 60 minutes.
A second study was then started around the
middle of 1972 because, at the time, there were no
reports in the literature on the relative sensitivity of
the various commercial CEP methods that have become available for routine HB Ag screening of
donors and patients and because it was felt that a
significantly more sensitive, yet relatively simple,
technique was needed. Abbott's Ausria-J 25® was
chosen for this purpose because it was reported to
meet these criteria (14). It was hoped that the
results of this comparative study would serve as a
guide in selecting one of the six CE'P methods and/ or
the RIA for donor screening. It was decided that a
change from the CEP to the RIA technique should
be made if the latter could be shown to be practical
and devoid of false positive reactions. Since a reversepassive hemagglutination (RPHA) technique was
available at that time, it was also included in these
comparative studies.
The Blood Bank routinely uses the CEP method
of Spectra Biologicals to screen donors . Five other
CEP methods used in this study were kindly supplied
to us by Abbott Laboratories, Ortho Diagnostics,
Pfizer, Squibb and Hyland. All CEP tests were performed according to the manufacturers' instructions.
In addition to CEP, Abbott kindly supplied us with
the reagents for RPHA as well as the reagents and
the gamma counter used with their RIA procedure.
Again the prescribed protocol of the manufacturer
was followed with one modification which consisted
of a reduction in the incubation time of test sera with
the antibody. The incubation time was reduced from
i 6 hours to 90 minutes.
Initially 90 sera were tested by the six CEP
methods. Of these, 72 were derived from blood
secured commercially, 11 were from donors suspected of having Gilbert's disorder and the remaining seven were from individuals known to be HB Ag
positive on the basis of previous testing. As seen
from Table 5, none of the sera from commercial
blood donors or from donors with Gilbert's disorder
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TABLE 4
COMPLEMENT-FIXATION (CF) TITERS OF HEPATITIS B ANTIGEN (HB AG) AND REACTIONS OF 300 SERA IN lMMUNODIFFUSION (ID)
AND CoUNTERELECTROPHORESIS (CEP) TESTS
No. of Sera Positive by
CEP
ID
(12% of total)
(10.6% of total)

CF Titer of HB Ag
(22. 3% positive)

Total No. of Sera Tested
233
19
12
16
14
6

< 1:2
1 :2- 1 :8
1 :16- 1 :32
1 :64- 1 :128
1 :256-1 :2048
1 :4096-1 :16384

0
0
2
14
14
6

gave a positive test. The seven sera previously known
to be positive by Spectra CEP technique were positive again on retesting but the other five CEP procedures detected only six of these. Shortly after these
tests were performed, kits for RIA and RPHA testing were made available to us. At the same time, and
by lucky coincidence, a panel of 20 sera arrived from
the American Association of Blood Banks ( AABB)
for proficiency and quality control testing. CEP and
RIA results on these 20 sera are shown in Table
6. AABB subsequently reported that 11 were positive. All 11 were detected by RIA and all but one
were detected by Spectra CEP which at the time
seemed to be the most sensitive of the CEP methods.
Next in sensitivity appeared to be the Ortho and
Pfizer CEP procedures, each of which detected nine
of the 11 positives. The other methods showed relatively poor sensitivity, failing to detect almost 50 %
of the positive sera.
Testing of 204 serum samples, representing a
mixed population of patients suspected of having
viral hepatitis, and "normal" hospital employees, was
then done by CF, RPHA, RIA and by the six CEP
methods. Results are presented in Table 7. Among
the six CEP methods, Ortho's proved to be the most
sensitive while Abbott's was the least, failing to de-

0
0
0
12
14
6

tect HB Ag in six sera. There was also a significant
difference between Ortho's sensitivity and that of the
other four CEP procedures each of which failed to
detect the antigen in five sera. These findings and the
fact that Ortho's method was nearly as sensitive as
the CF test in the present series indicated that when
the test conditions were adequate, relatively high
sensitivity could be attained with the CEP procedure.
Lewis and Coran ( 14) attributed the higher sensitivity of the Ortho technique to the considerably
larger volumes of test sera and antisera used in this
method as compared to the others. Nevertheless,
these results confirmed our previous findings, namely
that generally, CEP methods are less sensitive than
CF. These results also revealed that it is possible
to get CEP positive-RIA negative results. These
findings are in disagreement with those of Lewis and
Coran ( 14) .
The present study did not provide evidence that
Abbott's RPHA method, a version of hemagglutination, is more sensitive than CF or Ortho's CEP. It
was noted that RPHA results were more difficult to
interpret, since the differences between weakly positive and negative reactions were not clear and could
not provide for a clear-cut diagnostic reading.
Like other studies ( 5, 13, 24), RIA appeared

TABLE 5
RESULTS OF TESTING 90 SERA
Category of Donors
Commercial
MCV Known Positive
Gilbert's
CEP Methods:

A
0
7
0
Spectra

BY

SIX CEP PROCEDURES (A-F)

Test Procedure & No. Positive
B
c
D
0
6
0
Hyland

0
6
0
Ortho

0
6
0
Pfizer

E

F

0
6
0
Abbott

0
6
0
Squibb

Total No.
Samples Tested
72
7
11
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TABLE 6
COMPARATIVE SENSITIVITY OF THE RIA WITH CEP PROCEDURES ON PROFICIENCY SAMPLES FOR DETECTION OF HB AG
A

B

8
2
10
Spectra

6

Total No. Samples*
20
CEP Methods

CEP System
c
D

1
7
Hyland

7
2
9
Ortho

6
3
9
Pfizer

E

F

RIA Test

Results

4
2

5
1

11

6

6

11

Positive
W** Positive
Total Positive

Abbott

Squibb

* Submitted by the AABB for quality control
** Weakly

to be the most sensitive technique, despite the fact
that the CEP and CF procedures could detect a
total of five positive sera which were negative by
RIA; RIA, however, was the only procedure giving
a positive reaction in all 11 sera (Table 7) . The
higher sensitivity of this technique seemed to be
further supported by testing 50 additional sera only
by RIA Spectra and Ortho. As seen in Table 8, two
sera failed to react by both Ortho's and Spectra's
CEP but gave a positive RIA result. In this series,
however, none of the sera positive by Spectra's
and/ or Ortho's CEP methods was negative by RIA .
In order to determine the specificity of the RIA
positive reactions, two approaches were taken. First,
three sera that were positive by RIA only were
concentrated by lyphogel to see if these concentrates

TABLE 7
COMPARATIVE SENSITIVITY OF THE RIA WITH CEP, CF AND
RPHA PROCEDURES FOR DETECTION OF HB AG
(204 samples*)
CEP Methods: A
D

A

= Spectra B = H yland C = Ortho
= Pfizer E = Abbott F = Squibb

CEP System
CF RPHA
B c D E F Test Test

19 17 22 15 15 18
3 5 5 7 6 4
22 22 27 22 21 22
2 0. 4 0 0
1 1 0 0 0

RCA
Test

28

28

38

28

28

38

0

Results
Positive
W** Positive
Total Positive
Nonspecific
Positive by one
method only

Proportion positive by one or more methods: 41 / 204
* From a mixed population: "normal" hospital
employees and patients suspected of having hepatitis.
** Weakly

would revert from negative to positive CEP on retesting. Only one of the three concentrated sera
converted to positive by both CEP procedures; the
other two sera remained negative. These results indicated that some of the positive reactions were
specific, thus implying that the nonreactivity of unconcentrated sera by CEP was due to the lower
sensitivity of this procedure as compared to that of
RIA. The second approach consisted of testing double
serial dilutions of five sera of known complementfixing titer by the two CEP methods and by RIA.
AB serum known to be negative by Spectra's and
Ortho's CEP methods and by RIA was used as a
diluent (7). These sera had been frozen at -20°C
for variable time periods up to several months. The
results (Table 9) indicate that Ortho's CEP and
Abbott's RIA are two-to-four times and 16-to-32
times as sensitive as Spectra's CEP, respectively.
These findings are in disagreement with those reported by others who showed that RIA is 1OO-to1000-fold more concentrative than CEP (5, 14, 24).
The lower comparative sensitivity in this study may
be due to the shorter incubation period.
No correlation was found among CF, CEP and
RIA titers. For example, serum # 5 with a CF titer
of 1: 8, 192 had an RIA titer only one dilution higher
than that of serum # 1 which had a CF titer of
1: 128. Environmental factors, such as temperature
and duration of storage as well as differences in
handling of sera, might have been responsible for
some of these changes. A second study was then
conducted in which five freshly drawn samples (three
known positive and two known negative) were tested
in a similar fashion . The CF titer of the three positive
sera was determined (Table 10) .
Unfortunately, the RIA results were erratic and
difficult to explain. For example, positive serum #2
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at a 1: 4 dilution but was negative undiluted and
when tested at 1:2, 1:8 and 1:16.
It has been reported that when normal human
sera are used as diluent they may enhance reactivity
of positive sera ( 6). This, however, does not explain
the erratic behavior of the RIA test in this series.
A technical error cannot be excluded entirely as the
possible cause and would suggest that this technique may be too exacting to be used as a screening
procedure. This could conceivably be responsible for
at least some of the false positive reactions described
in the last series.
Since not all RIA positive-CEP negative sera
became positive after concentration and in view of
the erratic results obtained in the last series, it is
impossible to ascertain the specificity of all RIA
positive reactions . This cautious statement is consistent with a recent report which described the occurrence of false positive reactions using Abbott's
RIA technique. It was demonstrated that reactivity
of an antibody present in human serum directed
against a guinea pig protein was responsible ( 2).

TABLE 8
COMPARISON OF RESULTS OBTAINED BY RIA
AND 0RTHO AND SPECTRA CEP METHODS
(50 samples)
No.
of Tests

%
of Tests

41
4
3
2

82
8
6
4

% Total

100

RIA

Ort ho
CEP

0

0

0

+
+
+

+
+

+

18

14

Spectra
CEP
·----

0
0

0
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reacted first, at dilutions 1 :64 and 1: 128 . Negative
results followed for seven serial dilutions to appear
positive again at a dilution of 1: 32, 768. Analogous
results were obtained with the presumably negative
sera #4 and #5 . Serum #4 was negative when
tested, undiluted and at 1: 2 and 1 : 8 dilutions, but
it was positive at 1 :4 and 1: 16. Serum #5 reacted

TABLE 9
TITER OF FIVE HB Ao PosmvE SERA* BY CEP (SPECTRA & ORTHo) AND BY RIA
Serum
Dilution
Undiluted
1 :2
1 :4
1 :8
I :16
1 :32
1 :64

Undiluted
1 :256
1 :512
1 :1024
1 :2048
I :4096
1 :8192
1 :16384
1 :32,768

CF Titer

Method 1
CEP
RIA
A

c

+
+
+
+
+

+
+
+
+
+
+
+

-

-

-

1 :128

Method 2
CEP
RIA
A

c

ND**
+
+
ND
+
+
ND
+
+
ND
+
+
W+***+
+
+
+
+
+
+
+

-

-

-

1 :512

ND
ND
ND
ND
+
+
+
+
+
-

Method 4
CEP
RIA

Method 3
CEP
RIA
A

c

+
+
w+

+
+
+
+

-

-

-

-

-

1 :512

A

c

ND
ND
+
+
+
+
+
+

+
+
+
+
+
+
+
w+

-

-

+
+
+
+
+
+
+
+
+
-

-

-

-

ND
ND
ND
ND
ND
ND
ND
+
+
+
+
+

Method 5
CEP
RIA
A

c

+
+
+
+
+
+
w+

+
+
+
+
+
+
+
+

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1 :8192

ND
ND
ND
ND
ND
ND
+
+
+
+
+
+
-

-

1 :8192

* The five sera in this experiment have been frozen for various time periods at - 20 °C. The above CF titers were those obtained
on the fresh samples prior to freezing.
* * ND = not done.
*** w + = weakly positive.
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TABLE JO
TITERS OF FIVE FRESH HB Ao PosmvE SERA BY CEP (SPECTRA & 0RTHo) AND BY RIA

A

Undiluted
I :2
I :4
1 :8
1: 16
1 :32
I :64
1 :128
1 :256
I :512
1 :1024
1 :2048
1:4096
1 :8 192
1 :16384
1 :32,768

+
+
W+**
-

A

c

+
+
+
+
+
+
w +
w+

+
+
+
+
+
+
+
+

c
+
+
+
+
+
-

-

-

-

-

-

-

-

CF Titer

* ND
** W +

Serum 2
CEP
RIA

Serum 1
CEP
RIA

Serum
Dilution

ND*
ND
ND
ND
+
+
+
+
+
-

I :128

I

A

c

+
+
+
+
w+

+
+
+
+
+
+
+
-

-

-

-

-

-

-

-

-

-

-

-

-

+

-

-

-

ND
ND
ND
ND
ND
ND
+
+
-

Serum 3
CEP
RIA

-

1 :512

ND
ND
ND
ND
+
+
+
+
+
+
+
+
-

-

-

Serum 4
CEP
RIA
A

c

-

-

-

-

-

-

-

-

-

+
+

Serum 5
CEP
RIA
A

c

-

-

-

-

-

-

-

-

-

+

-

-

-

-

1:512

2

2

= not done.
=

weakly positive.

Until further tests can be performed to demonstrate
the presence of HB Ag in the RIA positive-CEP
negative sera by other methods designed to eliminate
the human antiguinea pig protein interference, the
positivity of these sera must remain suspect.
In conclusion, this study supports the claim
that the RIA is the most sensitive of all assay
methods for detection of HB Ag in use today. Because of the inability to verify the presence of HB
Ag in those sera positive by RIA alone, however,
this claim must be taken only at face value. Further
studies are needed to confirm the specificity of these
positive reactions.
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Quality Control in the Office Laboratory*
JOSEPH H. RIDDICK, JR., M.D.
Associate Professor of Clinical Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University,
Richmond

"The poorest of all laboratory work is that done
in the private physician's office." That allegation was
made by the Director of the New York City Department of Health Bureau of Laboratories in a statement to a Senate Committee of the Judiciary Committee on Antitrust and Monopoly on February 7,
1967 ( 1). Statements such as this typify the public
relations problem facing directors of office laboratories today. The problem is twofold: First, how can
the quality of the office laboratory be assured and
documented? Second, how can this information be
disseminated to legislators and the general public?
The first is an easily solved technical problem toward
which this paper is directed. The second and probably the most difficult is a media problem beyond
the scope of a technical journal.
Laboratory quality assurance and documentation
are best considered as a subset of the more general
field of quality control, an industrial discipline with
its roots in the industrial revolution. Industrial quality control is the technique, for instance, whereby
the automotive industry may precisely design obsolescence into an automobile without impinging on
the warranty period in order to maximize profits.
Quality control in the drug industry assures not only
that the amount of drug in a pill falls within acceptable tolerances but that the pill itself is not malformed. A malformed pill results in very bad public
relations for the drug company, even if its function is
not impaired. The pigeon, an animal with a very
fine eye for detail, has been used successfully for
assembly line quality assurance in removing faulty
pills prior to packaging (2). Laboratory medicine
also produces a product which can be subjected to
quality control, the laboratory result.

* Presented by Dr. Riddick at the 44th Annual McGuire
Lecture Series, March 22, 1973, at the Medical College of
Virginia, Richmond.
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Error Frequency Distributions. Any discussion
of laboratory quality control should begin with a
brief account of practical statistics, since statistics is
the science whereby a decision can be made as to
whether a laboratory result is acceptable or unacceptable. An introduction to these statistics should
begin with the error frequency distribution.
If a unit of outdated blood bank blood is mixed
well and dispensed into 100 test tubes, this set of
tubes is called a "pool." The plasma glucose content
of any one of these tubes is the same as that of any
other, since all tubes came from the same bag of
blood. If one attempts to assay each of those 100
tubes of blood for glucose, however, the assay results will not be identical for all tubes. Some will be
above an average value and some below, as shown
in the histogram in figure 1. A few results will deviate
markedly from the average value but most will
cluster around the average. The smooth curve (sometimes called Gaussian or bell-shaped) drawn through
the steps of the histogram is called a frequency distribution plot, and it can be used to make a decision
as to when a laboratory result deviates too far from
the average value of the pool. If one calculates a socalled standard deviation (SD), one can define location of the cutoff point between acceptable and
unacceptable results. The use of the standard deviation has two advantages over a single intuitive guess
about where the line between good and bad data
lies. First, use of the standard deviation (actually ±
2SD) as a decision point guarantees that 95 % of the
results will be in the acceptable range on the average.
Second, standard deviation is used by most practitioners of laboratory medicine and is understood by
them, thereby providing a common ground for discussion. It might be mentioned that the frequency
distribution plot shown in figure 1 is a real life situation. That is, it is technically impossible to get
MCV QUARTERLY 9(4): 342-346, 1973
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Fig. I-Frequency histogram of Gaussian distribution with
overlying frequency distribution plot. Note that the majority
of values cluster around the peak of the curve.

identical results for the plasma glucose in each of
those 100 tubes. One can use more costly and difficult methods and the range on the horizontal axis
will narrow, but the results cannot be made identical.
This means that there is no "true" value for the
glucose in the plasma. Analytical balances used for
weighing the glucose also have error frequency
distributions.
Frequency Distributions of Normal Patient
Laboratory Determinations. Figure 2 shows the results obtained for blood urea nitrogen determined on
each of 495 "healthy" patients plotted in the same
fashion as the pool results in figure 1. As might be
expected, most of the results cluster around an average value with a few markedly deviant values to the
left and right of center. Notice that the frequency
distribution plot is skewed with more deviant values
to the right (occult disease?) than to the left. This
is because there is no such thing as a negative blood
200

150

urea nitrogen, so the curve is steeper on the left than
on the right.
Now, suppose one took a large number of
patients with renal disease, drew their blood, performed a blood urea nitrogen on them, and superimposed their frequency distribution plot on an
idealized plot of the frequency distribution of urea
nitrogen of "normal" patients (fig. 3). How might
one define the upper limits of "normal" using this
data? One might draw a vertical line at the lowest
point between the normal peak and the sick peak
and call this the upper limit of normal. It is obvious,
however, that the two curves overlap and in the areas
of overlap, some normal patients will be called sick
when they are not, and some sick patients will be
called normal when they are not. Anyone experienced with the SMA 12-60 has seen elevated uric
acids in perfectly normal people who never develop
gout. To further complicate things, a large laboratory error component will tend to broaden this range
of ambiguity to an even greater extent.
Effect of Methodology on Normal Ranges. Figure 4 shows frequency distribution plots of two different assay methods for blood glucose-the glucose
oxidase and the ferricyanide methods. The glucose
oxidase method is a so-called "true glucose" method
and produces comparatively low results, partly because it is subject to inhibition by some patients'
blood. The classical ferricyanide glucose method, on
the other hand, produces comparatively high results
because it measures not only true glucose but also
other reducing substances such as fructose and
glyceraldehyde. From the point of view of the patient
and his physician, the important thing is the normal
range. The glucose oxidase blood glucose normal
range is 10-20 mg percent lower than that of the
ferricyanide method. If one used both methods
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Fig. 2-Urea nitrogen frequency distribution plot. Notice
that there are far more deviant results on the high side of
the curve than on the low side; that is, the curve is skewed.
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CUTOFF BETWEEN
WELL AND SICK

F ig. 3- Superimposed frequency distribution plots of normal and abnormal urea nitrogen determinations. Note the
area of ambiguity or overlap between the sick and the well
person.
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Fig. 4-Frequency distribution plots for two different blood
glucose methods. Note that the normal range is different for
each.

simultaneously, one would widen the normal range
as shown in the composite curve in figure 4 and a
substantial increase in false negative blood glucose
results would occur. This could easily happen if two
different kits using different methodology were used
interchangeably. The result would be a component
of laboratory error which would widen considerably
the range of ambiguity of the blood glucose data.
Effect of Methodology on "Biologic Variation."
Figure 5 is a time-course plot of the blood sodium
level of the author drawn over a period of a month.
The upper curve (JHR) represents the human blood;
the two lower curves (Control 1 and Control 2) are
two commercial pools assayed simultaneously with
the human blood. Had there been no laboratory
error, the lower plots (Control 1 and Control 2)
would be perfectly straight lines parallel to the horizontal axis. Note that the two curves are sawtooth
instead, describing day-to-day laboratory error. Because of within-day random error, or perhaps because of pipetting error they are not exactly parallel
to one another. The most striking feature of
figure 5 is that the human serum drawn on the same
day shows the same pattern of variation. The implication is that a substantial component of so-called
"biologic variation" for serum sodium actually is
laboratory error. Carefully controlled studies such as
this, in fact, indicate that the flame photometer is
incapable of measuring the subtle changes of biologic
variation and that, in fact, all variations measured
in normal human blood sodium are actually laboratory error not biologic variation. Many other blood
components, potassium, for example, show similar
effects of day-to-day laboratory error. If one could
reduce the day-to-day error component in measuring
blood sodium, one might be able to pick up more

subtle changes, the normal range would undoubtedly
shrink and fewer false negative and false positive
results would occur. The cost of increased accuracy
and precision, however, is prohibitive at present.
Setting of Control Limits and the Effect on
Patient Care. Figure 6 is a graphic example of the
effect of control limits set too wide in the laboratory.
Bilirubin is traditionally a poor test from an accuracy standpoint because of the difficulty of maintaining adequate standards which will not deteriorate. The error shown in figure 6, however, is caused
by an improperly calibrated reference serum used
to calibrate the SMA 12-60 bilirubin. On day 20,
the laboratory used the last of a particular manufacturer's reference serum and began to use a new lot
from a different manufacturer. The effect was an
abrupt increase in every normal patient's bilirubin
of 0.4 mg percent and an increase in the bilirubin
of the patients in the moderately elevated range of
0 .7 mg percent. Obviously the normal range was
widened by this change. Tighter control limits would
have detected this change sooner. Furthermore, an
alert visual scan by a physician of the patient results
for the day would have proven to be an extremely
useful form of quality control. It was concluded that
one could not rely upon the manufacturer's brochure
provided with the lots of reference serum.
Some Simple Techniques for Quality Control.
One of the oldest forms of laboratory quality control
is the "repeat." If one doubts the validity of the
first result, send another one and compare the two.
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Fig. 5-Time course plot of the blood sodiu m level of the
author drawn over a period of 30 days. The upper curve
represents the human blood (JHR). The lower curves (Control 1 and Control 2) represent pooled control sera. The
parallel variation indicates that the greater part of the "diurnel variation" of the human sodium actually represents
analytical variation.
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Fig. 6-The effect of a change of control pool manufacturer
on day 20. Notice the striking change in levels of bilirubin
for the control pool.

This is of no use, however, if a very poor laboratory
is very good at reproducing its bad results on repeats.
The split sample is a slightly more sophisticated
form of the repeat. In this case, the original sample

is mixed well and divided into two parts. A phony
name is attached to one specimen and the second
member is submitted to the laboratory sometime
later. This technique is designed to foil the laboratorian who claims that "biologic variation" caused
the difference in the two results. A rule of thumb for
the split sample is that if the results of the two split
samples vary by more than 10% the results are
suspect. This figure varies from test to test. The
split sample is also useful in those tests for which
reference standards are not yet available such as
urinalysis, bacteriology and even some coagulation
studies.
Another more complex method of quality control is the mixed specimen. This works best with
blood chemistries. If you mix known amounts of
each of two patient specimens, the results of all
components ( excluding enzymes) will be proportional
to the original concentrations and volumes mixed.
The calculation for the predicted results is fairly
straightforward.
Most people rapidly tire of the exercise of preparing their own quality control samples and purchase these from some national program such as
the Proficiency Evaluation Program (PEP) for the
Physician's Office Laboratory.
Proficiency Evaluation Program for the Physician's Office Laboratory. Beginning in April, 1973,
the College of American Pathologists and the American Society of Internal Medicine are jointly sponsoring a quality control program designed specifically
for the physician's office laboratory. The data obtained are treated in an entirely confidential manner
and meet the demands of public health agencies,
legislators, professional associations and patients for
a third party evaluation of the office laboratory.
Quarterly kits are mailed out to subscribers containing seven vials of test unknowns and a blood smear.
These vials contain material for evaluating hemoglobin, red cell counts, hematocrit, glucose, bilirubin,
cholesterol, urea, uric acid, urine specific gravity,
urine protein, urine reducing substance, urine bilirubin, urine hemoglobin, urine pH, prothrombin
time, white cell count, urine bacteriology and peripheral smear. One hundred tests per year are performed on a quarterly basis and mailed into the
testing agency for evaluation. Four weeks after receipt, results from all subscribing laboratories are
pooled, processed by computer, and a computer
print out is mailed to all subscribers giving name of
constituent, method used, subscriber's result pass or
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fail code, average of all laboratories for comparison,
a good performance range and an acceptable performance range. In addition, a quarterly bulletin is
sent to all subscribers, describing findings and including a personalized certificate for wall-mounting.
The advantages of such a system are apparent.
First, the director gets a confidential warning that
his laboratory is having difficulty, thus giving him
the opportunity to correct the difficulty. Comparison
of results with peers is always informative as to the
wide interlaboratory differences. The effort expended
is minimal and does not disrupt the normal func-
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tion of the laboratory and the cost is far less than
manual preparation of samples and data collection.
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Commercial and Reference Laboratories*
GEORGE J. CARROLL, M.D.
Director of Laboratories, Louise Obici Memorial Hospital, Suffolk, Virginia;
Clinical Professor of Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond
It occurred to me in thinking over the area to be
covered that the title, although in general use today,
refers to generic terminology. I thought it might be
wise to define the two terms in relationship to the
term "laboratory." Webster defines "commercial" for
our purposes as "having financial profit as the primary aim" and "reference" as "any person or thing
referred to for information, recommendations, etc."
In my own mind in the strictest sense of the word, a
reference laboratory is one where materials tested by
stringent techniques are forwarded to participant
laboratories throughout the country. These tests are
analyzed and the results returned to the reference
laboratory for comparison with their results. These
results are then made available to the participants to
compare with their own and others in the program;
in short, a quality control program. The two best
examples I have are the College of American Pathologists' Proficiency Testing Service1 and Dr. F . William Sunderman.2 A step further down the line is a
combination of commercial and reference laboratories. Here, exotic tests or tests not ordinarily performed in a laboratory are referred to a laboratory
for testing. This, of course, is done for a profit. The
third step is the situation where all types of tests
referred to a laboratory are performed for a profit.
A good example of the commercial-reference laboratory is Bio-Science Laboratories in California. The
third step involves a myriad of laboratories-state,
interstate, and national-with which by now all physicians are familiar.

* Presented by Dr. Carroll at the 44th Annual McGuire Lecture Series, March 22, 1973, at the Medical College of Virginia, Richmond.
1 The College of American Pathologists Proficiency
Testing Service, 230 North Michigan Avenue, Chicago, Illinois 60601.
2 Dr. F . William Sunderman, Proficiency Test Service,
1833 Delancey Place, Philadelphia, Pennsylvania 19103.
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A physician who is practicing away from an
area where diagnostic procedures are immediately
available, and even in areas where good laboratory
medicine is practiced, has to decide what laboratory
or laboratories he will use. What steps should be
taken to make certain of good quality service from
the many laboratories that are at his disposal? The
first thing to remember is that the performance of
any medical laboratory test is not a simple procedure. It is a technique of medical practice which
should be as important to the physician as the delivery of a baby is to the obstetrician. The determination of a simple hemoglobin can present many
difficulties which can be compounded by time and
delay of transportation. A physician must examine
his conscience and determine firstly that he must demand quality to ensure good patient care. Once this
has been settled in the individual's mind, he should
analyze the speed of performance, the quality of
performance, the amount of quality control, how the
laboratory is operated and equally important, the
cost to the patient.
The speed of performance in some instances is
important but in other areas need not be a factor.
In office practice where a patient will not return to
the office for ten to fourteen days, practically all
laboratories will have returned the test results. This
is even true of some of the more exotic tests such as
aldosterone, estrogen levels, etc. In Virginia at the
present time, a number of laboratories are performing daily pickup service, with the return results reported on routine procedures the following day. This
might pose some minor delays in rural areas but
speed must not overshadow quality of work performed.
Quality and quality control are tied so closely
together that they can be discussed together. A
laboratory performing good quality laboratory medicine should provide you with well-trained technical
347
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personnel who are under well-trained supervisors
directing and reviewing the test procedures being
performed. Some laboratories operate on a twentyfour-hour basis with night-shift personnel who i:nay
not be adequately trained or if they are, are working
a second shift and so will not be working at peak
efficiency. Quality control charts of the laboratory
operator should be made available to you at regular
intervals to assure you that tests are performing
within acceptable standard deviation variations (usually not over 2 SD from mean).
I wish to point out at this time why results
from a commercial laboratory may differ from your
hospital laboratory. The point to emphasize is that
different methodologies between one automated piece
of equipment and another, and between automated
equipment and standard wet-bench-chemistry methods may have different normal values. This has
caused considerable furor in laboratory circles but
is a fact of life that must be accepted. In addition,
one should remember that enzyme tests, CPK,
SCOT, LDH, are very difficult to reproduce on automated equipment. Of these three, the CPK is the
most difficult to reproduce in terms of uniform levels
within a given laboratory and between different
laboratories. This is especially true of the ultraviolet
light (UV) determinations of CPK with conversion
to international units.
The delivery of good quality and good quality
care are dependent on how the laboratory is operated. The question to be raised here is: "What are
the professional qualifications of the people you
select to do your laboratory diagnosis?" Is the head
of the laboratory one who has been trained in laboratory medicine, a pathologist or otherwise, and most
important is this person a physician? It is quite important that you as a physician know the director,
his background and education, his staff and the facilities from which the laboratory operates. This is coming under much better control today at both the
federal and state levels. I feel that knowing your
consultant in laboratory medicine is just as important
as knowing other physicians with whom you consult.
This, of course, is not always possible but the closer
to home the commercial laboratory you use, the
closer the contact and knowledge you can have of its
operation and staffing. There are many companies
sponsoring commercial laboratories today. All of
the larger companies, such as Dow Chemical, Damon, Smith, Kline and French and Upjohn have a
pathologist as director. All of these you can be as-
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sured are turning out quality assurance work. There
are others in this vicinity, pathologist directed, with
excellent staffing, not associated with a major company that are also turning out quality work with
good quality control.
One of the problems with the number of commercial laboratories in this country has led to some
of the other smaller units bringing to light the "symptom of what is going on in many practices." Competition has made some of the laboratories lower the
quality of work to stay in business, and in some
instances has caused price reductions at the cost of
good quality assurance. This seems to occur because some physicians care very little about the
quality of the tests performed on their patients, but
prefer more tests for the cheapest price. In the final
analysis, the cost to the patient remains a major factor. Here also have arisen many of the problems to
which we as physicians must direct ourselves. I think
it ridiculous for a physician to change laboratories
in order to have a test done for twenty-five cents less.
This has actually occurred recently here in Richmond. Whether there was a difference of quality one
can only speculate. The bigger problem which we
as physicians must face is that in using any laboratory, the price to the patient must be fair for the
work rendered. It is ironic to realize that most physicians are marking-up tests done by outside laboratories by three-to-four to even ten times the amount
charged by the iaboratory. This has caused an understandably adverse reaction by the American Medical
Association and the Blue Plans. This has also stirred
reaction in our own state and has caused action by
the Medical Society of Virginia. It is apparent from
many studies that some differential is needed between hospital and doctor's office charges such as is
now in effect in California. My point in raising this
issue is that as physicians, the high volume, low cost
of tests performed by commercial laboratories should
still carry only a reasonable increase to the patient
and not the marked increase which is much more
prevalent than many physicians admit.
I have not covered the area of advertising in
the material presented here, because there is mixed
emotion by even those within the commercial laboratory field as to how this can best be accomplished.
I would be wary of the laboratory which advertises
by price cutting, for prices are now close to an all
time low level. I would insist on quality of work
with evidence of quality control. I might point out
here that one of the problems in mailing long dis-
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tance is that of deterioration and hemolysis of specimens. I know of one instance where material was
sent to a western laboratory for platelet counts and
where an observer noted all specimens which were
being counted by phase were hemolyzed. I am sure
the referring physicians were unaware of the method
used and that using any method platelets will have disintegrated within six-to-eight hours. Such specimens
reaching the west coast from nearly anywhere would
be useless for evaluation of platelets. This should reemphasize the need for knowing your referring
laboratory and its staff.
Remember that the cost to the patient is the
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important factor and the price passed on to him
should be a reasonable one and in line with the cost
for operating your practice. As I said earlier, every
doctor today, in the face of mounting pressures, must
examine his conscience and determine what quality
he will insist on for good patient care.
In summary, there are now in existence many
good commercial and reference laboratories. I would
use those laboratories with which you are most familiar, where you know the staff, those which can
demonstrate reasonable speed in testing and can
assure good quality testing and control at what you
feel is a reasonable cost to the patient.

Evaluation of Prepackaged "Kits"*
REX B. CONN, JR., M.D.
Professor of Laboratory Medicine, The Johns Hopkins University
School of Medicine, Baltimore, Maryland

The proliferation of commercially-available
"kits" for the clinical laboratory has resulted in such
a technological surfeit that one or more kits are
available for virtually every type of commonly performed test. Such kits offer prepackaged convenience
and, under some circumstances, economies in the
laboratory. A few offer technical procedures which
are superior to standard methods.
In spite of their apparent simplicity, commercial
availability of a reagent kit does not provide any assurance that it will perform satisfactorily or that the
resulting data will be accurate. In contrast to therapeutic agents, federal regulation of the manufacture
of diagnostic kits has only recently been instituted,
and it remains for the user to determine whether a
particular kit does in fact meet the specifications
stated in promotional material. The selection and the
continuing evaluation of diagnostic kits present problems to every laboratory, whether the laboratory is
in the physician's office or in a large hospital.
Perhaps the simplest type of kit is a prepared
reagent for a certain determination. This category
would include specific antisera for blood grouping or
other purposes, as well as standard chemical reagents. Usually, however, the word "kit" is used to
describe a prepackaged set of multiple reagents for
carrying out a certain test in the laboratory. Many
such multiple-reagent kits are based upon standard,
accepted methods; those from reliable manufacturers
offer the advantages of standard methodology and
elimination of reagent preparation. Some kits are
based upon manufacturer-developed methods which
are usually patented or kept as proprietary secrets.
Some of these manufacturer-developed methods are
acceptable; some, no doubt, have been developed
primarily to permit a wider profit margin. Lastly,

* Presented by Dr. Conn at the 44th Annual McGuire
Lecture Series, March 22, 1973, at the Medical College
of Virginia, Richmond.
350

several well-known firms are marketing kits which
are suitable only for their own analytical instruments. This presents a double dilemma for the purchaser, since it is necessary not only to evaluate the
kit but the instrument as well.
Selection of Kits. Most physicians are deluged
with flyers and advertisements which suggest that the
purchase of a few kits is an efficient and entirely
satisfactory method of installing an instant clinical
laboratory. These blandishments frequently lead to an
illogical and expensive system for providing laboratory data. The first question to be asked is not which
kits to buy but rather which determinations should
be done in the laboratory. If a test is definitely
needed, purchase of a kit is one of the alternative
methods for making it available. Particularly in the
physician's office, the convenience, the elimination
of reagent preparation and savings in personnel time
are advantageous. Use of a kit usually results in a
higher per-test cost than having the test done in a
large, automated laboratory, but the advantages of
using kits sometimes outweigh these higher costs.
Kits from different manufacturers will offer different
analytical methods, differing numbers of tests per kit,
different instrument requirements and, of course, different prices.
An important principle in selecting any type of
laboratory kit is to require the manufacturer to provide relevant experimental data which substantiate
any claims regarding performance of the kit. Descriptions such as accurate, precise, simple, inexpensive
and reliable are all relative. Unless the manufacturer
can produce data, preferably substantiated by an independent investigator, regarding these parameters
of performance, further consideration of using the
kit should not be entertained. Most reputable manufacturers will supply reprints of articles describing
such evaluations.
Evaluation of Kits. If a laboratory is to produce
M CV QUARTERLY 9(4): 350-354, 1973
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reliable data, a critical evaluation of each method
must be carried out prior to its introduction as a
routine procedure. It is immaterial whether or not
the procedure utilizes a prepackaged kit. Such an
evaluation should make full use of any data collected
by other laboratories, but an experimental evaluation
by the laboratory which is to use the kit is essential.
Although kits come in various forms, there are
two major categories of laboratory tests for which
they will be used-qualitative tests and quantitative
tests. Qualitative tests are those for which the results
can be expressed as a yes or no, positive or negative
or present or absent report. Pregnancy tests and tests
for urinary glucose are examples of qualitative tests.
Quantitative tests are those which are used for measurement of a specific constituent and results are
expressed in numerical terms. The evaluation of a
kit will differ depending on whether it is used for a
qualitative or quantitative procedure.
Comparison with Reference Method. Evaluation, no matter what is being evaluated, is a comparative process. If a kit merely supplies reagents
necessary to do a standard laboratory test, data on
the standard test are readily available in published
form. More often, the kit will be a modification of a
standard method or, occasionally, a new approach
to measuring the same constituent. In either situation, the manufacturer should provide experimental
data which compare the kit procedure to an accepted, established method.
For quantitative tests, the parameters which
should be examined are accuracy, precision and
range of linearity over which measurements can be
made. Accuracy is an elusive parameter to evaluate,
and a comparison of results using the kit with those
obtained by a standard method is acceptable. Precision can be evaluated by replicate determinations
and linearity by measuring a series of samples with
varying concentrations of the constituent being measured. An excellent example of such a comparison
is the study by Barnett, Cash and Junghans (2) in
which cholesterol measurements using 12 different
kits were compared to those using the Abell-Kendall
method. They concluded that only two of the 12
kits being marketed at the time of the study were
acceptable for clinical use . Other published evaluations should be equally disconcerting to any laboratory which uses a kit without first subjecting it to
rigorous performance trials. Kim, Waddell and
Logan ( 6) measured sodium and potassium with
chemical kits manufactured by the Stanbio Laborn-
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tory, San Antonio, Texas and by Medi-Chem, Santa
Monica, California. Results were compared with
those obtained by standard flame photometric techniques, and the authors concluded that both kits
gave "diagnostically unsatisfactory results." A study
by Dietz, Rubenstein and Lubrano (5) which involved serum cholinesterase measurements using the
Acholest® kit manufactured by E. Fougera and Co.,
Hicksville, New York, provides a shocking indictment of the lax standards set by some commercial
firms. The Acholest® method "failed to detect 12 of
20 cases at high risk of prolonged apnea after succinylcholine." Similar comparative studies of kits for
less complicated procedures such as glucose and urea
indicate that some are entirely suitable for these
measurements (7, 9, 11) . It is noteworthy that
Logan, Waddell and Krynski (9) found that the
kits which were the most expensive and which revealed the least information concerning their constitution gave the poorest performances.
The evaluation of comparative data for qualitative tests frequently is more difficult than for quantitative tests. The two parameters corresponding to
accuracy and precision are validity and reproducibility. Reproducibility can be studied through replicate tests on the same group of samples; validity,
however, like accuracy, may have to be evaluated
by comparison with a reference method. The objective for all qualitative tests is a positive result when
the constituent or disease is present and a negative
result when it is not. For example, serological tests
for syphilis are usually compared to the fluorescent
treponemal antibody-absorbed (FTA-ABS) test.
Since the serological test is used primarily as a
screening procedure, acceptable performance would
result in no false negatives and as few false positives
as possible. Frequently, the evaluation must include
consideration of the clinical context in which the
test will be used. Tests for pregnancy are usually
evaluated by testing large numbers of pregnant and
nonpregnant women. A test which gave positive
results in 97 % of women in the second trimester
of pregnancy clearly would not be as useful as one
which gave similar accuracy during the first three
weeks. The undesirability of false positive pregnancy
tests is readily apparent.
In addition to comparisons with reference
methods, information provided by the manufacturer
should include predisposing test conditions or patient abnormalities which will affect the test and give
inaccurate or undependable results. Such interfering
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conditions are particularly troublesome with newly
developed tests such as radioimmunoassays. Tests for
digoxin, for example, may measure not only digoxin
but also its metabolites ( 10) . More worrisome, however, are reports that therapeutically administered
compounds such as cortisol and spironolactone may
react with the digoxin-binding antibody to give erroneous results.
Laboratory Trials. Although few laboratories
will carry out an evaluation of a kit as elaborate
as those which are described in scientific journals, it
is falacious to assume that results similar to those in
published articles can be obtained automatically by
any kit purchaser. The procedures for experimental
evaluation may vary from kit to kit, but critical
testing of every type of kit by the laboratory in which
it is to be used is essential.
Meticulous examination of the instructions
which accompany the kit will frequently eliminate
unnecessary work. The instructions should present
a logical and detailed outline of each step in the
procedure, with a clear indication of where errors
might occur, what types of instruments are suitable,
in which steps timing is critical and how results are
to be calculated from instrument readings. The instructions should be followed compulsively under all
circumstances. Suitable standards should be included
with aJI kits for quantitative measurements and the
standards should have concentrations which span the
range of clinically useful measurements. Controls
should be run with each batch of any procedure,
whether it is a quantitative or a qualitative one and,
if possible, control solutions should be obtained from
a manufacturer other than the supplier of the kit.
Qualitative tests generally should have both a positive
and a negative control; these usually accompany the
kit, however, since they may be the only suitable
controls available.
Replicate determinations on different days of
one, or preferably several, control solutions provides
an indication of the precision which might be expected. If reproducibility is unsatisfactory, the problem may reside either in the kit or in the technique.
If errors can be traced to faulty technique which is
corrected, the experiments should be repeated ; if not,
the kit should not be accepted for routine use in the
laboratory. A second useful step in evaluating a kit
is separation of patient samples into two aliquots,
one to be run by the kit method and the other to be
submitted to a reference laboratory. A minimum of
a dozen, and preferably several times that number,
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split samples should be analyzed before acceptance
of the kit for routine use. Many manufacturers will
supply free samples of kits for preliminary evaluation; this practice, however, should have no influence
on the laboratory in regard to which kits are tested
and which are finally selected for routine use.
Evaluation of an instrument which is designed
for use with kits for a variety of procedures may be
quite time-consuming, since each procedure for
which a kit is available must be evaluated separately.
Logan and Sunderland ( 8) evaluated the Unitest
System® marketed by Bio-Dynamics, Inc., Indianapolis, Indiana, and Diagnotest® marketed by
Dow Chemical Company, Diagnostic Products Division, Indianapolis, Indiana. For each instrument,
some of the kits performed unsatisfactorily, and the
authors concluded that personnel without technical
training could not obtain reliable data with either
system.
Continuing Evaluation. Initial evaluation and
acceptance of a kit for routine use in the laboratory
does not assure continuing satisfactory performance.
Most important, the use of kits does not obviate
the need for strict quality control measures. Suitable
quality control solutions should be run with each
batch of procedures, strict limits for variation of the
control solution should be set and all data should
be rejected if control readings are out of the predetermined range. Lot numbers of each reagent or
kit should be entered into the laboratory log book
and when a new lot number is used, samples should
be run in duplicate with the old and the new reagents
to permit comparison between lots.
FDA Regulations Regarding Kits. It perhaps
should be stressed that most of the laboratory kits
on the market today were developed during a period
when there were no federal regulations setting minimum performance standards. As early as 1966 the
American Association of Clinical Chemists (1) published policies regarding reagent sets and kits which,
had they been followed by all manufacturers, might
have greatly reduced the number of subsequent
articles devoted to documenting the inadequacies of
many kits. Manufacturers also could voluntarily
submit kits to the College of American Pathologists
for evaluation; however, compliance with the recommendations of the college in the case of inadequate
kits was also voluntary. Published evaluations of all
types of kits clearly indicate that some are unsatisfactory, some are satisfactory and some are outstanding in meeting performance standards.
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In January 1972, the Food and Drug Administration announced that existing legislation gave them
authority to exercise regulatory control over diagnostic kits to ensure that they deliver a consistently
high level of quality and performance (3). A statement of procedures for developing policy and interpretive regulations was published in August 1972
(4). Briefly, these regulations require that diagnostic
kits be accurate and reliable, that manufacturers test
and evaluate kits prior to marketing them and verify
results against a generally accepted procedure, that
premarket testing is done to find if predisposing
patient abnormalities will affect the test and that the
labeling of all kits contains adequate directions for
use. The labeling directions must include complete
information on accuracy, reproducibility and sensitivity performance. The FDA intends to establish
standards of performance for each type of laboratory
kit and require manufacturers to meet these standards. Establishing pertinent standards will be time
consuming (the FDA intends to start with glucose
and hemoglobin), but merely requiring manufacturers to provide evidence that kits will perform as
claimed will be helpful for anyone who must decide
which kit to purchase. The FDA is already enforcing these regulations and has required two manufacturers of pregnancy test kits to recall their products.
Cost Evaluation. The cost of performing laboratory tests is causing increasing concern because of
the dramatic increase in the use of laboratory data in
patient care and because many of the newer tests are
more complicated and thus more expensive. Evaluation of a laboratory procedure should include the
cost of doing it. In a physician's office or a small
laboratory, such cost accounting can be quite simple,
since it is easy to calculate the cost per test done by
a kit method and to measure personnel time involved. Since most kits have expiration dates, the
cost per test of the kit should take into account the
necessity for discarding outdated reagents. Generally
speaking the cost of a quantitative measurement
carried out by a kit method will be considerably
higher than the same test carried out on automated
laboratory instruments. On the other hand, even
large laboratories use prepared reagents and kits for
performing some of the simpler tests and these tests
can be performed in the office laboratory at the same
or perhaps lower cost than in a large laboratory.
Higher costs for performing tests in physicians' offices may be offset by convenience to the patient or
the necessity for having data immediately available.
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Summary. Prepackaged laboratory kits for performing diagnostic procedures are frequently the
most suitable alternative in the selection of laboratory methods, especially in physicians' offices and
small laboratories. Because of the previous lack of
governmental regulations covering the manufacture
of kits, many kits now on the market do not perform
adequately and may produce misleading results.
Each laboratory must evaluate each type of kit
before it is put into routine use. This evaluation
should include a review of published experimental
data, comparison of results using the kit to results
using a reference method and an experimental
evaluation of the kit in the laboratory in which it is
to be used.
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Unique Characteristics and Implications of
Individual Health Profiles*
GEORGE Z. WILLIAMS, M.D., D.Sc.
Director, Institute of Health Research; Clinical Professor of Clinical Pathology,
University of California, San Francisco

During the era of prescientific medicine, people
were divided into two categories: those who were
sick and those who were not sick. Physicians found
it necessary to establish criteria to differentiate the
ill and separate them according to symptoms and
signs characteristic of classifiable diseases. Because
of preoccupation with disease, the concept of the
"normal" versus the pathological, as two opposite
and definable conditions, was inevitable in the absence of scientific knowledge of human chemistry
and physiology. This concept has carried over into
the present era of scientific medicine. Growing health
awareness and concern and the demand for preventive medicine, however, has sharply focused attention
upon the question of normalcy. This vestigial desire
for a neat, comfortable definition of "the normal"
was initially satisfied by the artifact of utilizing the
statistical mean and two standard deviations as descriptive of the "normal" population. As our knowledge of human physiology, chemistry and hematology
has enlarged, however, critical analysis of precise
measurements has demonstrated that there is no
universal "normal" state, nor a "normal" range of
values. Normalcy is a philosophical and social condition of not being recognized abnormal. Scientific
definition of "normal" is not only impossible but
meaningless. The large heart which is normal for a
big man is decidedly abnormal for a small man. The
normal erythrocyte count for a native of the high
Andes is abnormal for a native of the Virginia tidelands. Furthermore, the body is seldom free of some

* Presented by Dr. Williams at the 44th Annual McGuire Lecture Series, M arch 22, 1973, at the Medical College of Virginia, Richmond.
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reaction to bacterial invasion, foreign protein, or
localized tissue destruction. Dr. Edmond A. Murphy
(Perspect. Biol. Med., 15: 566, 1972) asks what
reason there is to believe that the notion of
normalcy has any useful meaning. He questions
the purpose of trying to convert a continuum of
graded risk and change into a fictitious dichotomy
of the normal and the abnormal.
There is a need, however, to recognize and
describe the deterioration of optimum health in the
individual person as a basis for rational preventive
medicine and predictive diagnosis. The prerequisite
is documentation of a reference base of values descriptive of optimum health of each individual.
The International Federation of Clinical Chemistry has established a committee on relative values
to recommend definitions and procedures for determining reference values. This committee is agreed
that the artificial concept of a normal average and
normal range should be avoided and considered
impossible to define scientifically. Preference is given
the term "reference values," defined as those values
of quantities which describe a definite "reference
state" of health or disease of an individual or of a
group of like people. The reference state may be
that of optimum health defined by a given set of limits
related to a person's genetic potential, environment
and life habits, or of relatively good health, compromised only by stabilized defects which do not
shorten survival. Other reference states related to
disease are useful in diagnosis and monitoring
therapy. Our present interest is focused on the
reference state of optimum health.
Only in the past decade have laboratory meth355
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ods and automated instrumentation become precise
enough to permit discovery of individual differences
in homeostatic control of blood chemistry and physiology and of the consequent documentation of a
reference profile of reliable values for each person.
Work started at the National Institutes of Health
during 1960, which is being continued in our Institute of Health Research,* has demonstrated that
chronological profiles of blood chemical, hematological, and certain physiological measurements are
unique for each individual and are surprisingly stable
over prolonged periods. Such a profile, when established during a time of vigorous health and wellbeing, becomes a clearly defined and reliable reference base for all future measurements, and more
importantly, for the discovery of early abnormal
trends in that particular person. We have found that
the individual range of variation for each constituent,
when corrected for laboratory bias, is quite small,
stable and far less than the range of values found to
be usual in a large population of "well" people.
Documentation of Individual Reference Profiles.
Because test methods are not sufficiently precise, it
is necessary to obtain a series of repeated sets of
measurements during a period of optimum health for
any given person, in order to establish his individual
reference values of blood chemistry, hematology and
physiology. The series of measurement data permits
the determination of the mean and the range of
variation of each measurement to best approach the
true values. Since it has been clearly demonstrated
in our laboratories, and confirmed by others, that
the observed range of repeated measurements of
blood chemical constituents consists of at least two
components, the bias of laboratory manipulations
and a physiological variation, all sets of observed
measurements should be corrected for the analytical
bias. Physiological shifts are characteristic of the
person being tested. Laboratory manipulations, instruments and conditions cause analytical bias. For
most blood chemical tests, this bias is at least as
large as, and for some tests substantially larger than,
the physiological variation manifested over periods
of weeks or months. This is illustrated in figure 1,
which is the plot of cholesterol values obtained
weekly for 12 weeks on a group of 29 healthy individuals. The horizontal axis represents the range of
two standard deviations, above and below the mean,
"'Under grant support from the National Institute of
General Medical Sciences, N .I.H.

WILLIAMS: INDIVIDUAL HEALTH PROFILES

for the entire group of 200 healthy persons in the
study. Each bar represents the mean and standard
deviation of the observed set of values for that individual. The middle, darker portion represents the
physiological changes which occurred over the period of observation and the open ends are the
proportion of the total variation due to analytical
bias. This plot also illustrates the uniqueness of the
mean and physiological variation for each individual.
We have interpreted the range of variation in
each person to portray a long-term homeostatic control of the particular blood constituent. This shows
the individual's healthy tolerance limits and built-in
control of variation, based on his genetic potential
and the usual circumstances for his life-style in
terms of diet, physical activity and reaction to his
environment.
The variation of any blood constituent in an
individual apparently is controlled by physiological
feedback communication mechanisms limiting the degree of variation. The range of values established
during a period of optimum health may be presumed to represent the efficiency of this control and
is assumed to be homeostatic in nature. Homeostatic
control apparently is effective in the individual over
long periods of time (years) for many blood con-
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stituents. It is reasonable to believe that the degree
of this homeostatic control of the range of variation
must have important implications in relation to state
of health and optimum function. Thus, substantial
changes in the range of variation of a blood chemical
must have medical meaning; for instance, for a consistently narrow range of glucose or uric acid or
cholesterol or an enzyme to broaden to a wide range
of daily or weekly variation may augur trouble.
When repeated measurements obtained are similar for other blood chemical constituents over a
defined period of optimum health, and the data are
plotted in a like manner, the resulting chart depicts
the unique blood chemical profile for that individual.
Figures 2 and 3 are the profiles of two people. No
two identical profiles have been foond in several
hundred healthy people.
Such a set of quantitative values, when established with rigidly controlled, precise analytical
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methods during a period of optimum health, constitutes the individual's reference base line to which
all subsequent values can be compared. Deviation
of any particular constituent or set outside the individual's reference range may be presumed to be
undesirable for this particular person-even though
the deviation may not extend beyond the conventionally accepted boundaries of "normal" for the
general population. Should several determinations,
at appropriate intervals, confirm the deviation to
remain outside this individual's reference range, it
should be interpreted as the beginning of a definite
pathologic trend, although otherwise undetectable,
that requires further investigation.
The "natural history" of the deterioration of an
optimum state of health associated with the development and onset of disease may be depicted diagrammatically as in figure 4. During some period of a
person's life, prior to onset of symptoms, there are
at least two phases-optimum health and a zone of
uncertainty during which health gradually and "silently" deteriorates to a condition of "predisease."
This phase may be detectable by predisease changes
in chemical and physiological quantitative values by
comparison with the person's health reference profile
of values and variations.
Figure 5 represents two possible deviation
events. Superimposed upon the healthy reference
profile of an individual are the results of annual sets
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of tests for several years. Note that in the instance of
uric acid there is a linear and persistent deviation of
these results in the direction of higher values. For
cholesterol, deviation is geometric in progression.
Even though these results are all within the range
usually considered normal for an adult, in this instance, they must be interpreted as definitely abnormal for this particular person. Here we have a
new tool for monitoring a person's health and for
detecting early trends in the deterioration of his
health, which may warn of impending pathology.
Furthermore, this technique allows rationalized management procedures to attempt reversal of early abnormal trends or correction of the conditions which
brought about this change. Figure 6 is the chronological graphic record of such a case over a ten-year
period. There was a gradual increase in blood uric
acid and cholesterol for several years, followed by
reversal of both to the individual's own normal range
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by institution of management procedures, including
monitored administration of allopurinol and a diet
and running exercise regimen. Other cases in our
experience encourage the belief that such "silent"
trends can be discovered during a reversible phase
and may result in either delay or prevention of progressive deterioration to overt disease.
The Future. We now have a scientific procedure
for establishing a reference base of optimal values
for people and the maintenance of prospective, lifetime profiles in regional data centers. It is possible to
design computer simulation models for each of these
profiles, including the body chemistry, physiology,
and later, mental and emotional test patterns to be
correlated with the person's life history. The individual models can be updated periodically to provide
follow-up health management guides for each person.
Such a data base will be invaluable for the physician
in guiding his diagnostic and therapeutic decisions
when a person requires medical care. Figure 7 is a
tentative diagram of such a model. When irreversible
changes do occur and definitive diagnosis is feasible,
the development of disease will be detected far
earlier than is now possible and presumably the
patient will react more amenably to rational therapy.
The physician team will have at hand not only a
subjective, recent history but also a well-documented
family and clinical history and a very useful physiological and chemical history. This is only one of the
many advances we may expect of rapidly accelerating technological progress in the new era of preventive medicine.
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The Value of Chemical Screening
Profiles on Blood*
SEYMOUR BAKERMAN, M.D.
Professor of Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

Chemical screening profiles on blood specimens
are designed to yield information that may lead to
new and additional clinical diagnoses, to revision of
clinically established diagnoses, to confirmed impressions of the physician and to following the course of
diseases during a patient's hospitalization. Screening
profiles on blood are designed to indicate diseases of
the liver, kidney, heart, striated muscle and other
organs; they may be helpful in the diagnosis of
anemia, diabetes mellitus, gout, congestive heart
failure, osteomalacia and hyperlipidemia, hyperparathyroidism and other diseases. When these screening
profiles were first introduced, there was widespread
skepticism among physicians as to their value and
their yield and some skepticism remains as to the
usefulness of a broad spectrum of laboratory tests.
The relative number of new clinical diagnoses
generated from blood chemistry screening profiles
has been reported in five studies of three different
patient populations: hospital patients, hospital clinic
patients and patients presenting to doctors' offices
(Table 1). The percentage of new diagnoses ranged
from 3-16.9% with the percentage tending to increase with the number and selection of tests. New
clinical diagnoses were obtained in 4% and 8.3%
of hospital patients, 3 % of hospital clinic patients,
and 5.5% and 16.9% of patients presenting to doctors' offices. The blood chemistries that were most
frequently abnormal were glucose, bilirubin, alkaline
phosphatase, serum glutamic oxalacetic transaminase
(SGOT), lactic dehydrogenase (LDH), uric acid,
cholesterol, creatinine, urea nitrogen and hemo-

* Presented by Dr. Bakerman at the 44th Annual McGuire Lecture Series, March 22, 1973, at the Medical College of Virginia, Richmond.
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globin; the diagnoses that were suggested and subsequently confirmed by the abnormal blood chemistries are given in Table 2. Diagnoses other than
those listed in this table were generated but at a
lower frequency.
Occasionally, elevated calcium led to a diagnosis of primary hyperparathyroidism and an elevated protein led to a diagnosis of multiple myeloma.
If these blood screening profiles had uniformly included other blood tests, such as iron and iron binding capacity for anemia, triglycerides for hyperlipoproteinemia and protein bound iodine (PBI) or
thyroxine (T-4) for thyroid disease, then the percentage of patients yielding new diagnoses would
have increased. It must be emphasized that the initial
chemical screening tests in themselves did not usually
lead directly to the assigned diagnosis but more
definitive tests were required.
Table 2 indicates the laboratory screening
values that generated new clinical diagnoses and in
most instances, required a change in treatment. Thus,
the screening tests contributed to the recognition of
otherwise unsuspected disease. The abnormal test
results may be of value in arriving at earlier diagnoses, earlier treatment and reduction of time for
subsequent investigation since the results are available sooner than under previous conditions where
laboratory tests were ordered individually. If clinical
features alone were used to guide the physician in
ordering laboratory tests, abnormal test values would
be obtained in less than 1.5 % of the patients ( 4) .
Selection of the most appropriate tests for chemical
screening is still not complete since different populations of patients may require different groupings of
chemical screening tests.
MCV QUARTERLY 9(4): 360-361, 1973
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TABLE 1
N EW DIAGNOSES OBTAINED BY CHEMICAL SCREENING PROFILES
ON BLOOD IN DIFFERENT PATIENT POPULATIONS
Patient Population

Percent of Patients Yielding New
Diagnoses

Hospital Patients

4.0
8. 3
Hospital Clinic Patients 3. 0
5.5
Patients Presenting to
16. 9
Doctors' Offices

(Belliveau et al., 1970)
(Carmalt et al., 1970)
(Young and Drake, 1966)
(Percy-Robb et al., 1971)
(Carmalt et al. , 1970)

ABNORMAL BLOOD CHEMISTRIES BY CHEMICAL SCREENING
PROFILES AND FREQUENTLY FOUND NEW DIAGNOSES

Glucose
Bilirubin
Alkaline Phosphatase
Serum Glutamic Oxalacetic
Transaminase (SGOT)
Lactic Dehydrogenase (LDH)
Uric Acid
Cholesterol

Creatinine
Urea Nitrogen
Hemoglobin

Data are not included on abnormal laboratory
values that tended to confirm the impressions of the
physician based on his history and physical examination of the patient. These profiles also contribute to
patient care by providing indicated laboratory tests
rapidly and efficiently (3). These profiles also help
to detect organ systems that may be functioning
normally and thus, may not require a doctor's attention. If these data were available, then the value of
chemical screening profiles would be even more
apparent.
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Multitest Screening 1n Hematology*
CHARLES L. JOHNSTON JR., M.D.
Professor of Clinical Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond

The concept of multitest screening for hematological disorders is not necessarily a new one. Implementation of such ideas has recently become possible,
for the automated electronic instruments performing sequential multiple analyses within very short
periods of time are a very significant advancement
in the technology of the hematology laboratory. It
must be emphasized, however, that the value of such
instrumentation lies not only in the rapidity, but also
in the accuracy and precision as well as the number
and nature of the tests performed. While the data on
samples have been reported on individual patients
three and a half years in our hematology laboratory,
it is only within the past few months that examples
of its utilization for screening studies have begun to
appear in the literature (1, 3, 5) .
Several automated instruments are available
that perform the routine counting and sizing of cells
in the blood. The Coulter model "S" is the one most
widely used ( 2) . This is the instrument we use and
it is the one used in the studies to be cited here. It
is an instrument that reports on seven parameters,
measuring the WBC, RBC, and mean corpuscular
volume (MCV), and utilizing the latter two computing the hematocrit and then the mean corpuscular
hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC). The time required
from the time of sample aspiration until the results
of the seven determinations are printed is 40 seconds.
I must emphasize that not only speed is achieved,
but precision and accuracy are far greater than many
previously used methods. Indeed, variation on replicate samples is less than 1 % and accuracy appears
to be of the same order.
Considering the availability of such accurate
data and the comparative ease with which they may
be obtained, it can be seen that these instruments

* Presented by Dr. Johnston at the 44th Annual McGuire Lecture Series, March 23, 1973, at the Medical College of Virginia, Richmond .
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can be valuable tools in screening for hematological
abnormalities. Indeed here at the Medical College
of Virginia, two interdepartmental cooperative
studies have been conducted within the past year.
One of these was presented in abstract form at the
December 1972 meeting of the American Society
of Hematology, and has recently been submitted for
definitive publication (5). The work in large part
was the project of Mr. Alvin Schmaier, currently a
third-year medical student, with assistance from Drs.
Maurer, Johnston and Scott. The other study has
been conducted as part of a larger study in approximately 530 Black children in the Head Start Program. These studies exemplify particularly well the
principle of multitest screening in hematology, and
it is to these and to a comparison of these with
previous studies (1, 3) that I wish to address myself.
I will not detail the technical operation of the
model "S" but note here that we have had the instrument in operation for more than three and a half
years. This has given us extensive experience in all
of the positive as well as the negative qualities of
the instrument. Because some of the parameters are
computed, our initial efforts were to compare these
with other methods then in operation and standardize
the data. This was accomplished by comparative data
obtained on 1,500 samples of EDTA anticoagulated
blood. No significant difference was found in the
hemoglobin determination, but the linearity was better in the model "S" determinations than with flowthrough determinations giving greater accuracy to
the former, particularly in the high > 16 gm and
low < 7 gm ranges. For reasons which have never
been satisfactorily explained either by us or by the
manufacturer, the WBCs average approximately
8 % lower by the model "S" than when determined
by our alternative or electronic back-up. This discrepancy is noted also in data from other institutions. The lower percentage has been consistent
MCV QUARTERLY 9 (4): 362- 367, 1973
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and therefore is not a factor. Finally, the comparison of the spun hematocrit with the computed
hematocrit (MCV x RBC) showed the latter to
be, on the average, 1 % higher-a difference that
is minimal and one that certainly can be disregarded. I should note here that this is somewhat
different from the study of England and Fraser
( 1) who set the electronics so that the hematocrit is 1.5% below the spun hematocrit. This
quite possibly might allow for differences of our
MCV norm 92 ± 6 (range 86-98) from theirs
(80-90). Indeed Pearson, et al. ( 3), describe a
range of 72-101 with a mean of 88.67 and a standard deviation of 5.3.
At the outset then, it becomes important to note
what the norms are for the population being studied
and these should be norms for the institution. The
data just given are presumed to be an adult population; however, it is not clear from either of the published reports cited above whether age differences
were taken into consideration in their studies. The
reason for concern with the age variability of the
MCV data will become apparent since this parameter
is one of the major criteria used to screen for the
thalassemia syndromes.
The other measured parameter of extreme importance in the screening efforts is the RBC. We
have come to regard this as extremely accurately
measured by the model "S." In contrast to the
earlier manual methods with an accuracy no greater
than 20 % , we now feel the accuracy and reproducibility of this measurement is on the order of
1 % , or in the range of 50,000 RBC/µl.
With these points in mind, I would like to discuss the application of multitest screening in hematology and share some of the results we have accumulated in specific studies. The first such study
undertaken here was a cooperative effort involving
the divisions of Clinical Pathology, Pediatrics and
Medicine. Mr. Alvin Schmaier, working as a summer
extern in the Department of Pediatrics, was responsible for the collection of samples anti collation of
the data. This portion of my report is in large part
his effort. It is a most commendable piece of work
which recently has been submitted for publication ( 5). The data given here are reproduced with
his permission.
This study took advantage of the fact that defective alpha chain synthesis may occur in the neonate
and result in the presence of the tetrameric hemoglobin, hemoglobin Barts (gamma 4). This form of
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hemoglobin rapidly disappears with onset of beta
chain synthesis and by six months of age no longer
can be identified. Cord blood studies have been performed but these naturally are limited in scope.
Alpha thalassemia heterozygotes have abnormal red
cell indices, and if these could be identified early, it
might be possible to select infants in the neonatal
period, or certainly within the first few weeks of
life, whose blood then could be subjected to hemoglobin electrophoresis.
Taking advantage of the fact that blood could
be obtained by capillary puncture with the use of
unopettes from Becton Dickinson especially for
model "S" counters ( order no. 5840, Becton Dickinson, Rutherford, N. J.), Mr. Schmaier began collecting capillary samples in triplicate from the newborn nursery, of course after receiving parental
consent. Table 1 shows the tabulation of the results.
In particular, I want to call attention to the MCV
and MCH. If one were to choose values for identification as suggested by other studies, one would
select only those with values below 80 fl! Obviously,
then the norm for this population group is quite different from adults, a fact that is well known ( 6).
We were unaware, however, of the limits using the
model "S" and these needed definition for the study.
A total of 200 newborn Black infants was
studied. Electrophoresis of the hemoglobin in these
newborns showed 181 to be normal; that is, only
hemoglobins A and F. Of the remainder, 13 showed
an additional abnormal hemoglobin either S or C,
while six showed the presence of hemoglobin Barts.
Of the six, one also showed C and one S hemoglobin.
As defined in Table 1, the lower limit of normal was
97 fl. In the samples studied, nine infants had MCV
less than 94 fl and MCH less than 29.5 fl. Since
these figures are less than normal the data would be
"suspect" and thus hemoglobin electrophoresis was
performed. In the group of 200 studied, all had
hemoglobin electrophoresis performed. Table 2
shows the hemoglobin electrophoresis and pertinent
model "S" data on those with abnormal MCV and
MCH. It is to be noted that hypochromia can no
longer be assessed by the MCHC ( 4); that is clearly
shown in this table. The most s·triking findings are
that of nine patients, six had hemoglobin Barts and
thus the alpha thalassemia trait. These were clearly
identified by the low MCV and low MCH. Two of
the patients had a second abnormality in that Hgb C
was identified in one and S in the other. In the total
sample, 13 infants were identified who had either
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TABLE 1
RED CELL INDICES IN NORMAL BLACK FULL-TERM NEWBORN INFANTS

Red Blood Cell Count ( X 10 6 / µI)
Hemoglobin (g / dl)
Hematocrit ( % )
Mean Corpuscular Volume (fl)
Mean Corpuscular Hemoglobin (pg)
Mean Corpuscular Hemoglobin Concentration (g/dl)

Mean

Standard Deviation

ks

lower Tolerance Limit

5.2
18.0
55.3
106.4
34. 5
32.5

0.6
2.0
6.1
5.7
2.2
1.0

1.0
3.3
10.0
9.4
3.6
1. 7

4.2
14.7
45.3
97.0
30.9
30.8

s = Standard Deviation
Constant k = L65
Lower tolerance limit = mean-ks
Sample size == 91
For example, for the mean corpuscular volume of 106.4µ 3 , the lower limit of normal is 97µ 3 (lower tolerance limit).

Hgb Sor C but no Barts and an MCV and MCH
within the normal limits. Thus in this study, all
infants with alpha thalassemia were readily identified
so that no "false negative" values were recorded.
There apparently were three false positives, with
data just below the norms set. Currently, there is no
explanation for these.
It can be seen then that Mr. Schmaier made
a significant contribution in the study and that it
is possible to screen infants using the multitest
principle. As a matter of fact, the incidence of
3 % hemoglobin Barts is consistent with the reported incidence in American Blacks.

Let me now turn to another study involving
muHitest screening with the evaluation of RBC
abnormality indices. Whereas the previous study
was concerned with alpha thalassemia trait, this
study was designed to study thalassemia traits perhaps encompassing both alpha and beta thalassemias. Again, this was a cooperative study involving the same divisions as those in the study
just cited.
The group screened was quite different, however. This was composed of 540 Black children
most of whom were enrolled in the Head Start
Program in Richmond. Our study was only part

TABLE 2
HEMATOLOGIC FINDINGS IN NINE INFANTS WITH MEAN CORPUSCULAR VOLUMES < 94 FL
AND MEAN CORPUSCULAR HEMOGLOBINS <29.5 PG
Infant
1
2
3
4
5
6
7
8
9

Hgb Pattern
F, A,
F, A,
F, A,
F, A,
F, A,
A, F,
F,A
F,A
F, A

S, Barts
C, Barts
Barts
Batts
Barts
Barts*

MCV (fl)

MCH (pg)

MCHC (gm/di)

Hgb Barts ( % )

Other Abnormal Hgb ( % )

93
93
87
94
93
90
91
93
91

28.5
28.2
27.7
29.1
29 . 5
28 .0
29.0
29.2
29 . 3

31.0
30. 7
32 . 0
31.4
32.1
31. 6
31.2
31.4
32.2

4.6
4.4
5. 1
6. 6
4.8
3.0

4.8
10. 6

MCV = mean corpuscular volume
MCH = mean corpuscular hemoglobin
MCHC = mean corpuscular hemoglobin concentration
RBC = red blood cell count
Hgb = hemoglobin
Hct = hematocrit
* Electrophoretic pattern at one month of age
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of a larger medical evaluation conducted under
the aegis of the Department of Pediatrics at the
Medical College of Virginia. As part of the study,
capillary blood samples were drawn by a registered
medical technologist at the various schools. Samples
were takep. for Coulter model "S" determinations
and hemoglobin electrophoresis. As in the earlier
study, unopettes for the model "S" (order no. 5840,
Becton Dickinson, Rutherford, N. J.) were used.
These were drawn in duplicate, the model "S"
parameters determined on both samples. Capillary
sampks also were used for the hemoglobin electrophoresis. Indices available for comparison were
dated prior to the advent of electronic counters
performing multiple simultaneous tests. Our experience with initial standardization of our model
"S" showed that our norm for the automated procedures of 92 ± 6 was higher than that generally
used · of 88 .± 8. It seemed likely, therefore, tqat
these older data could represent values lower tqan
might be obtained by the currently used automated
methods. Additionally, other than the standards
cited by Shumway (6), I am aware of no others.
As a result, it seemed preferable to determine our own
mean model "S" parameters for this age group.
As noted, the recently published works did
not specify the ages of the patients studied. It was
assumed, therefore, that these were adults. In both
studies, the lower limit of normal was 80. With
Shumway's data ( 6) suggesting a lower mean MCV
for pediatric age groups when compared with adults,
we felt that perhaps it would be wise to include
lower values. Thus for those studies, an MCV of 76
or greater was used for establishment of the mean
and those 75 or lower were excluded. It is gratifying
to note that 26% of the children studied had MCVs
76-79 and would have been excluded if the criteria
of other screening studies had been used.
For the moment, I would like to refer to the
results not as normal but rather as "mean model
'S' parameters." The health of the children was
not evaluated and the sampling was random. Data
from two children were excluded because of hemoglobin values less than 10 but with MCV over 80.
As a result, determination on 451 Black
children, ages four to eight, with MCV greater than
76 were available for analysis. The results of these
determinations are shown in Table 3. As noted,
these are mean model "S" parameters for the group
studied. These show the means with one standard
deviation as well as the range. Also shown is the

TABLE 3
MEAN MODEL "S" PARAMETERS
(451 Black Children MCV > 75)

Determination

Mean± SD

Range

Lower
Toi. Limit*

RBC
Hgb
Hct
MCV
MCH
MCHC

4.51 ± 0.31
12.3 ± 0.86
36.7 ± 2.4
81.8 ± 3.3
27. 3 ± I. 3
33.7±0. 8

3.81-5.19
10.4- 14.8
31.1-45.1
76.0-91.0
24 . 3-31. 3
31. 9-35. 7

4.0
10.9
32.7
76.4
25 . 2
32 . 4

* Lower Tolerance Limit

= x - ks
mean
k = 1.65 (95 % tolerance level)
s = standard deviation

x

=

lower tolerance limit using a 95 % tolerance interval (k = 1.65) . With these figures we could
be 95 % certain that 90% of the values would be
above the lower tolerance limit shown in the right
hand column.
It now becomes of great interest to compare
these results with those alluded to earlier as having
been determined by nonautomated methods and
reported by Shumway ( 6). This comparison is
shown in Table 4. The similarities are remarkable,
especially when one considers that our population
sample was not a selected one and was from children with Hgb greater than 10.4 gms and MCV
76 or greater. I think we can conclude that it might
be reasonable to accept these as normal values for
the age group.
Our original intent for the determination of
the indices was to see if it would be possible to
screen for thalassemia trait using microcytic hypochromic indices as the major criteria. The spectre
of iron deficiency, however, loomed large in front
of us since both thalassemia trait and iron de-

TABLE 4
Current Data
RBC
Hgb
Hct
MCV
MCH
MCHC

4 . 51 ± 0.31
12.3 ± 0 . 86
36 . 7 ± 2.4
81.8 ± 3.3
27. 3 ± I. 3
33.7±0.8

Shumway (6)
4.65
12 . 7
37 .0
80.0
27.0
34.0

±
±
±
±
±
±

.5
1
3
4
2
1
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ficiency are characterized by microcytic hypochromic
indices. At the time that these data were being collated for presentation, the results of the
hemoglobin electrophoresis were not available.
Thus, there were 84 children with MCV 75 or
less who needed to be differentiated if possible.
Pearson, et al. (3), in their studies, proposed a
scheme for thalassemia trait screening. This is shown
in a slightly modified fashion in figure 1. Note that
the first step in screening is to classify the subjects
into two groups according to the MCV which is
precisely what we did. The next step involves
quantification of A.2 hemoglobin which, as noted,
is not at the moment available.
This led to a search for an alternative method
for attempting to differentiate the MCV 75 and
below group. Recently, such a method has been
published by England and Fraser ( 1). They reported that by the use of the statistical discriminant
function (D.F .) they were able to differentiate between ·the disorders with a 99% success rate in
72 cases. As a result of their study, a slightly modified formulation is available and is shown as well
as the data for the study in Table 5. Thus, it seemed

MCV (Model "S")

MCV < 79 fl

~~

MCV >79 fl

that it might be possible to predict, in advance of
the receipt of the electrophoretic data, the groups
into which our 84 subjects might fall and effectively
separate the thalassemia trait from an iron deficiency. Accordingly, the appropriate data on those
children with MCV 75 or less were substituted
into the formula. The results are shown along with
the normal in Table 5. It can be seen that 11 of
the group had negative, while 73 had positive, D.F.s.
To show the distribution, a chart like that of England and Fraser ( 1 ) was prepared and is shown
in figure 2. The closed circles represent those subjects with a positive D.F.' and presumable iron deficiency. Those with the open circles represent the
negative D.F.' and presumable thalassemia trait.
Since the critical data currently are missing, I think
it is only possible to state that we are predicting
that these are the groups into which the subjects
fall. The data in Table 5 show certain of the mean
values to be sufficiently different to suggest that these
really are two distinct groups despite a few (four)
that were too close to O to call ( fig. 2). As soon as
the additional data are available, we will know how
well we are able to predict.
If I may be allowed to speculate, I expect a
high success rate. As evidence for this rather rash
statement, again direct your attention to figure 2.
Note that in the D.F.' negative area [D.F.' =
MCV -RBC - (5 x Hgb) - 3.4] there are
four x's. While this manuscript was in preparation,
I noted four patients' model "S" data that were
quite like those seen in the 11 children with negative D.F.s. I felt these were suspect on the basis

Dx: Normal
TABLE 5
Hgb A,> 3.5%
Dx:

f)

COMPARISON OF GROUPS

3.5%

t

t

Thalassemia

# of
Children

Serum iron

/

Normal
+ family study

i

451

\

BY

MCV AND D.F.'*

11

73
MCV < 76

Reduced
MCV > 75
Dx: Iron deficiency

Dx : a Thalassemia

Modified from Pearson, et al (3).

RBC
Hgb
Hct
MCV
MCH
MCHC
* D.F.'

Fig. I- Suggested schema for thalassemia trait screening.

4. 51±0.31
12.3±0.86
36.7 ± 2. 4
81.8±3.3
27.3 ± 1.3
33.7±0.8
=

D.F.'*5.54±0.19
12.5 ± 0 . 67
37. 7 ± 1. 79
*68.4 ± 3. 8
*22.6±1.75
33 . 3 ± 1.03

D.F.'+
4.86 ± 0 . 28
11.6 ± 0. 70
35.2±2.14
*72.9 ± 2.57
*24.0 ± 1.15
33 . 1 ± 0.93

MCV - RBC - (5 X Hgb) - 3.4
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Figure 2

>11
+10

+8

+6

+4

+2

TABLE 6

··-··········

•

•

• •
••
•
•
•
•
• • • •
• •
• •
•• • • • •
• • •
••
• • •
• • • •• •
••••
•••
•
• • •
•
• •• • • • •
..................................
•
................................
~

•

•
0

0

.....................................................................
0

-2
0

0

X (6.0%)

0

-4

0

MCV

MCH

D .F.

% A,Hgb

D.H.
W.F .
A.J.
P.F.

5.65
6.52
6.17
6.16

62
64
65
64

20
20
21
20

-3 .05
-9.92
-8.5
-6.5

6
6
7
(*)

* Elevated above normal- not quantified

to select those most likely to have beta thalassemia
trait. I await with eagerness complete collation of
data, predictions and electrophoresis in the 84
children noted.
In summary, it can be said that a sample of
multitest screening in hematology has been presented, made possible by the use of automated
counting apparatus. The ease, precision and accuracy of the determinations favor much wider
application. To this end studies are now cropping
up in the literature, almost with every new journal
that hits one's desk. Our efforts presented here show
that studies of "at risk" populations are not only
feasible but practical. Such examples as those given,
certainly advance our knowledge and facilitate our
know-how in difficult diagnostic areas.

0

REFERENCES
0

x (*)
-8
X (7.0%)
-10

RBC

0
0

-6

Patient

X (6.0%)

D.F. = MCV - RBC - (5 x Hgb) - 3.4
*Elevated above normal - not quantified
Fig. 2

of the experience I was accumulating. Hemoglobin
electrophoresis was performed in these, therefore,
and the A 2 hemoglobin quantified. Summary data
on these patients are given in Table 6. Such ability
to predict certainly suggests that the automated
multitest apparatus has given us remarkable ability
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Pitfalls in Unqualified Acceptance of
Laboratory Data*
MYRTON F. BEELER, M.D.
Professor, Department of Pathology,
Louisiana State University Medical Center, New Orleans

One can never be absolutely certain that any
single laboratory report is correct. As a general rule,
therefore, do not undertake potentially serious action
on behalf of any patient solely because of a single
laboratory report. This is especially important if the
result is unexpected or not in harmony with the rest
of the clinical information available.
What are the reasons for this seemingly deplorable situation and how can it be remedied? The
reasons are legion and I do not foresee the day when
they can be remedied to the point where no errors
ever occur. On the other hand, the situation has
improved considerably during the past decades and
there are reasons to hope for further improvement.
Such improvement will require greater effort from
physicians ordering the tests as well as those working
under their professional supervision, greater effort
on the part of reagent, laboratory-ware and instrument manufacturers and greater effort on the part
of laboratory personnel.
Let us begin with specimen collection. I fear
that even in these days, when each hospital patient
has a wrist band with his name and identifying number on it, and when hospital rules usually forbid two
patients with the same last name being placed in the
same room-or even on the same floor in some cases
-mistakes are occasionally made in patient identification. The errors arise in various ways. The blood
collector may not check the wristband and a new
patient may have been placed in the room, or the
blood collector may have entered the wrong room.
The collector may have asked, "Are you Mrs. Jean
Jones?" and have been answered, "Yes" by Mrs.

* Presented by Dr. Beeler at the 44th Annual McGuire
Lecture Series, Ma rch 23, 1973, at the Medical College of
Virginia, Richmond.
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Sally Smith who didn't understand the question and
who always answers questions positively. I have
heard that this is not an uncommon reaction among
patients, who wish to please those who are taking
care of them. Or the patient may actually be Mrs.
Jean Jones, but the collector may have picked up
Mrs. Sally Smith's pre-labeled slips and collection
containers. Pre-labeling, while time saving, can generate problems, since it makes this sort of mistake
easier. I have seen a nurse hand a sputum jar to a
patient about to undergo gastric lavage for suspected
tuberculosis and be told by the patient that the name
on the slip was not his own. Once such an incorrectly
identified specimen reaches the laboratory the error
is hardly likely to be caught.
Almost no other clinical feat appears more
difficult than obtaining ·an accurate 24-hour urine
collection. Bottles continually arrive in the laboratory bearing on the laboratory slip the information
that the patient's collection started at 8 a.m. on the
morning of the first day and terminated at 8 a.m. on
the morning of the second day. Nonsense! I'll bet
not one in one hundred patients voids on the hour
exactly. A nurse or nurse's aide has probably prelabeled the containers and slips and left them with
the patient with rapid-fire oral instructions or a neat
little card bearing written directions which the patient can't read, doesn't read or doesn't understand .
It is essential that someone who really understands
the procedure explain it to the patient in simple
terms. It is not important that the collection start
and stop on the hour or that it be exactly 24 hoursa fact which in my experience seems to escape most
medical students and probably most nurses. It is
important that the time be known exactly, that the
first specimen at the beginning of the collection
MCV QUARTERLY 9 (4): 368-370, 1973
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period be discarded and that all of the urine be
collected during the following collection period, uncontaminated by feces. Patients often forget when
they use a bed pan that urine passed along with the
bowel movement also counts. As a matter of fact,
errors in 24-hour urine collections are so universal
that many laboratories will not report results per 24
hours, but merely the volume of the urine and the
results per 100 ml or per milliliter, in order not to
return ridiculous results.
The type of container and what it contains is
also important. I know of an expensive study of
calcium and phosphorus metabolism conducted some
years ago at a famous clinic which was invalidated
because of improper cleaning and rinsing of the urine
containers. Heparinized blood used for collection for
blood ammonia determinations may be unsatisfactory as some heparins contain significant amounts of
ammonia. I know of a case in which a fibrinogen
band on electrophoresis of what was thought to be
serum was interpreted as a monoclonal gammopathy
or M peak when plasma was inadvertently substituted for serum. Nonsterile containers are often used
to collect and transport specimens for bacteriologic
study. Containers not chemically cleaned are often
used to collect specimens for trace metal analysis.
Manufacturers have suddenly, without prior notification, introduced changes such as siliconizing a widely
used brand of blood-collection tube and consequently
wreaked havoc with unsuspecting hematology laboratories using the tubes for whole blood clotting
times! The wrong anticoagulant can make the interpretation of a peripheral blood smear difficult or
impossible. Improper preparation of the patient is
also a common cause of unreliable laboratory results. Glucose tolerance tests on patients who have
been on starvation or reducing diets in the days preceding the specimen collection are not reliable for
purposes of diagnosing diabetes mellitus. Serum
lipids may be misleadingly normal if the patient has
been losing weight or has been on a starvation or
fat restricted, low calorie diet. It is not possible to
interpret the 24-hour urine calcium, if the calcium
content of the diet prior to the collection is not
known.
Inappropriate specimen handling and inadequate preservation also causes error. Glucose rapidly
metabolizes if plasma or serum is allowed to sit in
contact with red cells. Although variable, the average rate of reduction of blood glucose at 37 °C is
15 mg/ 100 ml/ hr. Bilirubin is oxidized rapidly when
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exposed to direct sunlight or even to fluorescent
lighting. Ammonia generation starts immediately
following withdrawal of the blood sample. The pH
rises if blood is exposed to air. There is a paradoxical rise in serum alkaline phosphatase (as much
as 10% ) when serum is refrigerated overnight.
Hemolysis of the sample can interfere with
many laboratory procedures by different mechanisms
including absorbance by hemoglobin at the wavelength used, inhibition of enzyme activity by hemoglobin (lipase) or contribution of intracellular substances present in higher concentration in red cells
than in serum (potassium, LDH) . Turbidity of the
serum may also interfere, particularly in photometric
procedures.
The problem of drug interference is so formidable that I hesitate even to mention it. Drugs may
interfere by altering the patient's biochemical and
physiological processes or by interfering with the
analytic procedures. This may result in raising or
lowering test results significantly or only slightly, or
may render the specimen totally unfit for testing.
The entire October 1972 issue of Clinical Chemistry,
the journal of the American Association of Clinical
Chemists is devoted to a computer printout of laboratory tests and drugs affecting them. It represents
9,000 filed entries developed in the Clinical Pathology
Department of the Clinical Center of the National Institute of Health and over 250 pages are
devoted to this problem in that one issue. It is beyond the capability of the human mind to remember
even a fraction of such a list. Even if it were not,
the lack of quantitative data concerning the degree
of interference and its consistency and the innumerable possible combinations and their varying effects
would cause this to be an almost unsolvable problem.
Even so, major effects of the commonest medications
on the frequently used laboratory tests should be
kept in mind. Examples of interference by physiologic mechanisms are the effect of "the pill" on thyroid function tests, and of morphine or codeine on
serum amylase. Examples of interference with chemical analyses directly include the effect of administration of iodine containing substances on the serum
protein bound iodine (PBI) and the effect of bromide
on the ferric iron cholesterol methods.
If the patient has been properly prepared, the
specimen properly collected and preserved and the
patient has received no interfering medications,
many potential pitfalls still await the procedure
within the laboratory. Once again, there is the pas-
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sibility of misidentification of specimens. I know of
no completely foolproof specimen identification system, although in recent years improved systems have
been evolved.
There is the ever present problem of unacceptable error originating in the actual laboratory procedure. First, let us acknowledge the hard fact that
no human act-or even the act of any machine
(although machines may come closer)-is perfectly
reproducible. There is an irreducible minimal variation inherent in the actions of the technologists, in
the limitations of glassware, reagents and instruments
with which we must all live. It is the business of the
clinician to acquaint himself with this variability as
estimated by his own laboratory for each of its
laboratory procedures, so that he may decide whether
two tests on the same patient can reasonably be
judged to be different. A simple, somewhat oversimplified rule of thumb is not to consider two test
results which are within three standard deviations of
each other (the standard deviation in this case estimated from daily quality control samples) to be
significantly different-or to indicate a possible
laboratory error-unless they should be different and
do not appear to be. There are two general sorts of
an alytic error-those that effect all the unknowns in
the batch in the same direction (bias) and those
that strike randomly. The systematic error or bias
can result from deteriorating standards, a bad reagent, improper instrument setting or operation. All
laboratories have or should have an adequate daily
control program whose primary purpose is to detect
this sort of error, so that it can be corrected before
erroneous results are reported. Random errors, on
the other hand, are generally not detected by the
usual quality control program. They can result from
pipetting errors, an intermittent instrument failure,
a random calculation error or from the lack of
specificity of the tests coupled with an abnormal
concentration of some other substance in the sample.
They can be minimized by good procedures, good
instruments, good instrument maintenance and welltrained, careful technologists. All calculations should
be performed independently by two different laboratory workers and results should, whenever possible,
be compared with previous results on the same patient or with other tests performed for the same
patient on the same day with an eye to their compatibility. Unfortunately, since errors can be in either
direction and of any magnitude, there is really no
greater reason to subject abnormally high or low
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results to closer scrutiny than normal results (unless
results are incompatible with life or ridiculously
abnormal). There does exist the possibility of greater
liability of significant inappropriate therapeutic intervention on the basis of abnormal laboratory results,
but lifesaving intervention not initiated because of an
erroneously reported normal laboratory value can be
similarly threatening. The physician ordering the test
can be of assistance by informing the laboratory if,
judged by other information available to him, it appears likely that a laboratory error has occurred.
The laboratory director should encourage this type
of feedback and should see that each instance is investigated thoroughly. The laboratory should indicate a willingness to repeat the test on a freshly
collected samr,le without additional charge-certainly if the first result was erroneous, and probably
even if the first one was not in error, provided, of
course, that the clinicians do not abuse this opportunity.
Even if the analytic procedure is reasonably
specific and the result is accurate, there are still pitfalls awaiting the unwary interpreter. These pitfalls
result from intra- and interpatient variability and the
many unsolved problems related to normal values and
interpretation of laboratory test results.
In summary, numerous pitfalls await anyone
brash enough to accept laboratory data in an unqualified fashion. Errors result from improper patient
preparation, improper specimen collection and preservation or identification, drug interference and technologist, glassware, reagent or instrument failure .
Errors can be minimized by education, interest and
cooperation among clinicians, laboratory directors,
nurses, technologists and all others involved. Such
errors cannot ever be completely erradicated. It
bears repeating, therefore-never undertake potentially serious action on behalf of a patient solely on
the basis of a single laboratory test result.
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Genetic-Metabolic News*
This is the first in a series of newsletters designed
to inform the Virginia medical community of recent
advances in the area of GENETICS and METABOLISM and to provide information regarding a
variety of services that are available at the Medical
College of Virginia. The number, complexity and
expense of tests that are now required in order to
make precise diagnoses in many of the newly described genetic and metabolic disorders make it
impossible for most clinical pathology laboratories to
provide these services.
Accurate and meaningful genetic counseling
must be based on precise diagnoses. Genetic counseling is imperative if we are to have some measure of
success in reducing the familial transmission of these
disorders. "An ounce of prevention is worth a pound
of cure."
Diagnosis and continued therapy of many of the
inborn errors of metabolism (i.e. phenylketonuria,
galactosemia, glycogen storage disease, maple sugar
urine disease, methylmalonic aciduria, etc.) require
highly sophisticated biochemical tests and enzymatic
analyses. Newer techniques for the detection of
carrier states (i.e. Tay-Sachs disease, sickle-cell disease) have stimulated the development of several
programs for mass screening for carriers. These
screening programs have already been successful in
identifying married couples where both husband and
wife are carriers of a gene for an inborn error of
metabolism and thus have a 25 % likelihood of producing an affected child.
One of the more exciting developments in the
past several years has been the ability to make chromosomal and metabolic diagnoses on cells in amniotic
fluid obtained transabdominally (i.e. by amniocentesis) at 14-16 weeks of pregnancy. This procedure
enables one to monitor certain "high risk" mothers
for an affected fetus prior to the 20th week of gestation-a time sufficiently early to allow the therapeutic
termination of pregnancy when indicated. Amniocentesis involves a very minimal risk to mother and
fetus. Indications for this type of study performed in
the Department of Obstetrics and Gynecology are
noted in the following pages.
Beginning on Tuesday, January 8, 1974 the National Foundation-March of Dimes Genetic Coun-

* Supported

by National Foundation-March of Dimes.

seling Clinic will accept for investigation and counseling any families desiring these services. No charge
will be made for the counseling services or for the
services of the metabolic tissue culture laboratory.
Where a precise diagnosis is not already well established, the family may be directed to various subspecialty areas, either as a private or general staff
patient, where more definitive studies can be carried
out on a fee-for-service basis. Charges for chromosomal studies are outlined in the following pages.
Medical personnel who desire further general information regarding the Counseling Clinic may write
or call Dr. Peter Mamunes at (804) 770-3033 or
770-5076 or Dr. R. B. Young at (804) 770-4206 or
770-5076 in the Department of Pediatrics. A listing
of the various genetic and metabolic services which
are currently available at the Medical College of Virginia is provided in the following pages for your
future reference. Where specific services are noted,
direct contact should be made with the persons
offering the services.

MEDICAL COLLEGE OF VIRGINIA
GENETIC AND METABOLIC SERVICES
1. National Foundation-March of Dimes
Genetic Counseling Clinic (Department of Pediatrics and Program in Human Genetics). The counseling services of this clinic are available at no charge
to patients referred for genetic counseling. This
clinic meets on the first and third Tuesday afternoons
of each month. For inpatients and families where
a precise diagnosis is not clearly established, appropriate referrals are made. Contact Dr. Peter
Mamunes or Dr. R. B. Young.
2. National Foundation-March of Dimes
Metabolic Tissue Culture Laboratory (Department
of Pediatrics). This laboratory provides the definitive
identification of certain metabolic defects which can
be measured by enzyme analyses of white blood
cells, red blood cells or fibroblasts from skin or
amniotic fluid. Since these studies are complex and
time consuming, they are performed only after preliminary screening studies have indicated the likelihood of a genetic defect.
Due to the very large number of genetic defects
now recognized to occur, this laboratory performs
tests only on a few specific disorders of carbohydrate,
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lipid and amino acid metabolism which have been
recognized to occur with a reasonable incidence
in this state. These include the glycogen storage
diseases, defects in intermediary carbohydrate metabolism which lead to hypoglycemia or developmental delay, various problems which cause organic acidosis, the aminoacidopathies and a small
number of abnormalities which are associated with
abnormal lipid storage (especially Tay-Sachs disease).
Where other diseases are suspected, specimens are
sent to other laboratories in the U .S. that have
specific interests in the particular disorder in question . Contact Dr. Robert Eanes or Dr. Peter
Mamunes.
3. MCV Metabolic Service Laboratory (Department of Pediatrics. Contact Dr. Peter Mamunes).
A. Urine for Metabolic Screening. To screen
for various inborn errors as a cause for psychomotor
retardation, failure to thrive, recurrent acidosis ,
seizure disorder, etc., a battery of qualitative tests
and high voltage electrophoretic separation of amino
acids is performed on a random urine specimen
( minimum 15 cc volume) . After acidification to
pH 1 (with a few drops of concentrated hydrochloric acid) the urine can be mailed to this laboratory at room temperature. Testing is performed
once per week. More specific quantitative procedures are undertaken where the screening tests
determine the need. The fee for preliminary metabolic screening tests on urine is $20.00.

B. Measurement of Specific Metabolite or Enzyme. As a part of its research activities (in mitochondrial metabolism, pathophysiology of Reye's
syndrome, organic acidemias and hypoglycemia)
this laboratory has established a substantial number
of quantitative procedures for metabolites and enzymes. When there is a need for a test not performed locally, referral to the appropriate source
laboratory is made.
C. Treatment of Inborn Errors of Metabolism.
Supervision of dietary and other treatment modalities for the inborn errors of metabolism is monitored
by careful analysis of accumulating substrate or intermedi ary metabolites. This program is supported
to a large extent by the Bureau of Child Health of
the Virginia State Health Department.

4. MCV Chromosome Service Laboratory (Department of Pediatrics and Program in Human
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Genetics). Chromosomal analysis is performed on a
fee-for-service basis on patients with: 1) multiple
congenital anomalies; 2) sex anomalies not fully
identified by sex chromatin (buccal smear) studies;
3) suspected chronic myeloid leukemia for identification of the Philadelphia-I (Ph 1 ) chromosome.
Blood specimens can be collected in micro capillary
tubes (heparinized) and mailed in special culture
tubes which are available on request. Culture and
analysis require approximately two weeks. Charge
for complete culture and photographic karyotyping
on peripheral blood leukocytes or bone marrow will
vary from $75.00 to $150.00 according to complexity. Special arrangements are necessary for the
scheduling of this test. Charge for routine buccal
smear for sex chromatin (Barr body) is $10.00 or
by fluorescent technique for identification of the
double Y bodies in the XYY syndrome is $20.00.
Contact Dr. Andrew Chen or Dr. R. B. Young.
5. MCV Amniocentesis Laboratory for Intrauterine Study of Chromosomal Anomalies (Department of Obstetrics and Gynecology). Patients may be
referred by their obstetrician or family physician
to be considered for amniocentesis and chromosomal
analysis. Parents in certain high risk situations should
be referred for counseling before conception when
possible or as early in pregnancy as possible. Arrangements could then be made for the amniocentesis
to be performed around the 14th-16th week of
pregnancy primarily in the following high risk
situations:
A. one parent a known carrier of a chromosomal translocation (i.e. 14/ cl translocation in mongolism) which carries · a onein-three to one-in-five chance of having
another affected child;
B. any family with a prior mongoloid child
(recurrence risk is approximately 1: 200);
C. any mother 40 years of age or older ( oc-

currence risk is approximately 1: 100);
D. any family where parents are known to be
carriers of a sex-linked recessive condition
such as hemophilia ( occurrence risk is 50%
in male children);
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E. any family where both parents are known
carriers of a biochemical disorder that is
capable of being detected in amniotic fluid
( now some 20 or more disorders). Most
of these disorders have autosomal recessive
transmission with a 25% recurrence risk.
Amniocentesis will be performed on an outpatient basis in the Department of Obstetrics and
Gynecology. In most cases amniocentesis will be
preceded by placental localization by diagnostic
ultrasound. Referred specimens of amniotic fluid
may be accepted if prior arrangements are made.
Total charges will range from $200 to $250. The
time required for tissue culture and photographic
karyotyping of the chromosome is approximately
three weeks. It is anticipated that almost all parents
will elect early termination of pregnancy if the fetus
is found to be affected. Immediate consultations between referring physician and the Department of
Obstetrics and Gynecology will be imperative in
these situations. Contact Dr. Fay Redwine, Dr. Edward Davis or Dr. Leo Dunn, Chairman.
6. Consultation and Evaluation Clinic Chromosomal Laboratory-Bureau of Child Health and Department of Pediatrics. Children being evaluated for
psychomotor retardation in any of the C&E clinics
throughout the state are eligible for chromosome
analysis without charge when these studies are clinically indicated. Any mongoloid (Down's syndrome)
patient may also be referred by his physici an for
chromosome analysis without charge. Further family
studies will be carried out when indicated.

7. Special Study Project of Multiple Spontaneous Abortions-Sponsored by Developmental
Disabilities Study Grant and Program in Human
Genetics. Chromosomal studies will be performed

free of charge for the next six months (December
1, 1973 to June 31 , 1974) on parents who have
had two or more spontaneous abortions to search
for possible translocations which may th en indicate
high risk of recurrence. Amniocentesis might then
be considered if a translocation is identified in either
parent. Contact Dr. Andrew Chen or Dr. R. B.
Young.
8. Tay-Sachs Screening Program-Supported
by the Department of Pediatrics, the Department of
Pathology, the Virginia State Health Department and
voluntary contributions from individuals and organizations. A Tay-Sachs carrier detection program -has
been established. Over 1,800 adult Jews in the
state have thus far been screened after an intensive education al campaign in the greater Richmond
area. Each of the 60 id entified carri ers has been
appropri ately counseled. Presently, we are advising
and supporting other Virginia communities in their
efforts to educate, test and counsel for this lethal ,
inherited metabolic disorder of the central nervous
system which affects primarily Jews. Because the
test ( done on one mill ii iter of serum) measures enzyme (hexosaminidase A) activity, special handling
of the specimen is required . All married Jews in
the childbearing age should definitely be tested .
Charge is a voluntary contribution. Contact Dr. Peter
Mamunes.
9. Sickle Cell Testing and Counseling. The
Virginia Sickle-Cell Anemia Awareness Program
(V ASCAP) tests for carriers of sickle trait in the
childbearing age and provides genetic counseling.
Blood samples may be sent by the patient's physician (mailing tubes can be provided) or the patient
may go to the testing clinic at I 008 East Clay
Street in Richmond. Call ( 804) 770-7797 for information.

For Specific Information in the Above Areas Contact:
Name
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.

Andrew Chen
Edward Davis
Leo Dunn
Peter Mamunes
Fay Redwine
R. B. Young
Robert Eanes

Department

Telephone (804)

Program in Human Genetics
Department of Obstet.-Gynecol.
Department of Obstet.-Gynecol.
Department of Pediatrics
Department of Obstet.-Gynecol.
Department of Pediatrics
Department of Pediatrics

770-4646 or 770-4645
770-4111
770-4111
770-3033 or 770-5076
770-4111
770-4206 or 770-5076
770-7610 or 770-5076
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in chronic pain: continued relief without risk of tolerance
Though Talwin®Tablets can be
compared to codeine in analgesic
efficacy, Talwin is not subject to
narcotic controls. For patients who
require potent analgesia for prolonged
periods, Talwin can provide consistent,
long-range relief, with fewer of the
consequences you've come to expect
with narcotic analgesics.

• Comparable to codeine in analgesic efficacy: one 50 mg.
Talwin Tablet appears equivalent in analgesic effect to 60 mg.
(1 gr.) of codeine. Onset of significant analgesia usually
occurs within 15 to 30 minutes. Analgesia is usually maintained for 3 hours or longer.
• Tolerance not a problem: tolerance to the analgesic effect
of Talwin Tablets has not been reported, and no significant
changes in clinical laboratory parameters attributable to the
drug have been reported.
• Dependence rarely a problem: during three years of
wide clinical use, only a few cases of dependence have been
reported. In prescribing Ta/win for chronic use, the physician
should take precautions to avoid increases in dose by the
patient and to prevent the use of the drug in anticipation of
pain rather than for the relief of pain. (See last page for a
complete discussion of Warnings under Brief Summary.)
• Not subject to narcotic controls: convenient to prescribeday or night-even by phone.

• Generally well tolerated by most patients: infrequently
cause decrease in blood pressure or tachycardia; rarely cause
respiratory depression or urinary retention; seldom cause diarrhea or constipation. if dizziness, lightheadedness, nausea or
vomiting are encountered, these effects may decrease or disappear after the first few doses. (See last page of this advertise- .
ment for a complete discussion of Adverse Reactions and a Brief
Summary of other Prescribing Information.)
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Talwin® Tablets brand of pentazocine (as hydrochloride)
Analgesic for Oral Use-Brief Summary
Indications: For the relief of moderate to severe pain.
Contraindication: Talwin should not be administered to patients who
are hypersensitive to it.
Warnings: Drug Dependence. There have been instances of psychological and physical dependence on parenteral Ta/win in patients with
a history of drug abuse and, rarely, in patients without such a history.
Abrupt discontinuance following the extended use of parenteral Ta/win
has resulted in withdrawal symptoms. There have been a few reports
of dependence and of withdrawal symptoms with orally administered
Ta/win. Patients with a history of drug dependence should be under
close supervision while receiving Ta/win orally.
In prescribing Ta/win for chronic use, the physician should take precautions to avoid increases in dose by the patient and to prevent the
use of the drug in anticipation of pain rather than for the relief of pain.
Head Injury and Increased lntracranial Pressure. The respiratory depressant effects of Talwin and its potential for elevating cerebrospinal
fluid pressure may be markedly exaggerated in the presence of head
injury, other intracranial lesions, or a preexisting increase in intracranial pressure. Furthermore, Talwin can produce effects which may
obscure the clinical course of patients with head injuries. In such patients, Talwin must be used with extreme caution and only if its use is
deemed essential.
Usage in Pregnancy. Safe use of Talwin during pregnancy (other than
labor) has not been established. Animal reproduction studies have not
demonstrated teratogen ic or embryotoxic effects. However, Talwin
should be administered to pregnant patients (other than labor) only
when, in the judgment of the physician , the potential benefits outweigh
the possible hazards. Patients receiving Talwin during labor have experienced no adverse effects other than those that occur with commonly used analgesics. Talwin should be used with caution in women
delivering premature infants.
Acute CNS Manifestations. Patients receiving therapeutic doses of
Talwin have experienced, in rare instances, hallucinations (usually
visual), disorientation , and confusion which have cleared spontaneously
within a period of hours. The mechanism of this reaction is not known .
Such patients should be very closely observed and vital signs checked .
If the drug is reinstituted it should be done wiih caution since the
acute CNS manifestations may recur.
Usage in Children. Because clinical experience in children under 12
years of age is limited, administration of Talwin in this age group is not
recommended.
Ambulatory Patients. Since sedation, dizziness, and occasional euphoria have been noted, ambulatory patients should be warned not to
operate machinery, drive cars, or unnecessarily expose themselves to
hazards.
Precautions: Certain Respiratory Conditions. Although respiratory depression has rarely ·been reported after oral adm inistration of Talwin ,
the drug should be administered with caution to patients with respiratory depression from any cause, severe bronchial asthma and other
obstructive respiratory conditions, or cyanosis.
Impaired Renal or Hepatic Function. Decreased metabolism of the
drug by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory tests have not indicated that
Talwin causes or increases renal or hepatic impairment, the drug
should be administered with caution to patients with such impairment.
Myocardial Infarction. As with all drugs, Talwin should be used with
caution in patients with myocardial infarction who have nausea or
vomiting.
Biliary Surgery. Until further experience is gained with the effects of
Talwin on the sphincter of Oddi, the drug should be used with caution
in patients about to undergo surgery of the biliary tract.

Patients Receiving Narcotics. Talwin is a mild narcotic antagonist.
Some pat ients previously given narcotics, including methadone for the
daily treatment of narcotic dependence, have experienced mild withdrawal symptoms after receiving Talwin.
CNS Effect. Caution should be used when Talwin is administered to
patients prone to seizures; seizures have occurred in a few such
patients in association with the use of Talwin although no cause and
effect relationship has been established.
Adverse Reactions: Reactions reported after oral administration of
Talwin include gastrointestinal: nausea, vomiting; infrequently constipation; and rarely abdominal distress, anorexia, diarrhea. CNS effects :
dizziness, lightheadedness, ssdation , euphoria, headache; infrequently
weakness, disturbed dreams, insomnia, syncope, visual blurring and
focusing difficulty, hallucinations (see Acute CNS Manifestations under
WARNINGS) ; and rarely tremor, irritability, excitement, tinnitus. Autonomic: sweating; infrequently flushing; and rarely chills. Allergic: infrequently rash ; and rarely urticaria, edema of the face. Cardiovascular:
infrequently decrease in blood pressure, tachycardia. Other: rarely
respiratory depression, urinary retention.
Dosage and Administration: Adults. The usual initial adult dose is 1 tablet (50 mg.) every three or four hours. This may be increased to 2 tablets
(100 mg.) when needed. Total daily dosage should not exceed 600 mg.
When antiinflammatory or antipyretic effects are desired in addition to
analgesia, aspirin can be admin istered concomitantly with Talwin .
Children Under 12 Years of Age. Since clinical experience in children
under 12 years of age is limited, administration of Talwin in this age
group is not recommended.
Duration of Therapy. Patients with chronic pain who have received
Talwin orally for prolonged periods have not experienced withdrawal
symptoms even when administration was abruptly discontinued (see
WARNINGS) . No tolerance to the analgesic effect has been observed.
Laboratory tests of blood and urine and of liver and kidney function
have revealed no significant abnormalities after prolonged administra·
tion ofTalwin.
Overdosage: Manifestations. Clinical experience with Talwin overdosage has been insufficient to define the signs of this condition.
Treatment. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled
ventilation should also be considered. Although nalorphine and levallorphan are not effective antidotes for respiratory depression due to
overdosage or unusual sensitivity to Talwin, parenteral naloxone
(Narcan®, available through Endo Laboratories) is a specific and
effective antagonist.
Talwin is not subject to narcotic controls.
How Supplied: Tablets, peach color, scored. Each tablet contains
Talwin (brand of pentazocine) as hydrochloride equivalent to 50 mg.
base. Bottles of 100.

50 mg. Tablets
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pentazoc1ne
brand of
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(as hydrochloride)

in moderate to severe pain
[M~ro.e) Winthrop Laboratories, New York, N.Y. 10016
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iseTOre prescnomg, p1ease consult
complete product information, a summary of which follows:
Indications: Tension and anxiety

states, somatic complaints which are
concomitants of emotional factors; psychoneurotic states manifested by tension,
anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic
relief of acute agitation, tremor, delirium
tremens and hallucinosis due to acute
alcohol withdrawal ; adjunctively in skeletal muscle spasm due to reflex spasm to
local pathology, spasticity caused by
upper motor neuron disorders, athetosis,
stiff-man syndrome, convulsive disorders
(not for sole therapy).
Contraindicated: Known hypersensitivity to the drug. Children under 6
months of age. Acute narrow angle glaucoma; may be used in patients with open
angle glaucoma who are receiving appropriate therapy.
\
Warnings: Not of value in psychotic
patients. Caution against hazardous
occupations requiring complete mental
alertness . When used adjunctively in convulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
seizures may require increased dosage of
standard anticonvulsant medication;
abrupt withdrawal may be associated
with temporary increase in frequency
and/ or severity of seizures. Advise
against simultaneous ingestion of alcohol
and other CNS depressants . Withdrawal
symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating) . Keep addictionprone individuals under caref4,I surveil:
lance because of their predisposition to ~ ( /.
Ill. ~//
habituation and dependence . In pregnancy, lactation or women of childbearing
_/
age, weigh potential benefit against
possible hazard .
Precautions: If combined with other
psychotropics or anticonvulsants, consider carefully pharmacology of agents
employed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other antidepressants may potenticite
its action. Usual precautions indicated in
patients severely depressed, or with latent
depression, or with suicidal tendencies.
Observe usual precautions in impaired
renal or hepatic function . Limit dosage to
smallest effective amount in elderly and
debilitated to preclude ataxia or oversedation.
Side Effects: Drowsiness, confusion,
diplopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jaundice, skin rash, ataxia, constipation,
headache, incontinence, changes in salivation, slurred speech, tremor, vertigo,
urinary retention, blurred vision . Paradoxical reactions such ·as acute hyperexcited states, anxiety, hallucinations,
increased muscle spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported; should these occur,
discontinue drug. lsolatec;i reports of neutropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.

Ifthere's good reason
to prescribe
for psychic tension...

When, in spite of counseling,
the patient's pattern ofoverreaction to stress
affects his ability to function

Dependable response
.1s a good reason
to ConsiderValium
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